See the document

Transcription

See the document

The crucial link
ANNUAL REPORT
2012
www.gustaveroussy.fr
On the front page:
KEVIN PULIDO,
patient at Gustave Roussy’s
Child and Adolescent
Cancer Department.
The crucial link
Past, present and future; care-givers, patients
and families; research, care and teaching;
local, national and international partners…
So many bonds forged each day by
Gustave Roussy’s teams. So many relationships
nurtured around the care provided by the teams of
doctors and care-givers, the energy of researchers
and the solidarity of families and volunteers.
So many forces working together to beat cancer.
SUMMARY
Discover Gustave Roussy
02
Interlinked portraits
04
Our Key Missions
08
Key figures
10
Actors of the cancer network
11
Governance
12
Highlights 2012
14
Management board interview
16
See further
20
A global problem
22
A global mementum
24
The scientific project Cancer Campus
25
Therapeutic innovations
26
Precision medicine
28
Act on…
Care
Research
Teaching
Fundraising
Financial Results
30
32
38
42
46
50
2012 activity
52
Auditor’s report
53
2012 balance sheet
54
2012 profit and loss account
56
Overall annual use of resources
58
Uses of donations and bequests
59
Gustave Roussy’s
scientific publications
Synthesis
International comparisons
International publications
60
60
62
63
Our 2012 annual report
and its annexes can be found online
• The activity of the departments and the tumor boards
• Presentation of the research groups
gustaveroussy.fr heading: annual reports
ANNUAL REPORT 2012 / GUSTAVE ROUSSY 03
CATHERINE VERGELY,
director of ISIS, an association of parents and friends of the
children treated at Gustave Roussy.
“There are dozens of volunteer associations helping out at
the Gustave Roussy Institute. Our work has been recognised
to be of public interest; we form an integral part of the
hospital system by helping to improve the quality of life
of cancer patients. We know that our role is important.”
“I’ve had highs and lows, as the weeks
go by. Sometimes, activities organised
for the patients by volunteers have
helped us escape. These moments
are truly important.”
KEVIN PULIDO, a patient
at Gustave Roussy’s Department
of Child and Adolescent Cancer
Pr FABRICE ANDRÉ, oncologist and Head of The Unit
for Translational Research at Gustave Roussy.
“Generosity of the public and solidarity of our donors are
essential for the success of cancer research programs
currently being conducted at Gustave Roussy. I would
sincerely like to thank all our donors; it is their generosity
that allows us to exist.“
“Donating money to research is something
very tangible. Every month, by donating
a few dozen euros by automated bank transfer,
I am actively helping to fund a team.
My contribution allows a research program
to exist. The more of us there are, the more
we can do to advance research.”
CHRISTELLE DUMONT,
sponsor of Professor Fabrice André’s team
for research against breast cancer.
CAROLE MAZELIER,
medical-technical manager in nuclear medicine.
“Every day, thanks in particular to the
training we are given, I can improve my
skills for the benefit of the patients and
thus serve them better. I share that with
all my colleagues. We see what is at
stake and it makes our work all the more
meaningful.”
“I am keen to pass on, through the training
I provide to the medical teams at Gustave
Roussy, the correct methodology for
conducting clinical studies under optimal
conditions for patients.”
Dr ISABELLE BORGET,
a university lecturer in health economics at
Université Paris-Sud Gustave Roussy.
“I am proud to follow a training
program focused on innovation and
to rub shoulders with the brilliant
people at Gustave Roussy. I consider
myself very lucky to have had
this opportunity to spend 3 years
studying in such a stimulating
and scientific environment.”
NILS TERNÈS, master’s student,
part of the “Path to excellence in cancer studies
group – Fondation Philanthropia”, and pursuing
an education at the Cancer Sciences School –
Université Paris-Sud and Gustave Roussy.
Pr MARTIN SCHLUMBERGER,
director of the Cancer Sciences School
“Training young talent is fundamental
to make sure there is a constant
renewal of innovation in care and
oncology research. These are
the talents which, tomorrow,
will beat cancer.”
DISCOVER GUSTAVE ROUSSY
OUR KEY
MISSIONS
THREE PILLARS: CARE,
RESEARCH AND EDUCATION
AT THE FOREFRONT OF CENTERS
IN THE FIGHT AGAINST CANCER
The Gustave Roussy cancer center, founded in
1926 by professor Gustave Roussy, distinguished
itself from the very beginning by its wholly
integrated approach to research, care and
teaching; today, it is one of the ten world leaders
in the fight against cancer.
A key actor on the European and international
oncology scene, Gustave Roussy applies a global
approach to cancer, employing multidisciplinary
teams to care for each patient and define by a
multidisciplinary process the best treatments for
them. Top level research, conducted at the very
heart of the Institute, is aimed at the integration
of basic, translational and clinical approaches,
so that the results can be applied as quickly
as possible for the benefit of the patient.
The teaching provided to the students,
researchers and practitioners, enables them to
bring into practice new developments in cancer
treatment, and introduce innovations.
Its internationally renown professionals are
specialists with regard to all different types of
cancer, at all stages and at all ages.
As an expert center in dealing with complex
cancers, Gustave Roussy brings together
cutting-edge medical care and human support.
Gustave Roussy’s specificity is also based on
its therapeutic innovation, which today puts
it at the forefront in very promising areas such
as personalised medicine – which takes into
account the patient and their tumour’s genetic
characteristics – and tomorrow’s therapies
(immunotherapy, DNA repair inhibitors,
epigenetic modulators).
The Institute is a driving force in the dissemination
of knowledge and training by exporting its working
models, its experience and medical expertise
abroad. Further, numerous academic
partnerships are nurtured with the greatest
cancer centers in the world for worldwide
research projects.
Gustave Roussy’s holds a central position
in the project Cancer Campus – a campus of
international scope which structures, around the
Institute, university activities in research and
health innovation – and Grand Paris, a future
Greater Paris Area which links the major
economical centers of mainland France.
08 ANNUAL REPORT 2012 / GUSTAVE ROUSSY
A GLOBAL FRONT-RUNNER IN CANCER TREATMENT
INNOVATIONS FOR OVER 90 YEARS
• Our missions: care, research, train, and mobilise.
• Our vision: set up the best group of researchers, doctors, care-givers,
teachers and donors for the benefit of each patient.
• Our commitment: create the medicine of tomorrow by speeding up
the translation of scientific and medical discoveries to new treatments
for cancer patients.
• Our values
caring
creativity
distribution
energy
A mission of public interest
Gustave Roussy is a private health
care establishment of public interest
and a not-for-profit organisation.
As a Cancer Center, its status has
been established by decree (number
45-2221) of 1 October 1945, modified
by decree (number 2005-406)
of 2 May 2005 and by the “HPST”
law of 21 July 2009 concerning
hospital reforms and relative to
patients, health and territories.
There are 18 ex-officio members
on the Board of Directors,
chaired by the Prefect of the Paris
region, the Prefect of Paris.
He determines general policies,
conducts evaluation processes and
controls the execution of policies.
At executive level, Gustave Roussy
is led by a physician, appointed for
5 years by the Minister of Health,
after consultation with the Board
of Directors and the National
Federation of Cancer Centers.
The General Director, who manages
the general conduct of the
establishment, is aided by the
Assistant General Director who
is in charge of the operational
management of the Institute,
appointed by the Minister of Health,
and the Research Director who is
appointed for 5 years by a decree
of the Ministers in charge of Health
and Research.
Gustave Roussy is a member
of UNICANCER, which federates
the Cancer Centers in France.
KEY FIGURES
ACTIVITIES AND TEAMS
an overall budget of
2,600
290 M
€
employees
A research
budget of
60 M
Of which 20%
€
€20 M
530
physicians
965
270
care-givers
researchers
raised from the public
CARE
200,000
consultations
24%
47,000
356 hospital beds
of the patients
involved in a biomedical
research program (compared
with 11% nationwide)
patients of which
11,400 first visits
per year
and 88 beds/chairs
in day-care
RESEARCH
29
research
groups
300 clinical
1,300
studies in progress,
international scientific
publications
divided into 13 units
more than 50 sponsored
by Gustave Roussy
Almost
2,500
Over
130
patents
filed
patients treated
by a personalised approach between
2009 and the end of 2012
TEACHING
2,800 medical
students,
nurse students, engineers
and researchers trained every year
40,000 hours
of initial and/or in-house
training every year
17 University 26
degrees
university
teachers
214
teaching
practitioners
3,400
electronic or paper
publications
THE ACTORS OF THE CANCER NETWORK
As a global public health issue, the fight against cancer requests, by its very nature, a global and
combined approach between its many different actors: research centers, universities, hospitals, other
centers involved in the fight against cancer both in France and on the international scene, pharmaceutical and
biotechnological industries, supervisory authorities, patient associations, small and large donors, sponsoring firms…
So many driving forces joined together to encourage innovation in care and research.
Inca
French National
Cancer League
Plan Cancer
Departmental
p
Council
for the Paris region
ARC
Unicancer
Grand Paris
AP-HP
Departmental
p
Council
for the “Val de Marne” region
French Ministryy
of Higher
g
Education
and Research
Federation of Cancer
Centers of France
Front-line health professionals
French
Ministryy
of Social Affairs
and Health
Campus Grand Parc
ONCO 94
Cancer Campus
(Villejuif)
Inserm
Fondation
Gustave Roussy
Groupe
p
Dassault
Natixis
Printemps
Cancer
Sciences
School
Fondation
Philanthropia
Université Paris-Sud
Universityy Department
p
of Medical Studies
Universityy
Department
p
of Pharmaceutical
Studies
MMO
HAS
MD Anderson
Universityy Cancer Center
Department
p
of Sciences
SOCRATE
PACRI
PATIENTS
Donors
ARS
CNRS
UFR Law
Economics
Management
nt
MOSCATO
ANSM
Patient
Associations
EORTC
Union for
International
Cancer Control
Organisation
g
of European
p
Cancer Institutes
Universityy Hospital
Sharjah (UAE)
Erasmus
University MC
DKFZ
Karolinska
Institute
SAFIR
NCI
Donors “PA Attitude”
Research
sponsors
Odysséa
Gustave Roussyy
Transfert
“Route to excellence
in cancer studies –
‘Fondation Philanthropia’”
ENS Cachan
— INSTITUTIONS
— CARE ORGANISMS
— RESEARCH ORGANISMS
— TEACHING PARTNERS
— FUNDRAISING
AND PATRONAGE
Génopôle
p Évryy
biocluster
Institut Curie
Institut Pasteur
WIN Consortium
GOVERNANCE
PROMOTING EFFICIENCY,
INTEGRATION, FORWARD-THINKING
AND TRANSPARENCY
Gustave Roussy has implemented, at the general management level, a governance model to guide
its activities in care, research and teaching. This model, which guarantees an overall perspective
and responsiveness, allows the main strategic and operational guidelines to be defined, while
assuring that long-term decisions are made and that sustainable growth is assured.
Gustave Roussy is implementing a contractualizing model with its medical departments
to define objectives and budgets. This principle of delegation and co-governance is a key element
in developing common projects and the participatory principles in running the institution.
THE COMPOSITION OF THE BOARD OF DIRECTORS OF GUSTAVE ROUSSY ON 31 JULY 2013
EX OFFICIO MEMBERS (18)
Mr Jean Daubigny
President,
Prefect of the Paris region,
Prefect of Paris
Professor Fabien Calvo
Representative of the National Cancer
Institute
Mr Thierry Damerval
Representative of the Institute of National
Scientific Studies and Medical Research
Mr Laurent Garnier
Member of Val-de-Marne’s General
Council
Mrs Mireille Faugère
Managing Director of Welfare –
Paris Hospitals
Dr Jean-Marie Le Guen
Member of the Council of Paris
Professor Serge Bobin
Dean of the Faculty of Medicine
Mr André Rouquié
Member of the Economic, Social
and Environmental Council
Mrs Véronique Paquis
Representative of the Ministry of Research
MEMBERS ACTING
IN AN ADVISORY CAPACITY
Mr Pierre Dartout
Prefect of the Department of Val-de-Marne
Represented by Mr Ivan Bouchier
Assistant Prefect of L’Haÿ-les-Roses
Professor Alexander M.M. Eggermont
General Director
of Gustave Roussy
Mr Claude Évin
General Director of the Paris regional
Health Agency
Professor Claude Huriet
Mr Jean-Pierre Davant
Mrs Annie Podeur
Qualified Individuals
Mrs Catherine Vergely
Mr Jean-Pierre Escande
Users’ Representatives
Dr Dominique Valteau-Couanet
Dr Sylvie Bonvalot
Members of the medical personnel
Mrs Christine Fontaine
Dr Pierre Duvillard
Members of the Works Council
INVITED MEMBERS
Mr Éric Vechard
ARS Territorial Representative
(Val-de-Marne)
MANAGEMENT AND ADMINISTRATION
OF GUSTAVE ROUSSY
Mr Charles Guépratte
Assistant General Director
Professor Éric Solary
Research Director
Mrs Sophie Beaupère
Director of Activities and Finances
SECRETARIAT
Mr Robert Servat
Director of Financial Affairs, Treasurer
Mrs Katia Laffargue
Cabinet Chief
Dr Ellen Benhamou Borowski
President of the Medical Commission
Mr Stéphane Stépanian
Director of Investments and of Logistics
Mr Philippe Bourassin
Director of Human Resources
Mrs Christine Lascombe
Communication Director
Professor Michel Ducreux
Medical Coordinator
Mrs Anne Montaron
Care Management
Mrs Psylvia Dewas-Tasseau
Project Manager
Mr Jean Gatinaud
Auditor (KPMG)
GENERAL MANAGEMENT
International
Task Team
General Director
A. M.M. Eggermont
C. Guépratte
Research director
É. Solary
Internal contractualisation assistance and performance support task team
V. Brière
ACTIVITY UNIT
Medical Coordinator
M. Ducreux
RESEARCH AND TEACHING
TUMOUR BOARDS
DEPARTMENTS
Research Management
É. Solary
Cervico-facial Pathology
S. Temam
Medical Oncology
K. Fizazi
Clinical Research
Management
G. Vassal
Thoracic Pathology
B. Besse
Child and Adolescent cancer
research department
D. Valteau-Couanet
Teaching Management
M. Schlumberger
HEAD OF STRATEGY
Quality and Management
of Risks Management
E. Minvielle
Gastro-digestive
D. Malka
Breast
S. Delaloge
Gynecology
C. Lhommé
Endocrine tumors
E. Baudin
Radioprotection
N. Guilabert
Urology
B. Escudier
Legal Affairs Department
N. Verotte
Dermatology
C. Robert
Communication Management
C. Lascombe
Soft Tissues - Bone
A. Le Cesne
HEAD OF PROJECTS
Care Sectors
M. Di Palma
Project Cancer Campus
G. Lenoir
Neurology
F. Dhermain
Haematology
V. Ribrag
Paediatric Pathology
J. Grill
Early Trials
J.-C. Soria
Genetical oncologist
O. Caron
DEPARTMENT OF HUMAN
RESOURCES AND FINANCE
General surgery
D. Elias
Cervico-facial cancer research
F. Janot
DITEP*
J.-C. Soria
Acute care
B. Gachot
Medical imaging
M. Schlumberger
Medical Pathology
and Biology
J.-M. Bidart
Pharmacy
F. Lemare
DISSPO**
S. Dauchy
Activity and finances
management
S. Beaupère
Medical information service
M. Mons
Financial/treasury affairs
R. Servat
Human resources
Ph. Bourassin
Care management
A. Montaron
Information systems
management
N. Mezaour
Investments and logistics
management
S. Stépanian
Fundraising and Partnerships
E. Le Roy
“Fondation Gustave Roussy”
Ambulatory care
M. Di Palma
Operating rooms
J.-L. Bourgain
Radiotherapy
E. Deutsch
Medical physics
D. Lefkopoulos
* DITEP: Department of therapeutic innovations and early
trials (created in September 2013).
** DISSPO: Interdisciplinary Department of supportive care
for onco-haematology patients.
DISCOVER GUSTAVE ROUSSY
HIGHLIGHTS 2012
JANUARY
INAUGURATION OF THE NOVALIS TX
Gustave Roussy installed a high-precision stereotactic
radiotherapy system, financed partly by the Institute’s donors.
LAUNCH OF THE PROGRAMME
“LIVING WITH CANCER”
unconventional care
facilities are set up
to improve the wellbeing of patients:
art, culture, sport,
physical well-being.
To find out
FEBRUARY
page 34
MARCH
ALLIANCE OF PARISIAN
INSTITUTES FOR CANCER
RESEARCH (APICR)
Gustave Roussy brings
together its teaching activities
within the Cancer Sciences School,
together with Université Paris-Sud,
to offer training programs
in new cancer-related jobs.
in cancer research in the Paris region, in the
context of APICR, a national project of “Future
Investments in Health”.
To find out
APRIL
To find out
page 42
FIRST PUBLIC/PRIVATE
PARTNERSHIP IN
CLINICAL RESEARCH
FOR GUSTAVE ROUSSY
This partnership with Sanofi aims to
facilitate the patients’ access to new
drugs according to their tumour’s
molecular profile.
page 40
JUNE
Launch of the international
study WINTHER, the first of its
kind in the world. This trial is
conducted over a period of two
years in Gustave Roussy (Fr),
MDAnderson (USA), McGill
University (Canada), Sheeba
Medical Center (Israel)
and Val d’Hebron (Spain).
To find out
page 29
JULY
ACCREDITATION OF “SIRIC STATUS”
Roussy the label “Integrated cancer research site”
for the SOCRATE project, which brings together three
innovative programs (DNA repair, tumour immunology,
molecular medicine).
OCTOBER
SEPTEMBER
FOUNDING
OF THE THORACIC
ONCOLOGY INSTITUTE
Gustave Roussy and the
Marie Lannelongue surgical
center have founded a joint
institute to offer global and
multidisciplinary care to patients
with thoracic cancers.
THE ODYSSÉA RACE
IN PARIS 2012
The 2012 edition of the event:
the Odysséa race raised €320,000
for the support breast cancer
research which was donated to
Gustave Roussy to finance its
clinical research programs and
the development
p
of p
personalised
treatments.
NOVEMBER
ARRIVAL OF A STATE OF THE ART
MRI SCANNER
Gustave Roussy
strengthened its
technical platform with a
high resolution and highprecision MRI Scanner of
3 Tesla, which is capable
of detecting very small
tumors and a spectral
scanner which allows
the dose of X-rays in
MRI-guided radiotherapy
to be reduced by 30%.
RECOGNITION OF
THE SAFIR 01 TRIAL
AT THE ESMO CONGRESS
The first results of the SAFIR 01
study demonstrates the feasibility
and value of analysing molecular
portraits of breast cancers, in
order to detect molecular changes
that can be treated with targeted
therapies.
To find out
page 29
DECEMBER
PARTNERSHIP WITH
NATIXIS TO SUPPORT
RESEARCH
Natixis has chosen to sponsor three
new research groups at Gustave
Roussy over a three year period
to contribute to the development
of personalised medicine, in the
context of Gustave Roussy’s program
“Révolution Cancer”.
MANAGEMENT BOARD INTERVIEW
INCREASE IN ACTIVITIES
AND PROJECTS
COHESION AND MOBILISATION
OF TEAMS DEDICATED TO PATIENTS
The increase of Gustave Roussy’s activity is accompanied by the launch of major projects and of
structural research programs. Interview with Professor Alexander M.M. Eggermont (General Director),
Charles Guépratte (Assistant General Director) and Professor Éric Solary (Research Director).
What are the results of Gustave Roussy’s activity
throughout 2012 ?
ALEXANDER M.M. EGGERMONT : After
many years of growth, number
of interventions and overall
productivity has risen again in 2012.
This effort, in which all of the
Institute’s teams have participated,
demonstrates their strength and
collaborative spirit. This year has
also been marked by the launch
of a number of major projects,
in particular the construction
of a building largely dedicated to
personalised medicine – or
precision medicine –, the founding
of the Cancer Sciences School,
and the development of major
research programs. In summary,
2012 was a remarkable year in
terms of the achievements of our
missions and the implementation
of our strategic vision.
of care. This is evidenced by a 2%
rise in overall activity concerning
full hospitalisation, and 4% for
ambulatory care. Our ability to
implement new structures, such as
the new “diagnosis in a day”
which, like the model of the one set
up 8 years ago for breast cancer,
has now been expanded to other
types of tumours too. The
considerable number of long-term
projects started in 2012
demonstrates the respo
onsiveness of
all the teams in the face
e of practical
developments. In 2012 we also
finalised the internal
contractualisation proce
ess with the
drafting of contracts settting out
targets and means by th
he medical
and surgical departmen
nts.
Additional income came
e from the
treatment of foreign patients with
CHARLES GUÉPRATTE : It is largely
this growth in activity which has
allowed us to balance our budget,
despite the freeze in public
financing caused by the challenging
economic conditions and which
made us initially fear a deficit.
Thanks to the continued
momentum, supported by everyone,
we have been able to increase the
number of patients treated while
maintaining an excellent quality
CHARLES GUÉPRATTE
serious medical conditions.
The value of our expertise is
demonstrated by our first
partnership with a foreign hospital;
a Gustave Roussy unit was
established in Sharjah (UAE).
Lastly, we must acknowledge
the support of private enterprise,
in particular donors and
sponsors (companies)
and associations.
>>>
>>>
In a difficult financial context, and
despite their own challenges, they
maintained their financial support
and solidarity.
A. E. : Indeed, that is an essential
factor. To develop our projects,
we must further increase our
resources. This is why we are going
to continue to enhance our
expertise, both in France and on
the international scene. After
Sharjah, we are planning to sign
new agreements with other
hospitals or Cancer Institutes
abroad. We also wish to position
ourselves to win tenders, in the
framework of the “Big Loan” (for
France), and the “Horizon 2020”
program at European level.
What is the current state of cancer research
and what are your plans in this field ?
ÉRIC SOLARY : The progress in
DNA sequencing has given us
a more precise knowledge of
tumour cells’ genetic
anomalies. Moreover it has
been demonstrated that novel
agents for immunotherapy
seem quite effective in treating
cancer. Further, a considerable
number of new drugs with
various mechanisms of action
have come onto the market.
These advances signify a
breakthrough in research and
care. The priority areas of
research at Gustave Roussy
are: precision medicine which
takes into account the patient
and their tumour’s genetic
specificity; immunotherapy;
DNA repair; haematology and
stem cells.
Pr ALEXANDER M.M. EGGERMONT
General Director
A. E. : These four priorities are
at the very heart of our
research programs, launched
in January 2013. Completed by
a medical-economic analysis,
they strengthen our project
which was supported by the
large fundraising campaign,
“Révolution Cancer”, initiated
in 2010. Each theme mobilises
basic, translational and clinical
research groups and
integrates studies of different
types of tumours, whether
common or rare. New research
teams have been established
and others will be set up
during the next five years. >>>
Pr ÉRIC SOLARY
Research Management
MANAGEMENT BOARD INTERVIEW
Massive
investments
in the fight
against
cancer.”
>>> The ICRS award
(the integrated cancer
research site) for our SOCRATE
program strengthens our
position: we employ an
integrated approach to treating
cancer which combines
research, clinical trials
and care.
E. S. : Further efforts should
enable us to better understand
the wide variation of tumours
and the mechanics of genetic
mutations. Clinical trials are
also necessary to validate the
concept of precision medicine
by achieving the right
combinations of drugs, in
particular, and eventually try to
implement these advances in
the early screening stage and
personalised preventions.
Pr ÉRIC SOLARY
Research
Management
Will Gustave Roussy continue
to invest in equipment?
C. G. : The research programs
which Alexander M.M.
Eggermont and Éric Solary
have just spoken about are
themselves accompanied by
investments in cutting-edge
equipment and the
development of technological
platforms. The Scientific
Project Management (SPM)
Unit has been created to bring
together the Research
Management, those in charge
of large research programs,
the Director of Human
Resources and the Activity
and Finances Management.
This unit validates each
research program’s financial
commitments, with regard to
equipment in particular. In a
larger context, Gustave Roussy
invests each year to renew its
materials and
d to ensure tha
that it
remains at the forefront of
technologyy.
So, in 2012 an MRI machine
was replaced, a new scanner
was installed and the Novalis
TX, a new and high-precision
radiation machine, went into
service, thus enabling us to
upgrade radiation therapy
services. It is our 7th acceler
erator,
and we intend to purchasse yet
another one in the years
rs to come.
E. S. : To conclude, I would like
to highlight the major interest
of another project, carried
out in conjunction with
the Curie Institute: the
construction of a 5,000m²
building at Villejuif, dedicated
to preclinical research.
This building will be part of
the
e large national research
facilities
ities in France.
How would you summarise
Gustave Roussy’s strategy
in the coming years ?
A. E. : In the Institute’s guiding
principles, you find a major
objective which is shared
by all three of us, and by all
employees: pursue a strategy
centered completely on the
patient. One of our priorities
is to offer the patient the very
best technological platforms
in imaging, radiotherapy and
in sequencing and other
cutting edge diagnostic
procedures, with as much
comfort as possible. We are
going to continue to invest in
Pr ALEXANDER M.M.EGGERMONT
General Director
these fields, hoping that we
can quickly transform the most
advanced technologies into
new standards.
Of course we will continue
further integration of our
significant commitments to
basic, translational and clinical
research with treatment
programs, both in the domain
of common and rare cancers.
We are planning to further
increase clinical trial activity,
especially in the field of early
drug development. On the
international scene, as Charles
Guépratte mentioned, our
objective is to valorise our
expertise and expand our
partnership strategy.
Gustave Roussy is an Institute
that benefits from its territorial
development as well as its
international scope. These two
dimensions are combined in
a project which is ongoing at
an urban campus – the Cancer
Campus – which federates,
inside a bio park, activities
in research and in health
innovation, with numerous
partners like the AH-HP
and both public and private
research institutions.
Gustave Roussy and the
Cancer Sciences School, which
is linked to the Medical Faculty
of the Université Paris-Sud, is
at the heart of a network which
has both a local and a global
dimension, bringing together
cutting-edge expertise, a wide
range of skills, modern tools
and committed teams: it is
an excellent combination
to improve patient care.
CHARLES GUÉPRATTE
See
further
A GLOBAL PROBLEM_22
A GLOBAL MEMENTUM_24
THE SCIENTIFIC PROJECT
CANCER CAMPUS_25
THERAPEUTIC INNOVATIONS _26
PRECISION MEDICINE_28
SEE FURTHER
THE FIGHT AGAINST CANCER,
A GLOBAL PROBLEM
According to the latest WHO report, approximately
13 million new cases of cancer are recorded each year
throughout the world. Thanks to the research conducted,
increasingly innovative therapies are proven
to be effective.
A BETTER UNDERSTANDING
OF THE DISEASE
The considerable achievements of the research
projects conducted over the past few decades
have given us a better understanding of the
causes and development stages of different
types of cancer and how best to treat them. The
transformation of a healthy cell into a tumour
cell is a process involving several stages. The
shift from a precancerous lesion to a malignant
tumour is the result of interactions between
genetic factors, which are specific to the patient,
and external elements. The latter are divided into
three categories: physical carcinogens (e.g: ultraviolet radiation, ionising radiation…), chemical
(e.g.: asbestos, elements resulting from tobacco
smoke, aflatoxin, arsenic…) and biological (e.g.:
infections caused by certain viruses, bacteria
or parasites…). Another crucial parameter is
ageing. Cancer incidence increases with age, no
doubt due to the accumulation of specific risks
throughout a lifetime, in combination with a loss
of effective repair mechanisms.
AN INCREASINGLY PRECISE
CHARACTERISATION
The fight against cancer involves prevention, early
detection, disease management and research.
With early detection and adequate treatment, the
chance for cure is high for many types of cancer,
in particular some of those which are the most
widespread (breast cancer, cervical cancer, oral
cavity cancers and colorectal cancer).
Cancer treatment involves commonly a combination of one or more types of treatment – surgery,
radiotherapy or chemotherapy. The aim is to cure
the disease or to considerably prolong the patient’s
life while also improving his quality of life during
the treatment period and the “post-cancer” stage.
Another component currently is the in-depth study
of molecular characteristics of both the patient’s
genetic constitution and the abnormalities of his
tumour. Cancer research, in developed countries,
has changed in dimension. Technological advances
allow an increasingly precise characterisation of
tumours. In clinical research, new drugs and new
therapeutic approaches are shown to be effective
each year. Molecular medicine, also known as
personalised medicine or precision medicine, has
opened up significant new possibilities. Finally,
immunotherapy has recently become a very
promising field to be explored in depth.
For Gustave Roussy, pain management, psychological
support, accompanying activities and palliative care are
now crucial elements of treatment planning.
The basic research conducted at the Institute has,
in particular, enabled new mechanisms to be discovered
which allow the cell to repair its DNA. In translational
research new genetic, hereditary or acquired, mutations
which are predisposed to the development of cancer have
been discovered these past years.
CANCER WORLDWIDE
5 RISK FACTORS CAUSE
ALMOST 1/3 OF THE DEATHS
13%
global mortality rate
13 million
50%
new cases per year
of patients diagnosed with
cancer will be alive in 5 years
Smoking
22%
of the mortality by cancer
38% will be cured
MAIN TYPES OF CANCER IN THE WORLD
High body mass index
6% —Breast
458,000 deaths
9.1% — Liver
695,000 deaths
8% — Colorectal
608,000 deaths
9.7% — Stomach
736,000 deaths
Low fruit and vegetable
consumption
18% — Lung
1,370,000 deaths
7.6
6million
49.2% —
Other types
of cancer
3,733,000 deaths
deaths per
year
Lack of physical exercise
27%
Only
of low-income countries have plans
to combat cancer that have been
allocated a budget
2/3
More than
of the deaths occur in
developing countries
Alcohol consumption
Source: WHO – Last report GLOBOCAN.
SEE FURTHER
A GLOBAL MEMENTUM
BUILD A LEADING GLOBAL CANCER
RESEARCH CENTER
Gustave Roussy’s dynamism on the international scene
is illustrated by the influx of international patients,
the export of medical and medico-technical expertise and
know-how as a high value French product, as well as by
the commitment to its prestigious academic partnerships.
A GUSTAVE ROUSSY UNIT
IN THE UNITED ARAB EMIRATES
The Institute is deploying a unique global strategy
which has already borne fruit by the signature of a
cooperation agreement for the founding of a breast
cancer unit in Sharjah (United Arab Emirates).
Jointly piloted by the Sharjah University Hospital
and Gustave Roussy, this multidisciplinary unit,
designed on the basis of the model as used at
Gustave Roussy, aims to propose at all stages a
coordinated model treatment plan to patients.
It covers the quick diagnosis of breast lesions,
the elaboration of treatment plan, breast cancer
surgery – including oncoplastic surgery – and
chemotherapy or other systemic therapy, in
particular outpatient treatment. Intended to last
5 years, the unit will receive regular visits from
one of Gustave Roussy’s medical teams specialising in mammary pathology. Other cooperation
projects are ongoing, in particular in Kuwait and
Kazakhstan. Depending upon the geographical
location, they are concentrated on the creation
of specific specialized structures (for palliative
care, skin cancer, sarcoma…), operational planning, treatment planning, and also on teaching
programs in various oncologic disciplines and
clinical research.
* Signature in effect from the 31st March 2013.
ACCESS TO TREATMENT… BEYOND BORDERS
Gustave Roussy has always embraced a tradition
of welcoming foreign patients who have serious
medical problems. In order to facilitate their treatment and take cultural differences into account, an
international unit was created in 2011. A total of
900 patients from abroad came to the Institute in
2012 (5% of its global activity). For Gustave Roussy,
this activity provides additional revenues, which
have allowed it to invest in the acquisition of new
cutting edge equipments.
EXCELLENCE IN ACADEMIC PARTNERSHIPS
Gustave Roussy has a strong tradition of sharing
its knowledge and practices with the international
medical and scientific community. The third priority
of international development, the partnerships
with foreign centers, allow for the process to be
accelerated, for the benefit of patients. One such
example is an agreement signed with DKFZ,
the largest cancer research center in Europe
(Heidelberg, Germany). With Gustave Roussy, complementarity is built around 4 programs: paediatric
oncology, molecular epidemiology, immunology/
immunotherapy and personalised medicine. Seen
in the light of “Horizon 2020”, the future European
research programs (and its financing), setting up
this French/German partnership takes on a true
significance. Other recent partnerships include:
those nurtured with the Erasmus University
Medical Center (Rotterdam) concerning RAMAN
spectroscopy – an innovative method to the invasive border of tumors and to diagnose pigmented
lesions and melanoma, also with the Karolinska
Institute, the NKI (Amsterdam), the MD Anderson
Cancer Institute (Houston), and cofounder with
Gustave Roussy of the WIN Consortium.
CANCER CAMPUS:
A RESPONSE
TO ACCELERATE
INNOVATION IN
CANCER RESEARCH
GUSTAVE ROUSSY
AT THE CENTER OF
A TERRITORIAL, MEDICAL
AND SCIENTIFIC PROJECT
Launched in 2006, Cancer Campus aims
to develop a center for research and
innovation at Villejuif. Its objective will be
to create a biocluster, dedicated to the
fight against cancer, of international
stature.
T
back to 2006 when Cancer Campus was
founded with the idea of creating, around
Gustave Roussy, a scientific campus open
to companies specialising in life sciences and
health innovations, around a common basic infrastructure for research and training: laboratories,
biotech companies, imaging, medical engineering
and systems, cutting-edge IT and telemedicine.
In November 2011, the Bio Park was inaugurated at
Villejuif, the first step in the creation of the Cancer
Campus project.
The metro station Gustave Roussy on line 15 will
become operational in 2020 and will intersect with
line 14 (Orly Airport – Gare de Lyon) in 2027, which
will place the Institute at the very center of Grand
Paris.
SEE FURTHER
THERAPEUTIC INNOVATIONS,
A CLINICAL RESEARCH STUDY
OF GLOBAL SCOPE
As the leading center for clinical research in oncology with 24% of its patients included
in biomedical studies, Gustave Roussy is amongst the top 10 worldwide leaders in the field
of conducting early therapeutic trials, a feat well recognised by the ASCO (American Society
of Clinical Oncology) congress program committee in 2012.
T
plemented at
Gustave Roussyy are mainly conducted in the
field of drug development, imaging guided.
AUGMENT NEW DRUG DEVELOPMENT
PROGRAM
The research done with regard to drugs can be
divided into two areas: early testing (phases I and
II) and advanced trials (phases II randomised and
III). “Worldwide, the Institute is one of a handful of
establishments which are capable off implementing
useful precision medicine, that is, integrating not only
molecularr analysis of the tumour, but also recommending, accordingly, a drug which is adapted to its
particular characteristics”, emphasizes Professor
Jean-Charles So
Soria,, h
head
ad o
of the De
Department o
of
therapeutic innovations
novati
and
d early clinical trials.
tria
INTENSIFYING RESEARCH
In 2012, the phase I & II clinical trial activity
confirmed that Gustave Roussy is the leading
center in France for early therapeutic innovation.
With 57 phase I-II trials involving 524 patients,
Gustave Roussy carried out more than half of all
such activities in the 16 approved units for such
studies in France. These trials are either trials
conducted on all types of tumour, tumour-specific trials, haemato-oncology trials, or trials
with new drugs associated with radiotherapy.
The clinical drug development unit was extended
3 PHASES FOR THE CLINICAL TRIALS OVER 5 YEARS
In a randomised trial, the participants are divided randomly between two treatment arms.
PHASE I - II
RANDOMISED
PHASE II
100 to 300 patients
200 to 400 patients
with additional beds in 2012 and will become a
separate medical department in 2013. “Setting
up a department dedicated to therapeutic testing
not only reflects the importance of early testing in
clinical research at Gustave Roussy, it also bears
witness to a strong desire to strengthen bonds with
trial implementers, ‘organ’ committees as well
as the research teams and platforms”. Professor
Jean-Charles Soria continues: “in particular, we
are participating very actively in the development of
a new class of inhibiting agents, called FGFR, and
Gustave Roussy is the only center in the world to
have at its disposal their entire spectrum.”
PHASE III
500 to 2,000 patients
EVIDENCE OF PROGRESS
BY RANDOMISED TRIALS
(phases II randomised, and III)
A hallmark of 2012 was the reporting by
Gustave Roussy Investigators on a number
of major advances in the development of
new immunotherapies for melanoma,
therapeutic strategies for testicular
cancer, personalised treatments for
thyroid cancer and post-operative lung
cancer at the ASCO annual meeting in
Chicago in 2013.
Innovations
ON DIFFERENT FRONTS
The therapeutic innovations developed by
Gustave Roussy touch on numerous fields
including: microwave technology which
destroys tumours (alternative to surgery);
the development of new and high-precision
radiotherapy technologies reducing
secondary effects, and so-called “all-in”
surgery (complex surgical interventions that
can take up to 16 hours and involve a large
medical team with several surgeons).
SEE FURTHER
PRECISION MEDICINE,
A PERSONALISED APPROACH
TO CLINICAL REALITY
Personalised medicine, a major aspect of the Institute’s
strategic project, made significant progress in 2012. Studies
conducted by Gustave Roussy demonstrate that highthroughput analysis technologies which identify molecular
anomalies particular to a tumour, are now no longer reserved
for basic research and can be transferred to clinical practice.
Making tomorrow’s treatments available to a growing
number of patients is becoming a reality.
study of personalised medicine used against
breast cancer, promoted by UNICANCER. These
studies confirm that precision medicine may well
play an important role in the future, and affirm
that Gustave Roussy is at the forefront in this field,
internationally.
S
tandard therapeutic approaches have
resulted in todays situation where one
out of every two cancer patients still dies
as a result of his cancer. The aim of personalised medicine is to identify the anomalies
proper to each tumour and then to develop tests
for detecting them; patients identified as carrying
the anomaly can then be prescribed specific and
targeted treatment. Recently, important technological advances have allowed the implementation
of this innovative approach in clinical practice.
Gustave Roussy has created all necessary infrastructure and developed a number of clinical trials
in this domaine: promising results across two
major studies, in particular: MOSCATO, promoted
by Gustave Roussy, and SAFIR 01, a prospective
SOCRATE
THREE RESEARCH PROGRAMMES
FOR FUTURE CANCER STUDIES
Gustave Roussy was awarded the accolade “IRSC”
(Integrated Research Site for Cancer) by the National
Cancer Institute, in reference to its SOCRATE* project.
One of the SOCRATE programs concerns primarily
personalised medicine.
*
Stratified Oncology Cell DNA Repair And Tumor immune Elimination.
To find out
page 40
MOSCATO: ENCOURAGING RESULTS
The MOSCATO trial covers a large variety of
tumours, including: lung, head and neck, urogenital, cervical and gastro-intestinal cancers.
Presented at ASCO’s 49 th annual meeting,
MOSCATO uses high-throughput genomics as a
decision-making tool for targeted molecular treatments. Specifically, this trial accrued 129 patients
in nine months: in 112 a biopsy of their tumour was
obtained.To analyse the tumour DNA and to spot
the point mutations and chromosome aberrations,
two technologies were used: sequencing, using a
new-generation high-throughput sequencer and
comparative genomic hybridization.
A therapeutic target could be identified for 53 of the
patients (47%), of which 33 received a treatment
adapted to their molecular anomaly. Seven partial
responses to the treatment were observed, corresponding to a response rate of 21% which is higher
than the classical response rate for phase I trials
(5 to 10%). More and more patients are being
SAFIR 01
Targeted therapies
for breast cancer thanks
to molecular diagnosis
brought in to MOSCATO, in order to confirm initial
results: the goal is to enlarge the trial to cover
900 patients.
ALGORITHMS AND NEW GENERATION
TRIALS
Work is currently ongoing concerning decision-making algorithms. The goal is to create
an intelligent database, populated by billions of
patients, in order to be able to form the best treatment plans for each of them. With this in mind,
the bio-computing center has been bolstered by
recruiting international-level researchers and
purchasing some new equipment; these have all
been brought together in the brand new molecular
medicine building (building works started in 2012
and were completed in June 2013).
WINTHER
AN INNOVATIVE CLINICAL TRIAL
Launched in 2012, Winther is a clinical,
academic and international trial coordinated by
Gustave Roussy. It is the first clinical trial to
propose, to all patients in the study, a choice of
therapies, guided by personalised biological analysis.
Each of them is offered a personalised treatment
which has been based on a complete biological analysis.
A double biopsy of the tumour and of healthy tissue
of the organ of origin is taken from each patient, while
the complete genomic characteristics of the tumour,
modulated by those of the healthy tissue, guide the
choice of therapy which is discussed with the aid of
a bio-computing decision-making tool. The main
objective is to compare the progression-free survival
when a treatment suggested by biology is used,
to the progression-free survival when the last standard
treatment is prescribed. The European Community
has provided a subsidy to support this trial.
This acknowledgment by Europe is a measure
of the Winther trial’s scientific value – in particular,
its concept and methodology.
SAFIR 01 is a large prospective study in
metastatic breast cancer patients where the
choice of therapy is determined by a genomic
profile of a biopsy of a metastasis. The objective
is to identify a gene anomaly for which there is
a “targeted” drug available, or being developed,
which will act specifically on the cells which
contain this anomaly.
The study, conducted by the institute, reveals
that genomic profiles can be prepared daily
and on a large scale in clinical practice, and
demonstrates the importance of molecular
diagnosis for directing patients to targeted
treatment. It is an important step in the
implementation of personalised medicine.
In addition, gene sequencing allows for a better
understanding of the metastatic process.
The researchers are pursuing their work with
the launch, in 2013, of SAFIR 02, which aims to
prove the effectiveness of personalised
medicine in cancer treatment for patients
affected by lung or breast cancer. The
preliminary results of SAFIR 01 in 2012 were
promising and considered to be a major
achievement at the ESMO (European Society
for Medical Oncology) congress. Following their
updated presentation at the 49th ASCO congress,
SAFIR 01 was chosen for the “Best of ASCO,
ground-breaking studies” award.
25%
of the patients
present signs of effectiveness
Act
on...
CARE_32
RESEARCH_38
TEACHING_42
FUNDRAISING_46
ACT ON CARE
GIVING PATIENTS
THE BEST CHANCE
Providing quality patient care is Gustave Roussy’s primary
mission, and this consumes much of resources. Each day,
teams of doctors and care-givers devote their energy
to consultation, diagnosis and treatment of adults
and children.
T
welve clinical and medical-technological
departments and fourteen multidisciplinary
committees comprised of surgeons, medical oncologists, radiotherapists, radiologists
and pathologists specialising in organ pathology,
work together every day to provide optimal care.
Cutting-edge technology, laboratories and integrated research teams allow new therapies to be
proposed, and adapted, thereby offering patients
realistic chances of recovery. Special remedies
are employed in complex cases and for rare
tumours – pathologies which make up 20% of its
activity – and the Institute welcomes all types of
patients and treats all types of cancer.
CARE ACTIVITIES IN 2012
For the third consecutive year, Gustave Roussy
saw an increase in activity, as a result of a concerted effort from all of the Institute’s teams.
The number of patient consultations increased
by 1.3% (on 2011) with an increase of 4% in hospitalised patients (an increase of 5,688 patients).
With regard to hospitalisation services, the overall
occupancy rate – another key indicator for care
activities – went up to 90% in 2012 (88% in 2011).
Some departments saw a significant increase in
activity, the fruit of new approaches employed with
regard to patient care.
For example, the ambulatory care activity
exceeded the yearly targets and has increased by
6% with 2,238 additional hospital visits; this
increase is slightly greater for some of the other
departments including: the medical oncology
department (+5%), outpatient surgery (+6%) and
outpatient imaging (+29%).
Full hospitalisation activity is in line with objectives, with a growth of 2%, reaching 11% in cervical-facial oncology, 3% in medical oncology and
9% in radiotherapy hospitalisation.
PATIENTS ADMITTED TO HOSPITAL BY MALIGNANT TUMOUR SITES
DISCUSSED BY EACH TUMOUR BOARD
Breast 23.7%
Head&Neck 11.9%
Digestive 10.8%
Gynaecology 8%
Skin 7%
Haematology 6.7%
Paediatric 6.6%
Lung 6.6%
Urology 6.3%
Thyroid
and neuroendrocrine 4.7%
Sarcoma
and mesenchymal 4.2%
Neurology 1.8%
Early clinical trials
across tumor types 1.2%
Others 0.6%
The activity of interventional radiology (medical
imaging) increased by 7.4%, while the number of
patients and conventional radiology interventions
increased slightly. The total number of procedures
completed increased by 4%.
>>>
90%
(88% in 2011)
A positive development in the
hospitalisation services occupancy rate.
>>>
increase of 16.7% in procedures completed, due
to an increase in the number of psychologist
consultations (+23.1%) and follow-ups with a care
provider (+45.8%). Medical nutrition consultations
rose by 24.8% and dietician consultations by
37.5%.
AN INNOVATIVE TECHNOLOGICAL
PLATFORM FOR CARE SERVICES
2012 saw a number of major investments to keep
up to date with the developments in technical
equipment.
The diagnostic imaging platform received new,
sophisticated equipment beginning with the
acquisition of a second scanner, a best-of-class
model featuring dose-reduction algorithms and a
module for spectral and monochromatic analysis,
to obtain perfect organ contrast. In September
2012, a new MRI scanner was also put in operation, replacing the MRI 1.5T installed in 1998 and
revamped in 2005. The new MRI has a magnetic
field of 3 Tesla and a 70cm opening tunnel. A
second examining table has also been purchased,
so that children can be sedated and heavy patients
resuscitated. Other investments have also been
made throughout 2012 – in particular, thanks to
gifts and bequests: 1 Gamma Camera Discovery
NM 630 and 1 Solution Rapid-Arc for the Novalis
radiotherapy machine.
INNOVATIVE TECHNICAL PLATFORMS
• 14 operating theatres
• The largest interventional radiology suites
for oncology in Europe
• 1 MRI
• 2 scanners
• 10 ultrasound scanners
• 2 gamma-cameras
• 6 external beam accelerators
• 1 Novalis TX radiotherapy accelerator
2012 ACTIVITY
• Number of patient
consultations: +1.3%
• Number of hospitalised patients: +4%
• Ambulatory activity: +6%
• Overall hospital activity: +2%
• Interventional radiology activity: +7.4%
• Supportive care: +16.7%
To find out
gustaveroussy.fr
heading : annual reports
AN ORGANISATION TO HEIGHTEN
PERFORMANCE: OBJECTIVES AND MEANS
CONTRACTS (O.M.C)
Following a trial period in two departments – Medical
oncology and Radiotherapy – that is currently being
implemented, internal contractualisation reached an
important milestone in 2012 with a number of
departments drafting their own multi-year Contracts
defining objectives and means.
By these contracts, each party – clinical and medico-technological departments on the one hand
and general management on the other – undertakes to implement a three year departmental
project, setting out the establishment’s strategy.
This method of contractualisation entails setting up
a special body to manage means and take related
decisions. This method results in better management of the actual situation on the hospital floor,
since the necessary applications are implemented
with the contractualisation support service. In
2012, there were six professionals appointed to
delegated management positions for the twelve
departments. One of the benefits of these contracts
is that they improve patient service.
ACT ON CARE
RECONCILING CUTTING-EDGE
MEDICINE AND CARE:
“CARING DIFFERENTLY”
Gustave’s Roussy’s teams of doctors and care-givers ensure that patient care
always integrates the treatment of the cancer, the particular characteristics
of each pathology and of each patient as a person. This way of thinking
is reflected in the considerable progress that has been made in the very nature
of the care – programs for teenagers and young adults, same-day diagnosis –
as well as in the patient’s physical, psychological and social quality of life.
SUPPORTIVE CARE, ANOTHER PILLAR OF
THE CARE PROVIDED AT GUSTAVE ROUSSY
The Department of Supportive Care coordinates
all the care intended to improve the patients’
quality of life during the treatment and “post-cancer” phases: pain management, psychological
consultations and palliative care. Adopted in 2012,
the “Living with Cancer” program completes the
Supportive Care program and offers less conventional therapies based around four aspects of
care: well-being and self-perception (relaxation,
aesthetic care), artistic and cultural aspects
(music, poetry), adapted sports activities. The
activities implemented in the context of the “Living
with Cancer” program contribute to improving
one’s bodily image, damaged by illness and treatments, and can restore the patient’s self-confidence. These aspects form part of the overall
personalised care provided by the teams at
Gustave Roussy. They illustrate the “tailor-made”
nature of patient care which is considered to be
so fundamental at the Institute.
A PROGRAMME FOR ADOLESCENT
PATIENTS AND YOUNG ADULTS
In 2012, Gustave Roussy celebrated the 10th anniversary of the “Teenagers and Young Adults”
program, which is dedicated to the specialised
care provided for teenager and young adults with
cancer. At the pivotal age of 13-25 years old, these
patients don’t always have the same likelihood of
post-cancer recovery or life quality, depending on
whether they are treated in the adult oncology
or the paediatrics departments. This program
provided by Gustave Roussy relies on a mobile
transversal team placed under the medical
responsibility of a paediatrician and an adults’
doctor. It aims to provide equal access to care, a
good quality of life during and after the disease
and access to research protocols in order to
improve the chances of recovery. Adolescents are
hospitalised in a dedicated unit within the
Adolescent and Child Cancer Department. The
young adults are cared for within the Medical
Oncology Department, with a relaxation area
reserved for them.
>>>
>>>
This is completed by a job-search program for 15
to 25 year olds, an important step in helping them
overcome the physical and psychological effects
of cancer. This initiative is innovative: no other
center provides such care in France. Around 245
young cancer patients are monitored each year
by Gustave Roussy; 80 of these are new patients.
SAME-DAY DIAGNOSIS AND FAST-TRACK
PATIENT CONSULTATIONS
In 2004, Gustave Roussy was the first center in
France to introduce patient consultations which
diagnosed breast cancer in a day. Since then,
the Institute has extended this Anglo-Saxon
model to other types of cancer: cancers with a
long latency period between first diagnosis and
treatment. Time is of the essence in such cases
and a delay between the diagnosis and the start
of treatment can be crucial.
These same-day consultations are currently
offered for breast cancer and three other types
of cancer: thyroid tumours, ovarian tumours
and sarcomas.
The Institute has introduced thyroid cancer
diagnosis morning sessions for patients with
nodules, during which all the tests necessary
for the diagnosis are carried out (neck ultrasound, biopsy, blood test and, if necessary,
thyroid scan).
If necessary, this is followed by a meeting with a
surgeon and a date may be set for the operation.
In 2012, there were 8 to 10 such consultations
each week. A consultation with a gynaecological
surgeon is also available for suspicious ovarian
tumours: blood test, meeting with a surgeon
and then with an anaesthetist, meeting with a
dietician and a nutritionist, pelvic or colposcopy
MRI scans.
>>>
ACT ON CARE
>>>
There are many steps that can lengthen the diagnostic pathway and delay diagnosis and, ultimately,
have an impact on prognosis. Gustave Roussy, one
of three national reference centers for sarcoma
care, has eventually introduced an initial one-day
consultation for suspicious tumours.
This allows patients to be diagnosed and receive
tailored care: liver biopsy using ultrasound or
scanner and assessment. As a result, the risk of
relapse for abdominal sarcomas can be halved,
and reduced to less than 10% for limb sarcomas,
with only a 1% risk of amputation in the reference
centers.
In 2012, more than 500 new patients underwent
these multidisciplinary sarcoma consultations,
putting the Institute amongst the five most active
centers worldwide in this area.
FOREIGN PATIENTS: A TRADITION
OF WELCOME AND ACCESS TO CARE
Patients coming from abroad have been welcomed
at the Institute since the international unit was
founded in 2011; in 2012 almost 900 foreign
patients were treated, representing approximately
5% of the Institute’s activity. These foreign
patients, attracted by the high quality care, have
serious medical conditions requiring most often
complex cancer treatments.
They come to the Institute for medical care far
superior to that which they are offered in their
country of origin.
KEY CARE
UNIT FIGURES
• 47,000 patients of which
11,400 first visits
• 200,000 consultations
• 356 hospital beds
• 88 outpatient places
• 42,000 ambulatory visits
• 12,700 surgical procedures
• 7,200 radiotherapy sessions per year
• 75,000 chemotherapy
preparation sessions
CARE
HIGHLIGHTS 2012
THE FRENCH
NATIONAL
AUTHORITY
FOR HEALTH
Gustave Roussy received
the V2010 certificate,
in recognition of the quality
and security of health care
provided. This award caps
a long process that
commenced in 2010.
FOUNDING
OF THE THORACIC
ONCOLOGY INSTITUTE
GUSTAVE ROUSSY
QUALIFIED
for the “Culture
Culture and Health”
He
label, launched by the French
Regional
al Health Agenc
Agency and the General Management of
Cultural
ral Affairs, to en
encourage the use of art in hospitals.
GUSTAVE ROUSSY’S
HEALTH PROFESSIONALS
are trained in therapeutic education,
defined as all the advisory and learning
activities which engage patients and help
them live better with cancer. Therapeutic
education is a national priority which has
been integrated into the Hospital, Patient,
Health and Territory Law 2 and is also
included in the Institute’s mission statement.
at the initiative of Gustave Roussy
and the Marie Lannelongue Surgical Center.
It will be a first in France, and the objective
is to offer a comprehensive care service
to patients with thoracic cancers.
THE CHILD
AND TEENAGER
CANCER DEPARTMENT
restructured its department,
one aspect of which involves
outreach procedures aimed
at getting parents and volunteers
involved. The goal is to create
a structure tailored to young
patients with long-term monitoring.
In order to finance the works,
a fundraising campaign (Poussons
les murs) was launched.
The project starts in 2013.
ELECTRONIC
MEDICAL TREATMENT RECORD,
the treattment part of the Electronic Medical Record, entered
the param
meterisation phase. Shared tools which will improve
data safety,
y, coordination and the traceability. This major
revamp of th
he Institute’s computer systems is expected
to be deployed
ed in 2013.
ACT ON RESEARCH
PROMOTE RESEARCH
AS A DRIVER OF INNOVATION
Within Gustave Roussy, all the types of expertise
necessary for developing cutting-edge cancer research
are brought into play. They are based on the principle
of integrated research which encompasses basic
research, clinical research and, between the two,
translational research.
I
t is the guarantee of continuity between
research and care which favours diagnostic and
therapeutic progress, as well as the efficient
transfer of the fruits of progress to patients.
Gustave Roussy’s research is organised around
three elements: clinical research, accredited
research (INSERM and CNRS units) carried out
by IICRV (the Institute of Integrated Cancer
Research at Villejuif), and the shared technological platforms.
Researchers and clinicians work together to
deepen their knowledge and implement therapeutic innovations which will be useful to patients. The
research at Gustave Roussy is based around a
number of strategic priorities. Included amongst
these are:
• personalised medicine (or molecular medicine),
which aims to prove the effectiveness of the concept of biology and image-guided treatment;
• early testing, to develop new anticancerous
agents and their biomarkers;
• tumour immunology and immunotherapy;
• DNA repair;
• haematology/stem cells;
• health technology assessment (HTIA): with the
goal of evaluating the psycho-social and mediccal-economical impact of innovations in cancer
trea
eatment.
CLINICAL RESEARCH: PROMISING RESULTS
With one in four patients included in a biomedical
study in 2012, Gustave Roussy has become a
national and international reference with regard
to clinical trials. At the national level, only 11%
of cancer patients are included in clinical trials
and in many countries this percentage is only
around 5%, Gustave Roussy registered a 25%
inclusion rate in 2012, which was 10% more than
in 2011. Thus 2,813 people treated for a malignant tumour at the Institute benefited last year
from the most innovative diagnostic and therapeutic measures, and contributed to 322 biomedical research projects. This is a very significant
figure, and it represents the willingness of the
entire Institution to enable patients to benefit
from the most promising strategies available.
Gustave Roussy has boosted its ability to run its
own trials (20% of studies) and attract industrial
partners (accounting for 50% of studies). As
regards organizing and running trials, the
Institute demonstrated its abilities in 2012 by a
number of striking results/achievements:
• the ESTIMABLE trial led to improved care for
thyroid cancer patients;
• COU-AA-302, a large, multicentric international
phase III trial (involving 151 centers in 12 countries) established the potential interest of a new
drug associated with the common treatment of
metastatic hormone refractory prostate cancer;
• the MOSCATO trial, uses high-throughput
genomics as a decision-making tool for targeted
molecular treatment, has encouraging preliminary results, suggesting that high-throughput
molecular analysis of tumour DNA can enable
therapeutic targets to be repaired in almost 50%
of patients.
IMPROVE ACCESS TO INNOVATIVE
MOLECULES
Thanks to SITEP – renamed the Department of
Therapeutic Innovations and Early Clinical Trials –
the number of patients included in phase I trials
has considerably increased (22% of trials) >>>
PLATFORMS
>>>
and Gustave Roussy has become a preferred
partner for phase I trials involving both adults and
children. In 2012, a total of 524 patients were
included in the phases I and II trials, a welcome
increase on 2010 and 2011, with just 216 and 316
respectively. One of Gustave Roussy’s missions is
to offer patients, whose treatment has failed, fast
access to promising drugs that have not yet
received Marketing Authorization. Early testing is
becoming an indispensable pillar for the implementation of personalised medicine.
COMMITTING TO RESEARCH FOR
PERSONALISED CANCER TREATMENTS
The personalised medicine program – or molecular medicine – was launched to steer the use of
innovative therapies by the analysis of biomarkers
and images of the patient’s tumour.
The Institute has made significant investments in
this area in recent years, such as the construction
of a new research building dedicated to molecular
medicine, at a cost of €13.5 M, for current and
future research teams. The construction of this
building was launched in 2012.
RESOURCES
AVAILABLE FOR RESEARCH
The development of platforms reflects
Gustave Roussy’s desire to propose services
shared by accredited research and clinical
research, for medical-researchers inside and
outside the Institute. The creation in 2012 of the
Biocomputing platform and the developments to
the imaging and cytometrics platform reflect this
general movement.
Biocomputing platform
In 2012, the reorganisation of the bio-computing
services made it possible to introduce new services
such as analysing large volumes of data coming
from next generation sequencing (NGS), which
requires a major calculating infrastructure. Basic
research groups, as well all the clinical trial investigators can use it, since the sequencing is carried
out by the laboratory for translational research.
Cellular imaging
The imaging and cytometrics platform (ICP) at
Gustave Roussy ensures that there is a link
between basic research done on imaging and
clinical application of this research: this is a rare
asset. Equipped with more than fifteen latest-generation machines, this technological platform
provides services in three main areas: cytometry
(analysis and sorting of cells), cellular imaging
(microscopy) and small animal imaging. In 2012,
the platform participated in research projects
aiming to provide a better understanding in real
time of the mechanisms governing the development of tumours. In a larger sense, the platform
is increasingly requested for basic, translational
and clinical research program interface
>>>
developments.
• 29 research groups across 13 units
• 270 researchers: researchers, clinicians and post-docs
• 300 ongoing clinical studies, of which more than 50 are
supported by Gustave Roussy
• More than 1,300 international scientific publications (125 IF>10)
• €60 M funding from the Institute’s overall budget
• More than €53 M funding from external resources
• €50 M in research contracts
ACT ON RESEARCH
>>>
MAJOR RESEARCH PROGRAMS
Three years of work were required to structure the
main research programs which will, in part, shape
the research plan at Gustave Roussy for the next
five years. As with the “Révolution Cancer*” program, which has already raised almost €10 M
through donations, these new programs finance
the Institute’s main research priorities in a number
of ways, and impact our momentum greatly.
MMO
The research topics of the program Molecular
Medecine in Oncology cover personalised medicine, immunotherapy, Induced Pluripotent Stem
Cells (IPS) – an alternative to embryonic stem cells
– as well as the medico-economic study of personalised medicine. Costing €11.8 M, this project
is piloted by Professor Éric Solary. Five new
research groups and two extra technological
platforms have been brought on board for this
purpose. This program will improve the
Biocomputing and genomics infrastructures.
SOCRATE
The NCI (National Cancer Institute: INCa) has
awarded Gustave Roussy the title “ICRS”
(Integrated Cancer Research Site “SIRIC”), for
the SOCRATE project, and has allocated €3.35 M
to it. This project aims to facilitate the transformation from empirical cohort medicine to
biology-guided medicine. The first part, dedicated to DNA repair and to radiobiology, should
enhance our understanding of the molecular
medicine involved in maintaining genetic stability
and allow the development of new diagnostic,
prognosis and therapeutic tools.
NEW BASIC
RESEARCH GROUPS
Starting in 2012, Natixis has committed, alongside
Gustave Roussy, to support the creation and installation
of three new basic research groups over three years.
Thus in December 2012, the first team, headed by
Dr Jean-Luc Perfettini, was established to research
“Cell death and Senescence” linked to radiotherapy
treatment. Two other groups were formed soon thereafter,
headed up by Dr Fanny Jaulin, researching the causes of
formation and dissemination of colon cancer metastases,
and Dr Mehdi Khaled, specialised in melanoma research.
The second part concerns anti-tumour immunologyy and is expected to facility the development
of therapeutic vaccinations, in particular. The final
part is entirely dedicated to personalised medicine
and individual treatments, according to the
tumour’s molecular anomalies.
“Fondation Philanthropia”
Created by the Lombard Odier & Cie bank to
facilitate private donations, the “Fondation
Philanthropia” has decided to support innovative
approaches in the fight against cancer by donating
to 3 main programs run by Gustave Roussy:
• €2.42 M over four years dedicated to the development of a biocomputing algorithm to help
therapeutic decision-making in personalised
medicine;
• €1 M over four years for health technology
assessments (HTA) regarding socio-economic
aspects of cancer and the modelling of a new
patient treatment plans adapted for more chronic
cancer cases and adapted for the increase in
personalised treatments;
• €2 M allocated to the “excellent cancer path ‘Fondation Philanthropia’” implemented within the
Cancer Sciences School, aiming to train ten young
doctors or pharmacists in new clinical cancer jobs
and cancer research.
PACRI – Paris Alliance of Cancer Research
Institute
PACRI is one of two projects selected to as part of
an investment in “University Hospitals for Cancer
Centers” which aims to spawn international centers of excellence. PACRI favours new synergies
between the actors of basic, translational and
clinical oncology in the Paris region. By allowing
the mutualisation of technologies and research
platforms and encouraging an improved integration of genomics, epi-genomics and cellular
biology data, this program will contribute to the
assessment of new therapeutic plans to improve
the patients’ quality of life throughout the treatment period. Gustave Roussy has contributed
€2.5 M – out of a total of €10 M – to PACRI’s
funding.
>>>
fundraising campaign “Révolution Cancer” which began in 2010
and will be completed in 2013.
€5.4 M
donated by the
“Fondation Philanthropia”
PATENTS
Gustave Roussy’s patents:
tomorrow’s care
B
>>>
PARTNERSHIPS
The fight against cancer involves a multidisciplinary and collaborative approach. Researchers,
practitioners and industry have all partnered up
with the Institute to develop new therapeutic
strategies, focused on the patient.
On the academic front, close links have been
established in France with the Université
Paris-Sud, and in particular with its Faculty of
Medicine, the ENS Cachan, Génopôle d’Évry and
the CEA (Atomic Energy Commissioner). In the
context of Cancéropole Île-de-France – of which
Gustave Roussy is a founding member –, healthy
partnerships exist with AP-HP, the Curie Institute,
IUH Saint-Louis and the Pasteur Institute. The
same network dynamic exists on an international
level, based around specific research programs:
• The DKFZ (Heidelberg): for paediatrics/cerebral
tumours, immunology, molecular epidemiology
and functional imaging.
• Erasmus University (Rotterdam): for the RAMAN
spectroscopy program.
• The MD Anderson Center (Houston): for the
WINTHER trial in personalised medicine.
y regularly registering new patents
through its subsidiary company
“Gustave Roussy Transfert”, the Institute
transforms its research into breakthroughs
benefiting its patients. In 13 years,
Gustave Roussy Transfert (which used to be
“IGR&D”) has registered more than 130 patent
families worldwide: biomarkers, molecules,
medical apparatus, therapy procedures,
software…
The 2012 “vintage” has turned out to be very
rich, especially in three thematic areas:
immunogenic cell death (stimulation of the
immune system to help destroy tumours),
circulating tumour cells (cells detached from
primary tumours, which are then tracked,
allowing the cancer to be characterised and the
treatment validated) and cellular cannibalism
(an elimination mechanism which could be used
to neutralise tumours using healthy cells).
Gustave Roussy Transfert is also involved in
the industrial implementation of these findings.
For that, the entity explores and communicates
these patents (through publications,
conferences, direct contact…) in order to
encourage industrial partners to develop
and commercialise the technologies which
will be used in tomorrow’s cancer studies.
The royalties from these patents are then
returned to the inventors and to the research
labs.
The fight against cancer requires a considerable
amount of scientific research, which itself implies
partnerships with pharmaceutical companies or
other private businesses. Based on the translational research concept, public-private partnerships guarantee the continuity between research
and care, so that therapeutic innovations can be
of direct benefit to cancer patients as quickly as
possible. In April 2012, Gustave Roussy and Sanofi
announced a partnership for clinical research,
destined to facilitate access to new drugs inspired
by the “molecular portrait” of the patients’ tumours.
ACT ON TEACHING
THE CANCER SCIENCES SCHOOL
ANTICIPATES THE REVOLUTIONS
IN CANCER STUDIES
Along with Treatment and Research, Teaching is one
of Gustave Roussy’s three core missions. Sharing
knowledge and training in cancer professions
is deeply anchored in the Institute’s culture; this takes
place at the Bicêtre Faculty of Medicine at the Université
Paris-Sud.
C
reated in 2012, the Cancer Sciences School
brings together Gustave Roussy’s teaching
activities and the Université Paris-Sud. An
essential actor in cancer training at the
university, 90% of the teaching is provided by
highly-qualified teaching staff who carry out their
clinical activities and research at Gustave Roussy,
as well as numerous other teachers from the
Faculties of Medicine, Pharmacy, Sciences and
Law-Economics-Management at Paris-Sud, the
top-ranking university in France.
The objective is to train 500 new professionals per
year (doctors, pharmacists, nurses, researchers,
scientists, engineers, care givers), in degree
programs or training which leads to a qualification
but not a degree. Equally, creating new professions in various areas, from basic and clinical
research to care and the accompaniment of
ill people, is considered important and is in line
with the Cancer Plan. Faced with unprecedented
therapeutic innovations, the Cancer Sciences
School is developing a new teaching model based
on the principles of cancer care: global, transversal and multidisciplinary.
The teaching courses comprise several
components:
• theoretical: physical or virtual classes;
• practical: immersion in the clinical departments
or laboratories, online seminars;
• contributive: sharing experiences, contributory
online sessions, constructive.
>>>
“FONDATION PHILANTHROPIA”
“Path to excellence
in cancer studies”
>>>
The Cancer Sciences School complements the
Faculty of Medicine and Gustave Roussy’s system
of training, by bringing together the majority of
academic and clinical research conducted at the
Université Paris-Sud, in collaboration with the
regional, national and international networks
already in place.
EDUCATION
The school for learning
The acquisition of oncology expertise is the result
of an education mixing theoretical knowledge with
clinical practice or research. The lectures and accompanying tutorials form the foundations of the
Cancer Sciences School.
The e-school for sharing
Digital technology has provided opportunities for
enriching learning tools and consolidating knowledge acquired through e-learning, social network
skills and the exceptional Images Center which
includes rooms equipped with networks, medical
imaging networks, databases of molecular, tissue
and dermatological pictures, and video, computer
graphics and illustration databases.
The d-school for innovating
Oncology is a science marked by recent breakthroughs and huge possibilities. The Cancer
Sciences School contributes by organising the
conditions of co-creation which allow students,
teachers and patients to collectively imagine new
solutions for training and teaching.
>>>
A
t the end of 2012, the program
“Path to excellence in cancer studies –
‘Fondation Philanthropia’” was founded,
with the intention of training ten future talents
in worldwide cancer studies.
The project, to which the “Fondation
Philanthropia” has contributed €2 M, aims to
trains ten young doctors or pharmacists
possessing considerable potential, in the
innovations and new professions of clinical
cancer studies and research.
More specifically, a dual degree will be
created at the Cancer Sciences School
-Université Paris-Sud and Gustave Roussy,
offering ten student interns tailored training
as part of a science thesis aimed at scientific
innovation and research in cancer studies.
The training, which will be both theoretical
and practical, will take place at Gustave Roussy,
with individual coaching by a senior doctor
or researcher at the Institute. During their
thesis, the interns will familiarise themselves
with personalised medicine.
From October 2013, these new PhD students
will attend the Doctorate School of cancer
studies, which is part of the Cancer Sciences
School, and which welcomes more than
200 PhD students in a three-year cycle.
ACT ON TEACHING
TRAINING
HIGHLIGHTS 2012
CREATION
OF A DOZEN
MASTER’S CLASSES
for industrial health managers.
CREATION
OF TWO UNIVERSITY DEGREES
“Coordination in establishments and networks in cancer studies”
and “economic assessment of health products”.
DEVELOPMENT
OF E-LEARNING MODULES
• in interventional radiology,
• in intensive and acute care,
• in oncology/haematology.
DEVELOPMENT
OF MASTER’S
• in Clinical Sciences,
• in Cancer Care.
DOCUMENTARY RESOURCES
↗ Access to more than 4,800 medicine,
science and technology publications online
↗ More than 400 e-books
↗ Bibliographic databases: PubMed,
Medline, Scopus, ISI Web Of Knowledge,
Faculty of 1000, Cochrane Library
↗ Collection of video documents for surgery,
radiotherapy and cancer which can be
watched onsite
ACCESSIBILITY
BY EXTRANET
at the medical
and scientific library.
IMMEDIATELY OPERATIONAL FOR STUDENTS: A REGULAR
ASSESSMENT OF THE RESOURCES SYSTEM FOR TEACHING
RESPONSIVE TO NEEDS
IN NEW CANCER PROFESSIONS
DISSEMINATE NEW KNOWLEDGE
AND PRACTICES
Personalised
medicine
Center of knowledge
in cancer sciences
Home support
for patients
Modelling
new professions
Pharmaceutical industry
First-aid training
specific to cancer
TEACHING RESOURCES
40
2,800
and Master’s classes
(nurses, engineers, researchers
and doctors)
seminars
students trained per year
214
40,000
- 14 practitioners/doctors
in pharmacy,
- 115 non-university
practitioners/doctors
in medicine,
- 85 non-practitioners
per year (initial and/or
in-house training)
employees
hours of training
17
university
degrees
26
university teachers:
- 14 “PUPH(1)”, 1 “PU(2)”
and 2 “MCU(3)” at
the Faculty of Medicine,
- 1 “PUPH” and 1 “MCU”
at the Faculty of Pharmacy,
- 3 “PU” and 1 “MCU”
at the Faculty of Science,
- 1 “PU” at ENS Cachan
(1) PUPH: University Professor and Hospital Doctor.
(2) PU: University Professor.
(3) MCU: University Lecturer.
ACT ON FUNDRAISING
GENEROSITY IN ACTION
TO SUPPORT INNOVATION
IN TREATMENT AND RESEARCH
Gustave Roussy, a collective-interest health establishment,
is authorised to receive donations and bequests, as is its
research foundation (the “Fondation Gustave Roussy”).
Public generosity, year after year, has become essential
for financing the innovations developed at Gustave Roussy,
for supporting excellence in research and for ceaselessly
improving the quality of care provided.
T
hanks to the ever reliable support of donators
and sponsors, Gustave Roussy was able to
commence, in 2012, construction of a new
research building dedicated to molecular
medicine, to completely renovate the paediatric
department and to acquire cutting-edge imaging
equipment.
The confidence of donators and sponsors allows
the Institute to keep funding innovation and create
the cancer care of tomorrow, all in name of the fight
against cancer.
INCREASED RESOURCES RAISED FROM
THE PUBLIC
Donations
More than 20,000 new donators gave money to
Gustave Roussy in 2012 for the first time. A total
of €7,059,916 was raised in 2012, which represents
a 6% increase on 2011. Although the number of
donations decreased slightly in 2012, this has been
compensated by an increase in the average amount
donated.
€16,152,793
in funds raised
from the public
€17,911,717
cash outflows financed
by the funds raised
from the public
Bequests
The value of the bequests received is determined
by the total amounts collected throughout 2012
and by the annual variation of bequest stocks on
31 December 2012. In 2012, bequests received
rose to €9,002,574, an increase of 31.8% in comparison to 2011. This high increase is essentially due to the higher number received, twice the
number received in 2011 (more than €5 M extra
receipts than in 2011).
Other revenues linked to public generosity
These financial revenues have been realised
thanks to the investment of donations and bequests in ad hoc bank accounts (investment in
the context of management mandates in monetary instruments).
Since 1 January 1998, financial revenue has been
incorporated with bequeathed funds.
In 2012, financial revenues stood at €90,000, a
decrease of €45,000 in view of the low yield on
money markets during the year.
>>>
>>>
USE OF RESOURCES
The total amount of cash outflows financed by
resources raised from the public in 2012 was
€17,911,717. Total cash outflows for 2012 increased to €7,409,551, a 2.1% increase on 2011.
Social missions
Social missions comprise actions realised directly
by Gustave Roussy in France, the payment made
by the Institute to the “Fondation Gustave Roussy”
and the international mission of the Franco-African
Paediatric Oncology Group. Social missions implemented in 2012 stood at €4,152,267 (a decrease
of 0.5% in comparison to 2011).
• Actions realised directly by Gustave Roussy in
France concern financing basic research activities
conducted by the Institute (€1,000,000), direct
support to medical teams through targeted donations (€1,085,799), improvement of the patient
reception and quality-of-life through dedicated
accounts destined to finance innovative projects
to receive patients and fund social service activities
(€48,174).
• The yearly payment to the “Fondation Gustave
Roussy” stood at €2 M in 2012. Since 2005, following a decision of Gustave Roussy’s Board of
Directors, an annual donation originating from
donations and bequests is transferred to the
Foundation to help finance research. These donations are then assigned to research projects by
multiannual agreement. Six multiannual agreements were signed in 2012.
THANKS TO DONATIONS AND BEQUESTS
Many actions have been
accomplished in 2012
S
election of investments realised thanks
to donations and bequests in 2012:
• Construction of a modular building dedicated
to molecular medicine: €13.5 M over two
years (2012 and 2013). It is dedicated to
research and teaching. This was partly
funded (€3.5 M) by donations and bequests
in 2012.
• Financing research: €1 M was assigned to
basic research teams and €2 M was paid to
the “Fondation Gustave Roussy”, for
developments and human resources in the
communal technological platforms, for
development, strategic and administrative
support for research and for international
collaboration programs. In total, more than
€3 M of donations and bequests were
ploughed back into research.
• Acquisition of an MRI machine: €1.8 M.
• Acquisition of a Discovery 750 HD SCANNER:
€1.03 M.
• 1 Gamma Camera Discovery NM 630:
€406,000.
• 1 Solution Rapid-Arc for the Novalis
radiotherapy machine: €417,000.
• The international mission realised by the
Franco-African Paediatric Oncology Group is
destined to train doctors in French-speaking
African countries to treat cancer and to facilitate
their access to drugs. The payment to this international mission accounted for a bit more than
€18,000 in 2012.
>>>
€2,133,973
actions realised directly
by Gustave Roussy in France in 2012
ACT ON FUNDRAISING
IT HAPPENED IN 2012!
FUNDRAISING EVENTS
ODYSSÉA
In October 2012, 26,000 people participated in the
Odysséa walk/run in Paris to support the fight
against breast cancer. Gustave Roussy will use the
money they raised for research into personalised
treatments for breast cancer – €320,000.
“SHOPPING SOLIDAIRE”
The 4th version of “Shopping solidaire”, organised
by Spring Nation (selling branded products
at a discount), allowed funds to be collected
for research into personalised treatments
for breast cancer – €65,000.
“L’ÉTOILE DE MARTIN”
The association, set up to support paediatric
cancer research and to contribute to the
well-being of ill children, conducted
numerous fundraising events in 2012 and sent
Gustave Roussy’s paediatric department a
cheque for €270,000.
THE ASSOCIATION
“IMAGINE FOR MARGO”
Rallying against child cancer, the association organised the first
version of the run “Children without cancer” in September 2012;
the funds raised were donated to the ITCC consortium (Innovative
Therapies for Children with Cancer), which is chaired
by Gustave Roussy – €200,000.
“LES AMIS
DE MIKHY”
The association donated money
to Gustave Roussy to support
projects aiming to counter the pain
experienced by hospitalised children
and those accompanying them –
€40,000.
PATRONAGE
LE CRÉDIT MUTUEL
“TOGETHER AGAINST MELANOMA”
MEETING OF SPONSORS
AND RESEARCHERS
THE LION’S CLUBS
In 2012 the bank committed
to supporting the head of the
dermatology department, Dr Caroline
Robert, team’s projects in the fight
against melanoma. The bank will
enlist the help of its network for five
yyears through
g the generous
g
project
p
“Together against melanoma”.
At the end of February 2012,
a hundred sponsors helped with
the presentation of objectives
and results for the research teams
that they support and visited their
laboratories.
Mobilised around their association
“Tulips against cancer”, the Lion’s
Clubs actively support numerous
projects of the paediatrics
department, as well as an
immunotherapy research
program directed by Professor
Laurence Zitvogel.
Created in 2005, the purpose of this research
foundation, recognised to be of public utility, is to source additional financial support to
quicken the pace of the research conducted at
Gustave Roussy.
“RÉVOLUTION CANCER” 2010-2013
In 2010, the “Fondation Gustave Roussy” considerably reinforced its fundraising initiative
by targeting sponsoring businesses and large
donators. To this end, it launched the campaign
“Révolution Cancer 2010-2013”, an ambitious
fundraising program which aims to raise €10 M
over three years to finance research into personalised medicine. As of the end of 2012, €1 M
remained to be collected.
€2,8 M
Donations collected
by the Foundation in 2012.
HIGHLIGHTS OF THE FOUNDATION IN 2012
Natixis supported the program
The Charter Committee renewed its
“TRUSTED DONATION”
accreditation with the “Fondation Gustave Roussy” for another
three years, following a favourable report given by the certification
body in 2012.
“RÉVOLUTION
CANCER”
under a sponsorship agreement,
by directly helping three young
research teams – directed by
Dr Perfettini, Dr Jaulin
and Dr Khaled.
To find out
page 40
The Swiss foundation,
“FONDATION
PHILANTHROPIA”
GAVE A VERY LARGE SPONSORSHIP
AMOUNTING TO €5.4 M TO THE
“FONDATION GUSTAVE ROUSSY”,
for the years to come.
This will be used to finance three projects favouring
the development of personalised medicine in the
areas of research, treatment and training.
To find out
VÉRONIQUE WEILL,
Director of AXA Group operations,
JOINED THE FOUNDATION’S
SUPERVISORY BOARD
AS A QUALIFIED PERSON.
Véronique Weill is a member of AXA’s Executive
Committee and also sits on the Scientific Board
of the AXA Research Fund.
page 43
Financial
results
2012 ACTIVITY_52
AUDITORS REPORT
ON THE ANNUAL ACCOUNTS_53
2012 BALANCE SHEET_54
2012 PROFIT AND LOSS ACCOUNT_56
OVERALL ANNUAL USE
OF RESOURCES_58
USES OF DONATIONS
AND BEQUESTS_59
FINANCIAL RESULTS
2012 ACTIVITY
AND RESULTS
In terms of hospital activity, 2012 marks a significant
change to Gustave Roussy’s development model: after
three years of focusing on further developing the range
of treatments, the current emphasis is on maintaining
the level of success achieved whilst keeping overall
spending under control.
A
lthough an active recruitment policy has
been pursued over the past three years,
resulting in a labour force increase of
6.4% and 245 new hires under permanent
contracts, corresponding largely to the recruitment procedure designed by the employment
arbitration committee, Gustave Roussy nevertheless almost broke even in 2012, with a deficit
of just €547,201 for a overall budget of €290 M
(0.19% of revenue).
This result compares reassuringly favourably with
the deficit of almost €2.5 M in the 2012 budget.
This €1.9 M improvement came from increased
revenue from all sources (Health Insurance activity: +€3 M; Paying and foreign patients: +€2.6 M;
Other income: +€2.1 M). Expenses have risen at
a lower rate (€5.8 M), with €3.5 M allocated to
provisions for risks and extraordinary items which
were not budgeted. In view of this result, the capacity for self-financing rose to €13.9 M. Annual
resources rose to €29.9 M, thus overtaking the
total annual outflows (€29.4 M) due to major investments (€21.5 M) and other spending (€7.9 M,
of which €5.9 M was used in the repayment of
loans). The contribution to working capital thus
rose to €493,646. At the same time, the negative
working capital requirements improved by more
than €14 M (a sharp increase in research credits).
Consequently, ready cash flow grew by €14.5 M.
As in previous years, the financial balance ratios
have improved; this improvement concerns both
the financial independence ratio (56.7%) and the
debt to revenue ratio (31.6%), which are moving
gradually towards the criteria established by
decree.
While there have been few changes to hospitalisation circumstances, the development of the technological platform continued, with an increase in
outpatient surgery and an update to the imaging
platform (acquisition of a new scanner and a
latest-generation MRI) in particular.
The number of patients hospitalised increased
by 4% with 5,688 extra patients treated. The
number of hospitalisations is thus in line with
objectives; an increase of 2% has been registered in comparison to 2011, amounting to 323
extra hospitalisations. More specifically: outpatient procedures performed exceeded the target
by 4%, increasing by 6% (+2,238 stays); there was
a decrease of 2% in radiotherapy activity (1,734
sessions less), as a result of the partial functioning of the Varian, following a breakdown, and the
use of the Novalis.
Thus, PMSI(1) activity exceeded targets by 2%,
and the 2011 result by 7%, thanks to a number of
walk-ins in line with what was anticipated for full
and outpatient hospitalisations, and a PMCT(2)
close to the forecast.
All the research components have considerably
developed. Gustave Roussy won tenders for structured projects including the Site of Integrated
Cancer Research (SICR-SOCRATE) with an €8 M
budget over 5 years, and a grant of €5.4 M accorded by the “Fondation Philanthropia” at the
end of the year. This success motivated the Institute to propose that a new infrastructure, dedicated to research, be built. Consequently, it was
decided that a 6,000m² building, dedicated to
personalised medicine, will be built at a cost of
merely €13.5 M.
(1) PMSI: Program for the Medicalisation of Informations Systems.
(2) PMCT: Average Burden of Cases Treated.
+4%
Increase in the number
of patients hospitalised
AUDITOR’S REPORT
ON THE ANNUAL ACCOUNTS
Financial year ending 31 December 2012
To whom it may concern,
In accordance with our appointment by your Board of Directors, we hereby report to you for the year ending 31 December 2012 on:
- the audit of Gustave Roussy’s annual accounts, as attached to this report;
- the justification of our assessments;
- the specific verifications and information required by law.
The annual accounts have been drawn up by the Board of Directors. Our role is to express an opinion on these accounts,
based on our audit.
1- Opinion based on the annual accounts
We have conducted our audit in accordance with the professional standards applicable in France; these standards require that due diligence be practiced in order to obtain a reasonable assurance that these annual accounts contain no
significant anomalies.
An audit includes examining, on a test basis or through other selection methods, evidence supporting the amounts and
disclosures in the annual accounts. It also involves assessing the accounting principles used, any significant estimates
made and the overall presentation of the financial statements. We believe that our audit has provided us with sufficient
relevant information on which to base our opinion.
We certify that the annual accounts are, in accordance with accounting rules and principles, regular and sincere and
give a faithful idea of the result of the past fiscal year and of the financial situation and assets of the Institute at the end
of this fiscal year.
2- Justification of our assessments
Pursuant to the provisions of article L. 829-9 of the Commercial Code, relating to the grounds for our assessment, we
hereby inform you that our assessments focused on the appropriateness of the accounting principles applied and on
the reasonableness of the significant estimates chosen, in particular regarding the fixed assets, the receivables and the
provisions for liabilities and charges.
3- Specific verifications and information
We have also conducted, in accordance with the professional standards applicable in France, specific verifications required by the law.
We have no comments or reservations about the fair presentation and consistency of the annual accounts with the information given in the “Balance Sheet and the 2012 Financial Account” and in the documents addressed to the members
of the Board of Directors on the financial situation and annual accounts.
Paris La Défense, 30 April 2013
KPMG Audit
KPMG S.A.
Jean Gatinaud
Associate
FINANCIAL RESULTS
2012 BALANCE SHEET
Fiscal year ending 31 December 2012
Assets
2012
(in euros)
2011
Depreciations
and write-offs
Gross
Net
Net
FIXED ASSETS
Intangible fixed assets
- start-up costs
- costs of studies and research and development
- concessions and similar rights, patents, licences,
trademarks & processes, similar rights and assets
0.00
0.00
0.00
0.00
6,954,047.43
3,640,689.82
3,313,357.61
3,099,196.04
11,383,921.14
8,248,105.27
3,135,815.87
2,763,114.80
Tangible fixed assets
- land
6,387,508.90
2,986,570.10
3,400,938.80
3,407,236.69
259,376,871.11
115,705,956.30
143,670,914.81
148,110,638.90
- technical installations, plant and equipment
95,381,271.68
66,899,205.04
28,482,066.64
27,736,402.94
- other tangible fixed assets
28,152,688.09
21,837,544.35
6,315,143.74
6,574,933.44
9,522,574.14
0.00
9,522,574.14
1,750,144.75
212,722.45
0.00
212,722.45
212,722.45
15,344.90
0.00
15,344.90
15,344.90
2,000,000.00
0.00
2,000,000.00
0.00
21,807.15
0.00
21,807.15
17,307.15
419,408,756.99
219,318,070.88
200,090,686.11
193,687,042.06
- raw materials
2,212,555.25
0.00
2,212,555.25
2,276,32
327.60
- other supplies
424,421.46
0.00
424,421.46
446,6
,638.65
- products
104,811.71
0.00
104,811.71
104
04,993.71
7,126,443.88
0.00
7,126,443.88
8,167,671.24
167 671 24
- buildings
- tangible fixed assets in progress
Financial fixed assets
- investments and receivables related to investments
- other fixed securities
- loans
- others
TOTAL I
CURRENT ASSETS
Inventories and works in progress
- other inventories
Operating receivables
- patients and consultants
- pivot fund
- other third-party payers
9,792,177.28
506,589.92
9,285,587.36
6,145,727.05
27,960,352.77
0.00
27,960,352.77
31,469,214.30
1,178,603.67
0.00
1,178,603.67
967,832.20
Miscellaneous receivables
13,121,723.07
0.00
13,121,723.07
13,440,903.78
Investment securities
26,195,349.02
0.00
26,195,349.02
17,063,684.26
2,907,977.01
0.00
2,907,977.01
639,792.51
410,695.09
0.00
410,695.09
508,256.87
91,435,110.21
506,589.92
90,928,520.29
81,231,042.17
510,843,867.20
219,824,660.80
291,019,206.40
274,918,084.23
Liquid assets
Prepaid expenses
TOTAL II
OVERALL TOTAL
Liabilities
(in euros)
2012
2011
EQUITY
Contributions and association funds
Reserves
40,532,124.47
40,532,124.47
2,586,409.90
2,586,409.90
-29,289,509.46
-30,647,531.80
Retained earnings
Accumulated deficit
Fiscal year result (surplus or deficit)
-547,200.94
1,358,022.34
Investment grants
46,124,222.15
38,391,927.73
TOTAL I
59,406,046.12
52,220,952.64
10,648,486.45
10,334,085.21
PROVISIONS FOR LIABILITIES AND CHARGES
Provisions for liabilities
Provisions for charges
TOTAL II
0.00
200,000.00
10,648,486.45
10,534,085.21
93,564,839.31
94,081,339.26
LIABILITIES
Financial debts
- loans from credit institutions
- loans and miscellaneous financials debts
- credit lines
5,635.00
6,900.00
0.00
3,055,813.62
Accounts payable
- advances received
- supplier payables and
nd related accounts
- patient advances an
nd down-payments
0.00
0.00
25,146,229.46
23,414,276.12
4,148,255.80
4,902,425.64
- pivot fund/health iinsurance advance
11,984,656.46
14,727,062.46
- tax and social de
ebts
12,642,576.47
12,319,250.84
Miscellaneous liabilities
- liabilities in respect of fixed assets and related accounts
- other miscellaneous liabilities (pending donations and legacies,
accounts payable for research and teaching)
- deferred income
9,255,724.90
5,126,744.24
62,813,912.53
53,718,726.27
1,402,843.90
810,507.93
TOTAL III
220,964,673.83
212,163,046.38
OVERALL TOTAL
291,019,206.40
274,918,084.23
FINANCIAL RESULTS
2012 PROFIT AND LOSS ACCOUNT
BY NATURE
(in euros)
2012
2011
OPERATING REVENUE
Sales of medicines
Revenue from auxiliary activities
Revenue from hospital activity
Operating grants and investments
Reversals of write-offs, depreciations and provisions
Transfers of operating costs
Other everyday management revenue
TOTAL I
7,434,856.82
4,691,962.90
12,768,101.77
10,523,554.40
233,108,854.04
226,986,311.29
15,104,533.46
13,764,920.40
2,541,553.71
4,036,173.89
0.00
60,085.60
7,923,298.67
6,723,881.34
278,881,198.47
266,786,889.82
50,808,866.50
47,130,859.57
OPERATING COSTS
Purchases held in inventory; other supplies
Inventory changes
86,171.54
303,247.69
Cost of materials and supplies not held in inventory
18,674,013.32
16,920,296.80
External services and other external services
41,303,948.67
37,861,682.26
10,848,290.38
10,311,164.24
17,981.00
13,651.00
Remunerations and other personnel-related costs
94,270,942.16
88,923,218.94
Social security costs
42,431,548.58
39,978,330.98
18,915,307.28
18,125,340.08
TAXES, DUTIES AND ASSIMILATED PAYMENTS
On remunerations
Others
PERSONNEL COSTS
DEPRECIATION CHARGES AND PROVISIONS
On fixed assets: depreciation charges and amortisation
On current assets: provision for impairment
For liabilities and charges: depreciation charges and provisions
OTHER CHARGES OF EVERYDAY MANAGEMENT
TOTAL II
1 – OPERATING INCOME (I-II)
38,380.47
105,280.59
2,655,954.95
5,935,410.14
827,958.05
158,723.75
280,879,362.90
265,767,206.04
-1,998,164.43
1,019,683.78
(in euros)
2012
2011
FINANCIAL REVENUE
Investments and other financial fixed assets and other receivables
83,967.79
48,938.63
1,590.33
1,442.47
Reversals of provisions
0.00
0.00
Transfers of financial charges
0.00
0.00
Exchange gains
0.00
0.00
Net income from sales of marketable securities
0.00
0.00
85,558.12
50,381.10
Financial income from investments, discounts obtained and other financial revenue
TOTAL III
FINANCIAL CHARGES
Depreciation, impairment and provisions
0.00
0.00
3,661,694.30
3,915,120.31
Exchange losses
0.00
35.16
Net losses from disposals of marketable securities
0.00
0.00
3,661,694.30
3,915,155.47
2 – FINANCIAL INCOME (III-IV)
-3,576,136.18
-3,864,774.37
3 – OPERATING INCOME BEFORE TAX AND EXCEPTIONAL ITEMS (I-II+III-IV)
-5,574,300.61
-2,845,090.59
Interests and assimilated charges
TOTAL IV
EXTRAORDINARY INCOME
On management operations
- current financial year
- previous financial years
On capital operations
Reversals on provisions and depreciations
TOTAL V
168,535.40
75,911.76
2,067,856.77
3,733,376.26
4,627,144.73
3,363,153.62
0.00
0.00
6,863,536.90
7,172,441.64
EXTRAORDINARY CHARGES
On management operations
- current financial year
- previous financial years
On capital operations
51,556.75
4,016.22
1,782,398.58
2,919,494.34
0.00
39,969.84
Depreciation, impairment and provisions
- regulated provisions
0.00
0.00
2,481.90
5,848.31
TOTAL VI
1,836,437.23
2,969,328.71
4 – EXTRAORDINARY INCOME (V-VI)
5,027,099.67
4,203,112.93
- depreciation charges and extraordinary write-offs
Company Tax
0.00
0.00
5 – TOTAL REVENUE (I+III+V)
285,830,293.49
274,009,712.56
6 – TOTAL CHARGES (II+IV+VI)
286,377,494.43
272,651,690.22
-547,200.94
1,358,022.34
SURPLUS OR DEFICIT (5 – 6)
FINANCIAL RESULTS
OVERALL ANNUAL
USE OF RESOURCES (on 31 December 2012)
(in euros)
USES
Uses of N =
income
statement
Allocation
by use of
resources
raised by
the public on N RESOURCES
Report on the resources raised from
the public which have not been allocated
or used at the start of the fiscal year
1 – Resources raised by the public
1.1. Donations and bequests received
- Individual donations
which have not been allocated
- Individual donations
which have been allocated
- Bequests and other gifts
which have not been allocated
- Bequests and other gifts
which have been allocated
1.2. Other income linked to public
generosity
1 – Social missions
1.1. In France
- Activities carried out directly
240,496,042.40
240,477,748.52
237,978,133.86
4,152,267.52
4,133,973.64
2,133,973.64
- Basic and clinical research
46,882,365.76
2,085,799.51
186,460,183.22
48,174.13
4,635,584.88
0.00
2,499,614.66
2,000,000.00
2,000,000.00
499,614.66
0.00
18,293.88
0.00
18,293.88
2,000,000.00
0.00
0.00
18,293.88
0.00
18,293.88
2,675,356.19
2,675,356.19
2,675,356.19 2 – Other private funds
2,675,356.19 Gustave Roussy Foundation
- Patient care and quality of life
- Teaching
- Payments to other organisms
operating in France
- Gustave Roussy Foundation
- Gustave Roussy Transfer (IGR&D)
- Other organisms
1.2. Abroad
- Activities carried out directly
- Payments to a central organ
or other organisms
2 – Cost of fundraising
2.1. Costs of fundraising from calls to
general public generosity
2.2. Costs of fundraising from private
funds
2.3. Charges due to researching grants
and public tenders publics
3 – Operating costs
I. Total use of resources for
the financial year recorded
on the profit and loss account
II. Provisions expenses
III. Projected uses of allocated funds
IV. Surplus in the financial year’s
resources
V. TOTAL
VI. Share of the gross fixed asset
acquisitions for the financial year
financed by resources raised from
the public
VII. Neutralisation of depreciation
charges of fixed assets financed from
the date of the first application of the
Regulation by resources raised from
the public
VIII. Total cash outflows financed by
the resources raised form the public
0.00
0.00 Gustave Roussy Transfer (IGR&D)
0.00
0.00 Other bodies
50,972,627.56
294,144,026.15
2,694,335.42
8,196,040.97
305,034,402.54
581,927.56 3 – Grants and public tenders
4 – Other Income
7,409,551.27 I. Total resources for the financial year
recorded on the profit and loss account
II Reversals of provisions
III. Report on the resources allocated
but not used from previous financial
years
IV. Change in funds dedicated which
have been raised by the public
(cf. see table of dedicated funds)
V. Shortfall in the financial year’s
resources
VI. TOTAL
10,502,166.57 VI. Total cash outflows financed by the
resources raised from the public
Remaining resources raised from the
public which were not allocated or used
by the end of the fiscal year
17,911,717.84
Resources
collected on
N = income
statement
Monitoring
of resources
raised by
the public
and used on N
11,646,943.45
16,152,793.18
16,062,491.20
4,882,745.72
16,152,793.18
16,062,491.20
4,882,745.72
2,177,170.98
2,177,170.98
9,002,574.50
9,002,574.50
0.00
0.00
90,301.98
90,301.98
28,462,802.43
2,946,179.29
321,963.63
25,194,659.51
210,346,490.87
47,530,762.35
302,492,848.83
2,541,553.71
305,034,402.54
16,152,793.18
17,911,717.84
9,888,018.79
USES OF DONATIONS AND BEQUESTS
Justification of uses in 2012 and report in 2013
(in euros)
Biomedical
equipment
Seed
projects
IT &
Subtotal
furnishings Investments
Research
Foundation
Basic
research
Others
(GFAOP)
Total
WITHDRAWALS
Previous amounts earmarked
but not spent (balance on
31/12/2011)
2,606,995.44
0.00
0.00
2,606,995.44
0.00
0.00
0.00
2,606,995.44
Amounts used in 2012
4,717,951.18
5,232,277.45 31,477.49
9,981,706.12
2,000,000.00
1,000,000.00 18,293.88 13,000,000.00
TOTAL AMOUNTS
AVAILABLE FOR USE
7,324,946.62
5,232,277.45 31,477.49 12,588,701.56
2,000,000.00
1,000,000.00 18,293.88 15,606,995.44
SPENDING BREAKDOWN OF DONATIONS AND BEQUESTS FOR 2012
Gamma camera
406,180.40
406,180.40
406,180.40
Scanner
1,030,060.46
1,030,060.46
1,030,060.46
MRI 3T
1,826,306.21
1,826,306.21
1,826,306.21
416,635.48
416,635.48
416,635.48
1,559,229.08
1,559,229.08
1,559,229.08
Solution Rapidarc / Novalis
Other Biomedical uses
Building for molecular medicine
3,500,000.00
3,500,000.00
3,500,000.00
Works for the extension
of the MRI and scanner
1,050,561.67
1,050,561.67
1,050,561.67
Other works
681,715.78
Other fixed assets
TOTAL SPENDING
681,715.78
31,477.49
5,238,411.63
681,715.78
31,477.49
2,000,000.00
1,000,000.00 18,293.88
3,049,771.37
5,232,277.45 31,477.49 10,502,166.57
2,000,000.00
1,000,000.00 18,293.88 13,520,460.45
BALANCE TO BE CARRIED
OVER IN N+1
Earmarked but not spent
as of 31/12/2012
2,086,534.99
0.00
0.00
2,086,534.99
0.00
0.00
0.00
2,086,534.99
GUSTAVE ROUSSY’S PUBLICATIONS
SYNTHESIS OF GUSTAVE ROUSSY’S
INTERNATIONAL PUBLICATIONS
In 2012, Gustave Roussy’s teams were behind 124 international publications
which had an impact factor of greater than 10, and 45 of which were higher
than 20.
Publications with an impact factor higher than 20 in 2012
IF>20 (2012)
Cell
1
Lancet
9
Lancet Oncology
15
Nature Genetics
4
Nature Immunology
2
Nature Medicine
1
Nature Reviews Drug Discovery
1
Nature Reviews Molecular Cell Biology
1
New England Journal of Medicine
10
Science
1
TOTAL
45
Publications with an impact factor included between 10 and 20 in 2012
2012
Ar c hives of I nter na l Medic ine
1
Blood
16
C a ncer & Meta s ta s is r eviews
1
C ir c ul a tion R es ea r c h
2
C ur r r ent Opinion in I m m unol ogy
1
EMBO Journal
2
E MB O Mol ec ul a r Medic ine
2
E ur opea n H ea r t J our na l
1
Gut
3
J our na l of Al l er gy a nd C l inica l I m m unol ogy
1
J our na l of C l inica l I nves tiga tion
2
J our na l of C l inica l Oncol ogy
27
J our na l of E xper im enta l Medic ine
2
J our na l of the N a tiona l C a ncer I ns titute
2
Molecular Cell
4
Nano Letters
1
N a tur e R eviews C l inica l Oncol ogy
6
N a tur e S tr uc tur a l a nd Mol ec ul a r B iol ogy
1
Plos Medicine
2
P r oceedings of the N a tiona l Aca dem y of S c iences U S A
1
Tr ends in I m m unol ogy
1
T OTAL
79
International publications with an impact factor between 5 and 10 in 2012
In 2012, Gustave Roussy's teams have published 415 international
publications with an impact factor between 5 and 10.
To find out
See the full list of these
publications page 72.
INTERNATIONAL COMPARISON
Over the past 10 years, Gustave Roussy has produced 7,060 publications.
There were 21.38 citations per article (Web of Knowledge database).
France
Publications
Dates
H-index
Gustave Roussy
7,060
2003-2012
150
Institut Curie
4,896
2003-2012
118
Institut J Paoli-Calmettes
1,820
2003-2012
69
Centre Léon Bérard
2,034
2003-2012
77
Publications
Dates
H-index
Dana-Farber Cancer Institute
17,892
2003-2012
273
Memorial Sloan-Kettering
Cancer Center
20,433
2003-2012
222
M. D. Anderson Cancer Center
38,552
2003-2012
198
Publications
Dates
H-index
Gustave Roussy
7,060
2003-2012
150
Institut Curie
4,896
2003-2012
118
Netherlands Cancer Institute,
Amsterdam
4,148
2003-2012
144
Royal Marsden Hospital,
London
2,375
2003-2012
89
Istituto Nazionale Tumori,
Milan
2,602
2003-2012
58
Christie Hosp & Holt Radium
Inst, Manchester
2,767
2003-2012
65
Hospital Vall d’Hebron,
Barcelona
6,383
2003-2012
116
753
2003-2012
56
United States
Europe
Daniel Den Hoed Cancer
Center, Rotterdam
BY GUSTAVE ROUSSY
With an impact factor higher than 20 (45 publications in 2012)
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
K. T. Flaherty, C. Robert, and D. Schadendorf, “The authors reply : MEK Inhibition in BRAF-Mutated Melanoma,”
New England Journal of Medicine, vol. 367, no. 14, p. 1365, [2012].
J. Baselga, I. Bradbury, H. Eidtmann, S. Di Cosimo, E. De Azambuja, C. Aura, H. Gómez, P. Dinh, K. Fauria, V. Van
Dooren, G. Aktan, A. Goldhirsch, T.-W. Chang, Z. Horváth, M. Coccia-Portugal, J. Domont, L.-M. Tseng, G. Kunz,
J. H. Sohn, V. Semiglazov, G. Lerzo, M. Palacova, V. Probachai, L. Pusztai, M. Untch, R. D. Gelber, and M. PiccartGebhart, “Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label,
multicentre, phase 3 trial,” in Lancet, [2012], vol. 379, no. 9816, pp. 633–640.
F. Boissier, A. Khalil, L. Chalumeau-Lemoine, F.-X. Lescure, and A. Parrot, “Rash diagnosis of blood
expectoration.,” Lancet, vol. 379, no. 9821, p. 1170, [Mar. 2012].
J. Bourhis, C. Sire, P. Graff, V. Grégoire, P. Maingon, G. Calais, B. Gery, L. Martin, M. Alfonsi, P. Desprez, T. Pignon,
E. Bardet, M. Rives, L. Geoffrois, N. Daly-Schveitzer, S. Sen, C. Tuchais, O. Dupuis, S. Guerif, M. Lapeyre,
V. Favrel, M. Hamoir, A. Lusinchi, S. Temam, A. Pinna, Y. G. Tao, P. Blanchard, and A. Aupérin, “Concomitant
chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally
advanced head and neck carcinoma (GORTEC 99-02): An open-label phase 3 randomised trial,” The Lancet
Oncology, vol. 13, no. 2, pp. 145–153, [2012].
J. Bourhis, Y. G. Tao, P. Blanchard, C. Sire, and A. Aupérin, “Absent benefit of accelerated concomitant
chemoradiotherapy - Authors’ reply,” The Lancet Oncology, vol. 13, no. 4, pp. e136–e137, [2012].
J.-F. Brasme, M. Morfouace, J. Grill, A. Martinot, R. Amalberti, C. Bons-Letouzey, and M. Chalumeau,
“Delays in diagnosis of paediatric cancers: A systematic review and comparison with expert testimony in lawsuits,”
The Lancet Oncology, vol. 13, no. 10, pp. e445–e459, [2012].
S. Corbacioglu, S. Cesaro, M. Faraci, D. Valteau-Couanet, B. Gruhn, A. Rovelli, J. J. Boelens, A. Hewitt, J. Schrum,
A. S. Schulz, I. Müller, J. Stein, R. Wynn, J. Greil, K.-W. Sykora, S. Matthes-Martin, M. Führer, A. O’Meara,
J. Toporski, P. Sedlacek, P. G. Schlegel, K. Ehlert, A. Fasth, J. Winiarski, J. Arvidson, C. Mauz-Körholz, H. Ozsahin,
A. Schrauder, P. Bader, J. Massaro, R. D’Agostino, M. Hoyle, M. Iacobelli, K.-M. Debatin, C. Peters, and G. Dini,
“Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation:
An open-label, phase 3, randomised controlled trial,” Lancet, vol. 379, no. 9823, pp. 1301–1309, [2012].
L. Couronné, C. Bastard, and O. A. Bernard, “TET2 and DNMT3A mutations in human T-Cell lymphoma,” New
England Journal of Medicine, vol. 366, no. 1, pp. 95–96, [2012].
F. de Vathaire, C. El-Fayech, F. F. Ben Ayed, N. Haddy, C. Guibout, D. Winter, C. Thomas-Teinturier, C. Veres,
A. Jackson, H. Pacquement, M. Schlumberger, M. Hawkins, I. Diallo, and O. Oberlin, “Radiation dose to the
pancreas and risk of diabetes mellitus in childhood cancer survivors: a retrospective cohort study.,” The Lancet
Oncology, vol. 13, no. 10, pp. 1002–10, [Oct. 2012].
J. Delyon, C. Mateus, and T. Lambert, “The authors reply : More on Hemophilia A Induced by Ipilimumab,” New
England Journal of Medicine, vol. 366, no. 3, p. 281, [Jan. 2012.]
M. Ducreux, D. Malka, and J.-P. Pignon, “Chemotherapy for colorectal cancer - Authors’ reply,” The Lancet
Oncology, vol. 13, no. 1, [2012].
M. Fassnacht, M. Terzolo, B. Allolio, E. Baudin, H. Haak, A. Berruti, S. Welin, C. Schade-Brittinger, A. Lacroix,
B. Jarzab, H. Sorbye, D. J. Torpy, V. Stepan, D. E. Schteingart, W. Arlt, M. Kroiss, S. Leboulleux, P. Sperone,
A. Sundin, I. Hermsen, S. Hahner, H. S. Willenberg, A. Tabarin, M. Quinkler, C. De La Fouchardière,
M. Schlumberger, F. Mantero, D. Weismann, F. Beuschlein, H. Gelderblom, H. Wilmink, M. Sender, M. Edgerly,
W. Kenn, T. Fojo, H.-H. Müller, and B. Skogseid, “Combination chemotherapy in advanced adrenocortical
carcinoma,” New England Journal of Medicine, vol. 366, no. 23, pp. 2189–2197, [2012].
K. T. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe, M. Milhem, L. V Demidov, J. C. Hassel, P. Rutkowski,
P. Mohr, R. Dummer, U. Trefzer, J. M. G. Larkin, J. Utikal, B. Dreno, M. Nyakas, M. R. Middleton, J. C. Becker,
M. Casey, L. J. Sherman, F. S. Wu, D. Ouellet, A.-M. Martin, K. Patel, and D. Schadendorf, “Improved survival with
MEK inhibition in BRAF-mutated melanoma,” New England Journal of Medicine, vol. 367, no. 2, pp. 107–114, [2012].
K. T. Flaherty, C. Robert, D. Schadendorf, and M. S. Grp, “The autors reply : Early Surgery for Infective Endocarditis,”
New England Journal of Medicine, vol. 367, no. 14, p. 1365, Oct. [2012].
L. Galluzzi, O. Kepp, and G. Kroemer, “Mitochondria: Master regulators of danger signalling,” Nature Reviews
Molecular Cell Biology, vol. 13, no. 12, pp. 780–788, [2012.]
L. Galluzzi, L. Senovilla, L. Zitvogel, and G. Kroemer, “The secret ally: Immunostimulation by anticancer drugs,”
Nature Reviews Drug Discovery, vol. 11, no. 3, pp. 215–233, [2012].
S. Gouy, P. Morice, F. Narducci, C. Uzan, J. Gilmore, H. Kolesnikov-Gauthier, D. Querleu, C. Haie-Meder, and
E. Leblanc, “Nodal-staging surgery for locally advanced cervical cancer in the era of PET,” The Lancet Oncology, vol.
13, no. 5, pp. e212–e220, [2012].
[18]
[19]
N. Hamajima, K. Hirose, K. Tajima, T. Rohan, C. M. Friedenreich, E. E. Calle, S. M. Gapstur, A. V Patel, R. J. Coates,
J. M. Liff, R. Talamini, N. Chantarakul, S. Koetsawang, D. Rachawat, Y. Marcou, E. Kakouri, S. W. Duffy, A. Morabia,
L. Schuman, W. Stewart, M. Szklo, P. F. Coogan, J. R. Palmer, L. Rosenberg, P. Band, A. J. Coldman, R. P. Gallagher,
T. G. Hislop, P. Yang, S. R. Cummings, K. Canfell, F. Sitas, P. Chao, J. Lissowska, P. L. Horn-Ross, E. M. John,
L. M. Kolonel, A. M. Y. Nomura, R. Ghiasvand, J. Hu, K. C. Johnson, Y. Mao, V. Beral, D. Bull, K. Callaghan,
B. Crossley, A. Goodill, J. Green, C. Hermon, T. Key, I. Lindgard, B. Liu, K. Pirie, G. Reeves, R. Collins, R. Doll,
R. Peto, T. Bishop, I. S. Fentiman, S. De Sanjose, C. A. Gonzalez, N. Lee, P. Marchbanks, H. W. Ory, H. B. Peterson,
P. Wingo, K. Ebeling, D. Kunde, P. Nishan, J. L. Hopper, H. Eliassen, S. Hankinson, V. Gajalakshmi, N. Martin,
T. Pardthaisong, S. Silpisornkosol, C. Theetranont, B. Boosiri, S. Chutivongse, P. Jimakorn, P. Virutamasen,
C. Wongsrichanalai, A. Neugut, R. Santella, C. J. Baines, N. Kreiger, A. B. Miller, C. Wall, A. Tjonneland,
T. Jorgensen, C. Stahlberg, A. T. Pedersen, D. Flesch-Janys, N. Hakansson, J. Cauley, I. Heuch, H. O. Adami,
I. Persson, E. Weiderpass, C. Magnusson, J. Chang-Claude, R. Kaaks, M. McCredie, C. Paul, D. C. G. Skegg,
G. F. S. Spears, M. Iwasaki, S. Tsugane, G. Anderson, J. R. Daling, J. Hampton, W. B. Hutchinson, C. I. Li, K. Malone,
M. Mandelson, P. Newcomb, E. A. Noonan, R. M. Ray, J. L. Stanford, M. T. C. Tang, D. B. Thomas, N. S. Weiss,
E. White, A. Izquierdo, P. Viladiu, E. O. Fourkala, I. Jacobs, U. Menon, A. Ryan, H. R. Cuevas, P. Ontiveros,
A. Palet, S. B. Salazar, N. Aristizabal, A. Cuadros, L. Tryggvadottir, H. Tulinius, E. Riboli, N. Andrieu, A. Bachelot,
M. G. Le, A. Bremond, B. Gairard, J. Lansac, L. Piana, R. Renaud, F. Clavel-Chapelon, A. Fournier, M. Touillaud,
S. Mesrine, N. Chabbert-Buffet, M. C. Boutron-Ruault, A. Wolk, G. Torres-Mejia, S. Franceschi, I. Romieu,
P. Boyle, F. Lubin, B. Modan, E. Ron, Y. Wax, G. D. Friedman, R. A. Hiatt, F. Levi, K. Kosmelj, M. Primic-Zakelj,
B. Ravnihar, J. Stare, A. Ekbom, G. Erlandsson, W. L. Beeson, G. Fraser, J. Peto, R. L. Hanson, M. C. Leske,
M. C. Mahoney, P. C. Nasca, A. O. Varma, A. L. Weinstein, M. L. Hartman, H. Olsson, R. A. Goldbohm, P. A. van den
Brandt, D. Palli, S. Teitelbaum, R. A. Apelo, J. Baens, J. R. de la Cruz, B. Javier, L. B. Lacaya, C. A. Ngelangel, C. La
Vecchia, E. Negri, E. Marubini, M. Ferraroni, M. C. Pike, M. Gerber, S. Richardson, C. Segala, D. Gatei, P. Kenya,
A. Kungu, J. G. Mati, L. A. Brinton, M. Freedman, R. Hoover, C. Schairer, R. Ziegler, E. Banks, R. Spirtas, H. P. Lee,
M. A. Rookus, F. E. van Leeuwen, J. A. Schoenberg, G.-I. S., R. Selmer, L. Jones, K. McPherson, A. Neil, M. Vessey,
D. Yeates, K. Mabuchi, D. Preston, P. Hannaford, C. Kay, S. E. McCann, L. Rosero-Bixby, Y. T. Gao, F. Jin, J.-M. Yuan,
H. Y. Wei, T. Yun, C. Zhiheng, G. Berry, J. Cooper Booth, T. Jelihovsky, R. MacLennan, R. Shearman, A. Hadjisavvas,
K. Kyriacou, M. Loisidou, X. Zhou, Q.-S. Wang, M. Kawai, Y. Minami, I. Tsuji, E. Lund, M. Kumle, H. Stalsberg,
X. O. Shu, W. Zheng, E. M. Monninkhof, N. C. Onland-Moret, P. H. M. Peeters, K. Katsouyanni, A. Trichopoulou,
D. Trichopoulos, A. Tzonou, K. A. Baltzell, A. Dabancens, L. Martinez, R. Molina, O. Salas, F. E. Alexander,
K. Anderson, A. R. Folsom, M. D. Gammon, B. S. Hulka, R. Millikan, C. E. D. Chilvers, F. Lumachi, C. Bain,
F. Schofield, V. Siskind, T. R. Rebbeck, L. R. Bernstein, S. Enger, R. W. Haile, A. Paganini-Hill, R. K. Ross, G. Ursin,
A. H. Wu, M. C. Yu, M. Ewertz, E. A. Clarke, L. Bergkvist, G. L. Anderson, M. Gass, M. J. O’Sullivan, A. Kalache,
T. M. M. Farley, S. Holck, O. Meirik, and A. Fukao, “Menarche, menopause, and breast cancer risk: Individual
participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies,” The
Lancet Oncology, vol. 13, no. 11, pp. 1141–1151, [2012].
K. B. Jacobs, M. Yeager, W. Zhou, S. Wacholder, Z. Wang, B. Rodriguez-Santiago, A. Hutchinson, X. Deng, C. Liu,
M.-J. Horner, M. Cullen, C. G. Epstein, L. Burdett, M. C. Dean, N. Chatterjee, J. Sampson, C. C. Chung, J. Kovaks,
S. M. Gapstur, V. L. Stevens, L. T. Teras, M. M. Gaudet, D. Albanes, S. J. Weinstein, J. Virtamo, P. R. Taylor,
N. D. Freedman, C. C. Abnet, A. M. Goldstein, N. Hu, K. Yu, J.-M. Yuan, L. Liao, T. Ding, Y.-L. Qiao, Y.-T. Gao, W.P. Koh, Y.-B. Xiang, Z.-Z. Tang, J.-H. Fan, M. C. Aldrich, C. Amos, W. J. Blot, C. H. Bock, E. M. Gillanders, C. C. Harris,
C. A. Haiman, B. E. Henderson, L. N. Kolonel, L. Le Marchand, L. H. McNeill, B. A. Rybicki, A. G. Schwartz,
L. B. Signorello, M. R. Spitz, J. K. Wiencke, M. Wrensch, X. Wu, K. A. Zanetti, R. G. Ziegler, J. D. Figueroa, M. GarciaClosas, N. Malats, G. Marenne, L. Prokunina-Olsson, D. Baris, M. Schwenn, A. Johnson, M. T. Landi, L. Goldin,
D. Consonni, P. A. Bertazzi, M. Rotunno, P. Rajaraman, U. Andersson, L. E. B. Freeman, C. D. Berg, J. E. Buring,
M. A. Butler, T. Carreon, M. Feychting, A. Ahlbom, J. M. Gaziano, G. G. Giles, G. Hallmans, S. E. Hankinson,
P. Hartge, R. Henriksson, P. D. Inskip, C. Johansen, A. Landgren, R. McKean-Cowdin, D. S. Michaud, B. S. Melin,
U. Peters, A. M. Ruder, H. D. Sesso, G. Severi, X.-O. Shu, K. Visvanathan, E. White, A. Wolk, A. Zeleniuch-Jacquotte,
W. Zheng, D. T. Silverman, M. Kogevinas, J. R. Gonzalez, O. Villa, D. Li, E. J. Duell, H. A. Risch, S. H. Olson,
C. Kooperberg, B. M. Wolpin, L. Jiao, M. Hassan, W. Wheeler, A. A. Arslan, H. B. Bueno-De-Mesquita, C. S. Fuchs,
S. Gallinger, M. D. Gross, E. A. Holly, A. P. Klein, A. Lacroix, M. T. Mandelson, G. Petersen, M.-C. Boutron-Ruault,
P. M. Bracci, F. Canzian, K. Chang, M. Cotterchio, E. L. Giovannucci, M. Goggins, J. A. H. Bolton, M. Jenab, K.T. Khaw, V. Krogh, R. C. Kurtz, R. R. McWilliams, J. B. Mendelsohn, K. G. Rabe, E. Riboli, A. Tjønneland, G. S. Tobias,
D. Trichopoulos, J. W. Elena, H. Yu, L. Amundadottir, R. Z. Stolzenberg-Solomon, P. Kraft, F. Schumacher, D. Stram,
S. A. Savage, L. Mirabello, I. L. Andrulis, J. S. Wunder, A. P. García, L. SierrasesÃ maga, D. A. Barkauskas,
R. G. Gorlick, M. Purdue, W.-H. Chow, L. E. Moore, K. L. Schwartz, F. G. Davis, A. W. Hsing, S. I. Berndt, A. Black,
N. Wentzensen, L. A. Brinton, J. Lissowska, B. Peplonska, K. A. McGlynn, M. B. Cook, B. I. Graubard, C. P. Kratz,
M. H. Greene, R. L. Erickson, D. J. Hunter, G. Thomas, R. N. Hoover, F. X. Real, J. F. Fraumeni Jr., N. E. Caporaso,
M. Tucker, N. Rothman, L. A. Pérez-Jurado, and S. J. Chanock, “Detectable clonal mosaicism and its relationship to
aging and cancer,” Nature Genetics, vol. 44, no. 6, pp. 651–658, [2012].
[20]
[21]
[22]
[23]
[24]
[25]
[26]
[27]
[28]
[29]
[30]
[31]
[32]
[33]
[34]
H. C. Kluin-Nelemans, E. Hoster, O. Hermine, J. Walewski, M. Trneny, C. H. Geisler, S. Stilgenbauer,
C. Thieblemont, U. Vehling-Kaiser, J. K. Doorduijn, B. Coiffier, R. Forstpointner, H. Tilly, L. Kanz, P. Feugier,
M. Szymczyk, M. Hallek, S. Kremers, G. Lepeu, L. Sanhes, J. M. Zijlstra, R. Bouabdallah, P. J. Lugtenburg,
M. Macro, M. Pfreundschuh, V. Procházka, F. Di Raimondo, V. Ribrag, M. Uppenkamp, M. André, W. Klapper,
W. Hiddemann, M. Unterhalt, and M. H. Dreyling, “Treatment of older patients with mantle-cell lymphoma,” New
S. Leboulleux, L. Bastholt, T. Krause, C. de la Fouchardiere, J. Tennvall, A. Awada, J. M. Gómez, F. Bonichon,
L. Leenhardt, C. Soufflet, M. Licour, and M. J. Schlumberger, “Vandetanib in locally advanced or metastatic
differentiated thyroid cancer: A randomised, double-blind, phase 2 trial,” The Lancet Oncology, vol. 13, no. 9,
pp. 897–905, [2012].
C. J. Logothetis, E. Basch, A. Molina, K. Fizazi, S. A. North, K. N. Chi, R. J. Jones, O. B. Goodman, P. N. Mainwaring,
C. N. Sternberg, E. Efstathiou, D. D. Gagnon, M. Rothman, Y. Hao, C. S. Liu, T. S. Kheoh, C. M. Haqq, H. I. Scher, and
J. S. de Bono, “Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control
and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of
data from the COU-AA-301 randomised tri,” The Lancet Oncology, vol. 13, no. 12, pp. 1210–1217, [2012].
G. V Long, U. Trefzer, M. A. Davies, R. F. Kefford, P. A. Ascierto, P. B. Chapman, I. Puzanov, A. Hauschild, C. Robert,
A. Algazi, L. Mortier, H. Tawbi, T. Wilhelm, L. Zimmer, J. Switzky, S. Swann, A.-M. Martin, M. Guckert, V. Goodman,
M. Streit, J. M. Kirkwood, and D. Schadendorf, “Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant
melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial,” The Lancet Oncology,
vol. 13, no. 11, pp. 1087–1095, [2012].
S. Luc, T. C. Luis, H. Boukarabila, I. C. Macaulay, N. Buza-Vidas, T. Bouriez-Jones, M. Lutteropp, P. S. Woll,
S. J. Loughran, A. J. Mead, A. Hultquist, J. Brown, T. Mizukami, S. Matsuoka, H. Ferry, K. Anderson, S. Duarte,
D. Atkinson, S. Soneji, A. Domanski, A. Farley, A. Sanjuan-Pla, C. Carella, R. Patient, M. De Bruijn, T. Enver,
C. Nerlov, C. Blackburn, I. Godin, and S. E. W. Jacobsen, “The earliest thymic T cell progenitors sustain B cell and
myeloid lineage potential,” Nature Immunology, vol. 13, no. 4, pp. 412–419, [2012].
O. Mir and P. Berveiller, “Increased evidence for use of chemotherapy in pregnancy.,” The Lancet Oncology, vol. 13,
no. 9, pp. 852–4, [Sep. 2012].
O. Mir and R. Coriat, “Aprepitant for pruritus: drug-drug interactions matter.,” The Lancet Oncology, vol. 13, no. 10,
pp. 964–5, [Oct. 2012].
P. Morice, C. Uzan, R. Fauvet, S. Gouy, P. Duvillard, and E. Darai, “Borderline ovarian tumour: Pathological
diagnostic dilemma and risk factors for invasive or lethal recurrence,” The Lancet Oncology, vol. 13, no. 3,
pp. e103–e115, [2012].
P. Morice, C. Uzan, S. Gouy, C. Verschraegen, and C. Haie-Meder, “Gynaecological cancers in pregnancy,” Lancet,
vol. 379, no. 9815, pp. 558–569, [2012].
P. Morice, C. Uzan, and S. Uzan, “Cancer in pregnancy: A challenging conflict of interest,” Lancet, vol. 379, no. 9815,
pp. 495–496, [2012.]
M. Peifer, L. Fernández-Cuesta, M. L. Sos, J. George, D. Seidel, L. H. Kasper, D. Plenker, F. Leenders, R. Sun,
T. Zander, R. Menon, M. Koker, I. Dahmen, C. Müller, V. Di Cerbo, H.-U. Schildhaus, J. Altmüller, I. Baessmann,
C. Becker, B. De Wilde, J. Vandesompele, D. Böhm, S. Ansén, F. Gabler, I. Wilkening, S. Heynck, J. M. Heuckmann,
X. Lu, S. L. Carter, K. Cibulskis, S. Banerji, G. Getz, K.-S. Park, D. Rauh, C. Grütter, M. Fischer, L. Pasqualucci,
G. Wright, Z. Wainer, P. Russell, I. Petersen, Y. Chen, E. Stoelben, C. Ludwig, P. Schnabel, H. Hoffmann,
T. Muley, M. Brockmann, W. Engel-Riedel, L. A. Muscarella, V. M. Fazio, H. Groen, W. Timens, H. Sietsma,
E. Thunnissen, E. Smit, D. A. M. Heideman, P. J. F. Snijders, F. Cappuzzo, C. Ligorio, S. Damiani, J. Field, S. Solberg,
O. T. Brustugun, M. Lund-Iversen, J. Sänger, J. H. Clement, A. Soltermann, H. Moch, W. Weder, B. Solomon,
J.-C. Soria, P. Validire, B. Besse, E. Brambilla, C. Brambilla, S. Lantuejoul, P. Lorimier, P. M. Schneider,
M. Hallek, W. Pao, M. Meyerson, J. Sage, J. Shendure, R. Schneider, R. Büttner, J. Wolf, P. Nürnberg, S. Perner,
L. C. Heukamp, P. K. Brindle, S. Haas, and R. K. Thomas, “Integrative genome analyses identify key somatic driver
mutations of small-cell lung cancer,” Nature Genetics, vol. 44, no. 10, pp. 1104–1110, [2012].
S. Postel-Vinay and A. Ashworth, “AXL and acquired resistance to EGFR inhibitors,” Nature Genetics, vol. 44, no. 8,
pp. 835–836, [2012].
S. Postel-Vinay, A. S. Véron, F. Tirode, G. Pierron, S. Reynaud, H. Kovar, O. Oberlin, E. Lapouble, S. Ballet,
C. Lucchesi, U. Kontny, A. González-Neira, P. Picci, J. Alonso, A. Patino-Garcia, B. B. De Paillerets, K. Laud, C. Dina,
P. Froguel, F. Clavel-Chapelon, F. Doz, J. Michon, S. J. Chanock, G. Thomas, D. G. Cox, and O. Delattre, “Common
variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma,” Nature Genetics, vol. 44, no.
3, pp. 323–327, [2012].
I. Ray-Coquard, J.-Y. Blay, A. Italiano, A. Le Cesne, N. Penel, J. Zhi, F. Heil, R. Rueger, B. Graves, M. Ding, D. Geho,
S. A. Middleton, L. T. Vassilev, G. L. Nichols, and B. N. Bui, “Effect of the MDM2 antagonist RG7112 on the P53
pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proofof-mechanism study,” The Lancet Oncology, vol. 13, no. 11, pp. 1133–1140, [2012].
H. I. Scher, K. Fizazi, F. Saad, M.-E. Taplin, C. N. Sternberg, K. Miller, R. De Wit, P. Mulders, K. N. Chi, N. D. Shore,
A. J. Armstrong, T. W. Flaig, A. Fléchon, P. Mainwaring, M. Fleming, J. D. Hainsworth, M. Hirmand, B. Selby,
L. Seely, and J. S. De Bono, “Increased survival with enzalutamide in prostate cancer after chemotherapy,” New
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
M. Schlumberger, B. Catargi, I. Borget, D. Deandreis, S. Zerdoud, B. Bridji, S. Bardet, L. Leenhardt, D. Bastie,
C. Schvartz, P. Vera, O. Morel, D. Benisvy, C. Bournaud, F. Bonichon, C. Dejax, M.-E. Toubert, S. Leboulleux,
M. Ricard, and E. Benhamou, “Strategies of radioiodine ablation in patients with low-risk thyroid cancer,” New
M. Schlumberger, S. Leboulleux, and I. Borget, “Dr. Schlumberger and colleagues reply : Radioiodine Ablation in
Low-Risk Thyroid Cancer,” New England Journal of Medicine, vol. 367, no. 7, pp. 673–674, [2012].
L. Senovilla, I. Vitale, I. Martins, M. Tailler, C. Pailleret, M. Michaud, L. Galluzzi, S. Adjemian, O. Kepp, M. NisoSantano, S. Shen, G. Mariño, A. Criollo, A. Boilève, B. Job, S. Ladoire, F. Ghiringhelli, A. Sistigu, T. Yamazaki,
S. Rello-Varona, C. Locher, V. Poirier-Colame, M. Talbot, A. Valent, F. Berardinelli, A. Antoccia, F. Ciccosanti,
G. M. Fimia, M. Piacentini, A. Fueyo, N. L. Messina, M. Li, C. J. Chan, V. Sigl, G. Pourcher, C. Ruckenstuhl,
D. Carmona-Gutierrez, V. Lazar, J. M. Penninger, F. Madeo, C. López-Otín, M. J. Smyth, L. Zitvogel, M. Castedo, and
G. Kroemer, “An immunosurveillance mechanism controls cancer cell ploidy,” Science, vol. 337, no. 6102,
pp. 1678–1684, [2012].
M. R. Smith, F. Saad, R. Coleman, N. Shore, K. Fizazi, B. Tombal, K. Miller, P. Sieber, L. Karsh, R. Damião,
T. L. Tammela, B. Egerdie, H. Van Poppel, J. Chin, J. Morote, F. Gómez-Veiga, T. Borkowski, Z. Ye, A. Kupic,
R. Dansey, and C. Goessl, “Denosumab and bone-metastasis-free survival in men with castration-resistant prostate
cancer: Results of a phase 3, randomised, placebo-controlled trial,” Lancet, vol. 379, no. 9810, pp. 39–46, [2012].
C. Uzan, S. Gouy, C. Haie Meder, and P. Morice, “Authors’ reply : Lymphadenectomy for pregnant women with stage I
cervical cancer,” Lancet, vol. 379, no. 9830, pp. 1949–1950, [2012].
C. Uzan, S. Gouy, C. H. Meder, and P. Morice, “Lymphadenectomy for pregnant women with stage I cervical cancer
reply,” Lancet, vol. 379, no. 9830, pp. 1949–1950, [2012.]
W. T. A. Van Der Graaf, J.-Y. Blay, S. P. Chawla, D.-W. Kim, B. Bui-Nguyen, P. G. Casali, P. Schöffski, M. Aglietta,
A. P. Staddon, Y. Beppu, A. Le Cesne, H. Gelderblom, I. R. Judson, N. Araki, M. Ouali, S. Marreaud, R. Hodge,
M. R. Dewji, C. Coens, G. D. Demetri, C. D. Fletcher, A. P. Dei Tos, and P. Hohenberger, “Pazopanib for metastatic
soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial,” Lancet, vol. 379,
no. 9829, pp. 1879–1886, [2012].
Q. Wen, B. Goldenson, S. J. Silver, M. Schenone, V. Dancik, Z. Huang, L.-Z. Wang, T. A. Lewis, W. F. An, X. Li, M.A. Bray, C. Thiollier, L. Diebold, L. Gilles, M. S. Vokes, C. B. Moore, M. Bliss-Moreau, L. Verplank, N. J. Tolliday,
R. Mishra, S. Vemula, J. Shi, L. Wei, R. Kapur, C. K. Lopez, B. Gerby, P. Ballerini, F. Pflumio, D. G. Gilliland,
L. Goldberg, Y. Birger, S. Izraeli, A. S. Gamis, F. O. Smith, W. G. Woods, J. Taub, C. A. Scherer, J. E. Bradner, B.C. Goh, T. Mercher, A. E. Carpenter, R. J. Gould, P. A. Clemons, S. A. Carr, D. E. Root, S. L. Schreiber, A. M. Stern,
and J. D. Crispino, “Identification of regulators of polyploidization presents therapeutic targets for treatment of
AMKL,” Cell, vol. 150, no. 3, pp. 575–589, [2012].
P. J. Woll, P. Reichardt, A. Le Cesne, S. Bonvalot, A. Azzarelli, H. J. Hoekstra, M. Leahy, F. Van Coevorden,
J. Verweij, P. C. W. Hogendoorn, M. Ouali, S. Marreaud, V. H. C. Bramwell, and P. Hohenberger, “Adjuvant
chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): A
multicentre randomised controlled trial,” The Lancet Oncology, vol. 13, no. 10, pp. 1045–1054, [2012].
L. Zitvogel, O. Kepp, L. Galluzzi, and G. Kroemer, “Inflammasomes in carcinogenesis and anticancer immune
responses,” Nature Immunology, vol. 13, no. 4, pp. 343–351, [2012].
L. Zitvogel and G. Kroemer, “Reply to: Chemotherapy response of spontaneous mammary tumors is independent of
the adaptive immune system,” Nature Medicine, vol. 18, no. 3, p. 346, [2012.]
BY GUSTAVE ROUSSY
With an impact factor between 10 and 20 (79 publications in 2012)
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
L. Albiges, S. Oudard, S. Negrier, A. Caty, G. Gravis, F. Joly, B. Duclos, L. Geoffrois, F. Rolland, A. Guillot,
B. Laguerre, E. Legouffe, F. Kohser, P.-Y. Dietrich, C. A. Theodore, and B. Escudier, “Complete remission with
tyrosine kinase inhibitors in renal cell carcinoma,” Journal of Clinical Oncology, vol. 30, no. 5, pp. 482–487, [2012.]
I. Antony-Debré, D. Bluteau, R. Itzykson, V. Baccini, A. Renneville, F. Boehlen, M. Morabito, N. Droin, C. Deswarte,
Y. Chang, G. Leverger, E. Solary, W. Vainchenker, R. Favier, and H. Raslova, “MYH10 protein expression in platelets
as a biomarker of RUNX1 and FLI1 alterations,” Blood, vol. 120, no. 13, pp. 2719–2722, [2012].
T. Bachelot, C. Bourgier, C. Cropet, I. Ray-Coquard, J.-M. Ferrero, G. Freyer, S. Abadie-Lacourtoisie, J.-C. Eymard,
M. Debled, D. Spaëth, E. Legouffe, D. Allouache, C. El Kouri, and E. Pujade-Lauraine, “Randomized phase II trial
of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth
factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study,”
Journal of Clinical Oncology, vol. 30, no. 22, pp. 2718–2724, [2012].
V. Beral, C. Hermon, R. Peto, G. Reeves, L. Brinton, P. Marchbanks, E. Negri, R. Ness, P. H. M. Peeters, M. Vessey,
E. E. Calle, S. M. Gapstur, A. V Patel, L. D. Maso, R. Talamini, A. Chetrit, G. Hirsh-Yechezkel, F. Lubin, S. Sadetzki,
N. Allen, D. Bull, K. Callaghan, B. Crossley, K. Gaitskell, A. Goodill, J. Green, T. Key, K. Moser, R. Collins, R. Doll,
C. A. Gonzalez, N. Lee, H. W. Ory, H. B. Peterson, P. A. Wingo, N. Martin, T. Pardthaisong, S. Silpisornkosol,
C. Theetranont, B. Boosiri, S. Chutivongse, P. Jimakorn, P. Virutamasen, C. Wongsrichanalai, A. Tjonneland,
L. Titus-Ernstoff, T. Byers, T. Rohan, B. J. Mosgaard, D. Yeates, J. L. Freudenheim, J. Chang-Claude, R. Kaaks,
K. E. Anderson, A. Folsom, K. Robien, M. A. Rossing, D. B. Thomas, N. S. Weiss, E. Riboli, F. Clavel-Chapelon,
D. Cramer, S. E. Hankinson, S. S. Tworoger, S. Franceschi, C. La Vecchia, C. Magnusson, T. Riman, E. Weiderpass,
A. Wolk, L. J. Schouten, P. A. Van den Brandt, N. Chantarakul, S. Koetsawang, D. Rachawat, D. Palli, A. Black,
A. Berrington de Gonzalez, L. A. Brinton, D. M. Freedman, P. Hartge, A. W. Hsing, J. V Lacey Jr., R. N. Hoover,
C. Schairer, S. Graff-Iversen, R. Selmer, C. J. Bain, A. C. Green, D. M. Purdie, V. Siskind, P. M. Webb, S. E. Mccann,
P. Hannaford, C. Kay, C. W. Binns, A. H. Lee, M. Zhang, R. B. Ness, P. Nasca, P. F. Coogan, J. R. Palmer,
L. Rosenberg, J. Kelsey, R. Paffenbarger, A. Whittemore, K. Katsouyanni, A. Trichopoulou, D. Trichopoulos,
A. Tzonou, A. Dabancens, L. Martinez, R. Molina, O. Salas, M. T. Goodman, G. Lurie, M. E. Carney, L. R. Wilkens,
L. Hartman, J. Manjer, H. Olsson, J. A. Grisso, M. Morgan, J. E. Wheeler, J. Casagrande, M. C. Pike, R. K. Ross,
A. H. Wu, A. B. Miller, M. Kumle, E. Lund, L. Mcgowan, X. O. Shu, W. Zheng, T. M. M. Farley, S. Holck, O. Meirik, and
H. A. Risch, “Ovarian cancer and body size: Individual participant meta-analysis including 25,157 women with ovarian
cancer from 47 epidemiological studies,” PLoS Medicine, vol. 9, no. 4, [2012.]
J. Bergh, I. M. Bondarenko, M. R. Lichinitser, A. Liljegren, R. Greil, N. L. Voytko, A. N. Makhson, J. Cortes,
A. Lortholary, J. Bischoff, A. Chan, S. Delaloge, X. Huang, K. A. Kern, and C. Giorgetti, “First-line treatment of
advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective,
randomized phase III study,” Journal of Clinical Oncology, vol. 30, no. 9, pp. 921–929, [2012].
P. Blanchard, M. Rodrigues, and P. Colombat, “On the prevalence and causes of oncologist burnout,” Journal of
Clinical Oncology, vol. 30, no. 24, pp. 3029–3030, [2012].
D. Bluteau, A. C. Glembotsky, A. Raimbault, N. Balayn, L. Gilles, P. Rameau, P. Nurden, M. C. Alessi, N. Debili,
W. Vainchenker, P. G. Heller, R. Favier, and H. Raslova, “Dysmegakaryopoiesis of FPD/AML pedigrees with
constitutional RUNX1 mutations is linked to myosin II deregulated expression,” Blood, vol. 120, no. 13, pp. 2708–2718,
[2012].
C. Bourgier, A. Levy, M.-C. Vozenin, and E. Deutsch, “Pharmacological strategies to spare normal tissues from
radiation damage: Useless or overlooked therapeutics?,” Cancer and Metastasis Reviews, vol. 31, no. 3–4,
pp. 699–712, [2012].
L. Brugieres, A. Remenieras, G. Pierron, P. Varlet, S. Forget, V. Byrde, J. Bombled, S. Puget, O. Caron, C. Dufour,
O. Delattre, B. Bressac-de Paillerets, and J. Grill, “High frequency of germline SUFU mutations in children with
desmoplastic/nodular medulloblastoma younger than 3 years of age,” Journal of Clinical Oncology, vol. 30, no. 17,
pp. 2087–2093, [2012].
M. S. Cairo, R. Sposto, M. Gerrard, A. Auperin, S. C. Goldman, L. Harrison, R. Pinkerton, M. Raphael, K. McCarthy,
S. L. Perkins, and C. Patte, “Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent
age ( ≥15 years), are associated with an increased risk of treatment failure in children and adolescents with mature
B-cell non-Hodgkin’s lymphoma: Results of the FAB LM,” Journal of Clinical Oncology, vol. 30, no. 4, pp. 387–393,
[2012].
C. Callens, F. Baleydier, E. Lengline, R. Ben Abdelali, A. Petit, P. Villarese, A. Cieslak, V. Minard-Colin, A. Rullier,
A. Moreau, A. Baruchel, C. Schmitt, V. Asnafi, Y. Bertrand, and E. Macintyre, “Clinical impact of NOTCH1 and/or
FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma,” Journal of Clinical
Oncology, vol. 30, no. 16, pp. 1966–1973, [2012.]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
[22]
[23]
[24]
[25]
[26]
[27]
[28]
[29]
[30]
C. E. Cano, M. J. Sandí, T. Hamidi, E. L. Calvo, O. Turrini, L. Bartholin, C. Loncle, V. Secq, S. Garcia, G. Lomberk,
G. Kroemer, R. Urrutia, and J. L. Iovanna, “Homotypic cell cannibalism, a cell-death process regulated by the
nuclear protein 1, opposes to metastasis in pancreatic cancer,” EMBO Molecular Medicine, vol. 4, no. 9, pp. 964–979,
[2012].
D. Carmona-Gutierrez, G. Kroemer, and F. Madeo, “When Death Was Young: An Ancestral Apoptotic Network in
Bacteria,” Molecular Cell, vol. 46, no. 5, pp. 552–554, [2012].
C. Chargari and E. Deutsch, “MET targeting: Perspectives for the radiation oncologist,” Nature Reviews Clinical
Oncology, vol. 9, no. 9, [2012].
T. C. Chua, B. J. Moran, P. H. Sugarbaker, E. A. Levine, O. Glehen, F. N. Gilly, D. Baratti, M. Deraco, D. Elias, A.
Sardi, W. Liauw, T. D. Yan, P. Barrios, A. G. Portilla, I. H. J. T. De Hingh, W. P. Ceelen, J. O. Pelz, P. Piso, S. GonzaĎezMoreno, K. Van Der Speeten, and D. L. Morris, “Early- and long-term outcome data of patients with pseudomyxoma
peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy,” Journal of Clinical Oncology, vol. 30, no. 20, pp. 2449–2456, [2012].
G. Cornelis, O. Heidmann, S. Bernard-Stoecklin, K. Reynaud, G. Véron, B. Mulot, A. Dupressoir, and T. Heidmann,
“Ancestral capture of syncytin-Car1, a fusogenic endogenous retroviral envelope gene involved in placentation and
conserved in Carnivora,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109,
no. 7, pp. E432–E441, [2012].
F. Damm, O. Kosmider, V. Gelsi-Boyer, A. Renneville, N. Carbuccia, C. Hidalgo-Curtis, V. Della Valle, L. Couronné,
L. Scourzic, V. Chesnais, A. Guerci-Bresler, B. Slama, O. Beyne-Rauzy, A. Schmidt-Tanguy, A. StamatoullasBastard, F. Dreyfus, T. Prébet, S. De Botton, N. Vey, M. A. Morgan, N. C. P. Cross, C. Preudhomme, D. Birnbaum,
O. A. Bernard, and M. Fontenay, “Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate
with patient outcome in myelodysplastic syndromes,” Blood, vol. 119, no. 14, pp. 3211–3218, [2012].
E. Dardenne, S. Pierredon, K. Driouch, L. Gratadou, M. Lacroix-Triki, M. P. Espinoza, E. Zonta, S. Germann,
H. Mortada, J.-P. Villemin, M. Dutertre, R. Lidereau, S. Vagner, and D. Auboeuf, “Splicing switch of an epigenetic
regulator by RNA helicases promotes tumor-cell invasiveness,” Nature Structural and Molecular Biology, vol. 19,
no. 11, pp. 1139–1146, [2012].
A. De Masson, J.-D. Bouaziz, R. P. De Latour, S. Wittnebel, P. Ribaud, M.-T. Rubio, J.-B. Micol, F. Suarez, S. Nguyen,
J.-H. Dalle, K. Yakouben, M. Robin, A. Xhaard, L. Adès, J.-H. Bourhis, M. Rybojad, M. Bagot, and G. Socié, “Limited
efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD,” Blood, vol. 120,
no. 25, pp. 5089–5090, [2012].
C.-A. Dutertre, S. Amraoui, A. DeRosa, J.-P. Jourdain, L. Vimeux, M. Goguet, S. Degrelle, V. Feuillet, A.-S.
Liovat, M. Mueller-Trutwin, N. Decroix, C. Deveau, L. Meyer, C. Goujard, P. Loulergue, O. Launay, Y. Richard, and
A. Hosmalin, “Pivotal role of M-DC8(+) monocytes from viremic HIV-infected patients in TNF alpha overproduction in
response to microbial products,” Blood, vol. 120, no. 11, pp. 2259–2268, [Sep. 2012].
A. M. M. Eggermont and C. Robert, “Melanoma in 2011: A new paradigm tumor for drug development,” Nature
Reviews Clinical Oncology, vol. 9, no. 2, pp. 74–76, [2012.]
A. M. M. Eggermont, S. Suciu, A. Testori, M. Santinami, W. H. J. Kruit, J. Marsden, C. J. A. Punt, F. Salès, R.
Dummer, C. Robert, D. Schadendorf, P. M. Patel, G. De Schaetzen, A. Spatz, and U. Keilholz, “Long-term results of
the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation
in resected stage III melanoma,” Journal of Clinical Oncology, vol. 30, no. 31, pp. 3810–3818, [2012.]
A. M. M. Eggermont and C. Robert, “A new paradigm tumor for drug development,” Nature Reviews Clinical
Oncology, vol. 9, no. 2, pp. 74–76, [2012.]
T. Eisen, C. N. Sternberg, C. Robert, P. Mulders, L. Pyle, S. Zbinden, H. Izzedine, and B. Escudier, “Targeted
therapies for renal cell carcinoma: Review of adverse event management strategies,” Journal of the National Cancer
Institute, vol. 104, no. 2, pp. 93–113, [2012].
B. Escudier, C. Szczylik, C. Porta, and M. Gore, “Treatment selection in metastatic renal cell carcinoma: Expert
consensus,” Nature Reviews Clinical Oncology, vol. 9, no. 6, pp. 327–337, [2012].
E. Frisan, J. Vandekerckhove, A. De Thonel, C. Pierre-Eugène, A. Sternberg, J.-B. Arlet, C. Floquet, E. Gyan,
O. Kosmider, F. Dreyfus, A.-S. Gabet, G. Courtois, P. Vyas, J.-A. Ribeil, Y. Zermati, C. Lacombe, P. Mayeux, E.
Solary, C. Garrido, O. Hermine, and M. Fontenay, “Defective nuclear localization of Hsp70 is associated with
dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes,” Blood, vol. 119, no. 6, pp. 1532–1542, [2012].
L. Galluzzi, O. Kepp, and G. Kroemer, “Enlightening the impact of immunogenic cell death in photodynamic cancer
therapy,” EMBO Journal, vol. 31, no. 5, pp. 1055–1057, [2012].
L. Galluzzi, O. Kepp, C. Trojel-Hansen, and G. Kroemer, “Mitochondrial control of cellular life, stress, and death,”
Circulation Research, vol. 111, no. 9, pp. 1198–1207, [2012].
L. Galluzzi and G. Kroemer, “Autophagy mediates the metabolic benefits of endurance training,” Circulation
Research, vol. 110, no. 10, pp. 1276–1278, [2012].
E.-F. Gautier, M. Picard, C. Laurent, C. Marty, J.-L. Villeval, C. Demur, F. Delhommeau, E. Hexner, S. Giraudier,
N. Bonnevialle, B. Ducommun, C. Récher, G. Laurent, S. Manenti, and V. Mansat-De Mas, “The cell cycle regulator
CDC25A is a target for JAK2 V617F oncogene,” Blood, vol. 119, no. 5, pp. 1190–1199, [2012].
[31]
[32]
[33]
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47]
H. Ghesquières, G. Cartron, J. F. Seymour, M.-H. Delfau-Larue, F. Offner, P. Soubeyran, A. Perrot, P. Brice,
R. Bouabdallah, A. Sonet, J. Dupuis, O. Casasnovas, J. V Catalano, A. Delmer, F. Jardin, A. Verney, P. Dartigues, and
G. Salles, “Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study
is not affected by FCGR3A and FCGR2A polymorphisms,” Blood, vol. 120, no. 13, pp. 2650–2657, [2012].
L. Gineau, C. Cognet, N. Kara, F. P. Lach, J. Dunne, U. Veturi, C. Picard, C. Trouillet, C. Eidenschenk, S. Aoufouchi,
A. Alcaïs, O. Smith, F. Geissmann, C. Feighery, L. Abel, A. Smogorzewska, B. Stillman, E. Vivier, J.-L. Casanova,
and E. Jouanguy, “Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural
killer cell deficiency,” Journal of Clinical Investigation, vol. 122, no. 3, pp. 821–832, [2012].
S. Gourgou-Bourgade, C. Bascoul-Mollevi, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, Y. Bécouarn,
A. Adenis, J.-L. Raoul, V. Boige, J. Bérille, and T. Conroy, “Impact of FOLFIRINOX Compared With Gemcitabine on
Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized
Trial.,” Journal of Clinical Oncology, vol. 31, no. 1, pp. 23–9, [Dec. 2013].
D. Hannani, Y. Ma, T. Yamazaki, J. Déchanet-Merville, G. Kroemer, and L. Zitvogel, “Harnessing Ȗį T cells in
anticancer immunotherapy,” Trends in Immunology, vol. 33, no. 5, pp. 199–206, [2012].
S. D. Haveli, P. Walter, G. Patriarche, J. Ayache, J. Castaing, E. Van Elslande, G. Tsoucaris, P.-A. Wang, and H.
B. Kagan, “Hair fiber as a nanoreactor in controlled synthesis of fluorescent gold nanoparticles,” Nano Letters,
vol. 12, no. 12, pp. 6212–6217, [2012].
M. Ignatiadis, S. K. Singhal, C. Desmedt, B. Haibe-Kains, C. Criscitiello, F. Andre, S. Loi, M. Piccart, S. Michiels,
and C. Sotiriou, “Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: A pooled
analysis,” Journal of Clinical Oncology, vol. 30, no. 16, pp. 1996–2004, [2012].
A. Jacquel, S. Obba, L. Boyer, M. Dufies, G. Robert, P. Gounon, E. Lemichez, F. Luciano, E. Solary, and P. Auberger,
“Autophagy is required for CSF-1-induced macrophagic differentiation and acquisition of phagocytic functions,”
Blood, vol. 119, no. 19, pp. 4527–4531, [2012.]
M. Jemaà, I. Vitale, O. Kepp, F. Berardinelli, L. Galluzzi, L. Senovilla, G. Mariño, S. A. Malik, S. Rello-Varona,
D. Lissa, A. Antoccia, M. Tailler, F. Schlemmer, F. Harper, G. Pierron, M. Castedo, and G. Kroemer, “Selective killing
of p53-deficient cancer cells by SP600125,” EMBO Molecular Medicine, vol. 4, no. 6, pp. 500–514, [2012].
A. Joosse, S. Collette, S. Suciu, T. Nijsten, F. Lejeune, U. R. Kleeberg, J. W. W. Coebergh, A. M. M. Eggermont, and
E. De Vries, “Superior outcome of women with stage I/II cutaneous melanoma: Pooled analysis of four European
organisation for research and treatment of cancer phase III trials,” Journal of Clinical Oncology, vol. 30, no. 18, pp.
2240–2247, [2012].
C. Langenberg, S. J. Sharp, M. B. Schulze, O. Rolandsson, K. Overvad, N. G. Forouhi, J. Spranger, D. Drogan,
J. M. Huerta, L. Arriola, B. de Lauzon-Guillan, M.-J. Tormo, E. Ardanaz, B. Balkau, J. W. J. Beulens, H. Boeing,
H. B. Bueno-de-Mesquita, F. Clavel-Chapelon, F. L. Crowe, P. W. Franks, C. A. Gonzalez, S. Grioni, J. Halkjaer,
G. Hallmans, R. Kaaks, N. D. Kerrison, T. J. Key, K. T. Khaw, A. Mattiello, P. Nilsson, T. Norat, L. Palla, D. Palli,
S. Panico, J. R. Quirós, D. Romaguera, I. Romieu, C. Sacerdote, M.-J. Sánchez, N. Slimani, I. Sluijs, A. M. W.
Spijkerman, B. Teucher, A. Tjonneland, R. Tumino, D. L. van der A, Y. T. van der Schouw, E. J. M. Feskens, E. Riboli,
and N. J. Wareham, “Long-term risk of incident type 2 diabetes and measures of overall and regional obesity: the
EPIC-InterAct case-cohort study.,” PLoS medicine, vol. 9, no. 6, p. e1001230, [Jan. 2012].
P. Laurent-Puig, G. Manceau, V. Boige, and H. Blons, “Prediction of response to anticancer treatment as simple as
the resolution of ordinary differential equations?,” Gut, vol. 61, no. 5, pp. 637–638, [2012].
H. Leleu, F. Capuano, M. Ferrua, G. Nitenberg, E. Minvielle, and F. Schiele, “Onset-to-needle times in patients with
ST-segment elevation myocardial infarction: shortest referral route to a primary coronary intervention facility,”
European Heart Journal, vol. 33, no. 1, p. 843, [2012].
F. Lemonnier, L. Couronné, M. Parrens, J.-P. Jaïs, M. Travert, L. Lamant, O. Tournillac, T. Rousset, B. Fabiani,
R.A. Cairns, T. Mak, C. Bastard, O. A. Bernard, L. De Leval, and P. Gaulard, “Recurrent TET2 mutations in peripheral
T-cell lymphomas correlate with T FH-like features and adverse clinical parameters,” Blood, vol. 120, no. 7,
pp. 1466–1469, [2012].
C. Massard, S. Sandhu, M. Blanco, D. Papadatos-Pastos, C. Carden, J. De Bono, F. Saran, L. R. Molife, S. B. Kaye,
J.-C. Soria, and U. Banerji, “Author reply : Toward a better dialogue between neuro-oncologists and phase I
investigators,” Journal of Clinical Oncology, vol. 30, no. 5, pp. 562–563, [2012].
A. Mauguen, C. Le Péchoux, M. I. Saunders, S. E. Schild, A. T. Turrisi, M. Baumann, W. T. Sause, D. Ball, C. P. Belani,
J. A. Bonner, A. Zajusz, S. E. Dahlberg, M. Nankivell, S. J. Mandrekar, R. Paulus, K. Behrendt, R. Koch, J. F. Bishop,
S. Dische, R. Arriagada, D. De Ruysscher, and J.-P. Pignon, “Hyperfractionated or accelerated radiotherapy in lung
cancer: An individual patient data meta-analysis,” Journal of Clinical Oncology, vol. 30, no. 22, pp. 2788–2797, [2012].
E. Missiaglia, D. Williamson, J. Chisholm, P. Wirapati, G. Pierron, F. Petel, J.-P. Concordet, K. Thway, O. Oberlin,
K. Pritchard-Jones, O. Delattre, M. Delorenzi, and J. Shipley, “PAX3/FOXO1 fusion gene status is the key prognostic
molecular marker in rhabdomyosarcoma and significantly improves current risk stratification,” Journal of Clinical
E. Missiaglia, D. Williamson, J. Chisholm, P. Wirapati, G. Pierron, F. Petel, J.-P. Concordet, K. Thway, O. Oberlin,
K. Pritchard-Jones, O. Delattre, M. Delorenzi, and J. Shipley, “Reply to S. Stegmaier et al : Questionable Universal
Validity of PAX3/FOXO1 Fusion Gene Status As Molecular Marker for Improvement of Risk Stratification in
Rhabdomyosarcoma Therapy,” Journal of Clinical Oncology, vol. 30, no. 32, pp. 4040–4041, [Nov. 2012].
[48]
[49]
[50]
[51]
[52]
[53]
[54]
[55]
[56]
[57]
[58]
[59]
[60]
[61]
[62]
[63]
[64]
F. Nowak, J.-C. Soria, and F. Calvo, “Tumour molecular profiling for deciding therapy-the French initiative,” Nature
Reviews Clinical Oncology, vol. 9, no. 8, pp. 479–486, [2012.]
P. A. Oberholzer, D. Kee, P. Dziunycz, A. Sucker, N. Kamsukom, R. Jones, C. Roden, C. J. Chalk, K. Ardlie,
E. Palescandolo, A. Piris, L. E. MacConaill, C. Robert, G. F. L. Hofbauer, G. A. McArthur, D. Schadendorf, and
L. A. Garraway, “RAS mutations are associated with the development of cutaneous squamous cell tumors in patients
treated with RAF inhibitors,” Journal of Clinical Oncology, vol. 30, no. 3, pp. 316–321, [2012].
O. Oberlin, A. Rey, J. Sanchez De Toledo, H. Martelli, M. E. M. Jenney, M. Scopinaro, C. Bergeron, J. H. M. Merks,
N. Bouvet, C. Ellershaw, A. Kelsey, D. Spooner, and M. C. G. Stevens, “Randomized comparison of intensified
six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other
chemotherapy-sensitive childhood soft tissue sarcomas: Long-term results from the International Society of
Pediatr,” Journal of Clinical Oncology, vol. 30, no. 20, pp. 2457–2465, [2012].
K. A. Olaussen, F. André, and J.-C. Soria, “Auhor reply : DNA repair capacity in circulating lymphocytes and influence
on platinum effect in tumor cells,” Journal of Clinical Oncology, vol. 30, no. 13, pp. 1567–1568, [2012].
D. Olmos, R. P. A’Hern, S. Marsoni, R. Morales, C. Gomez-Roca, J. Verweij, E. E. Voest, P. Schöffski, J. E. Ang,
N. Penel, J. H. Schellens, G. Del Conte, A. T. Brunetto, T. R. J. Evans, R. Wilson, E. Gallerani, R. Plummer,
J. Tabernero, J.-C. Soria, and S. B. Kaye, “Patient selection for oncology phase I trials: A multi-institutional study of
prognostic factors,” Journal of Clinical Oncology, vol. 30, no. 9, pp. 996–1004, [2012].
C. Pecquet, C. C. Diaconu, J. Staerk, M. Girardot, C. Marty, Y. Royer, J.-P. Defour, A. Dusa, R. Besancenot,
S. Giraudier, J.-L. Villeval, L. Knoops, P. J. Courtoy, W. Vainchenker, and S. N. Constantinescu, “Thrombopoietin
receptor down-modulation by JAK2 V617F: Restoration of receptor levels by inhibitors of pathologic JAK2 signaling
and of proteasomes,” Blood, vol. 119, no. 20, pp. 4625–4635, [2012.]
D. Peiffert, L. Tournier-Rangeard, J.-P. Gérard, C. Lemanski, E. François, M. Giovannini, F. Cvitkovic, X. Mirabel,
O. Bouché, E. Luporsi, T. Conroy, C. Montoto-Grillot, F. Mornex, A. Lusinchi, J.-M. Hannoun-Lévi, J.-F. Seitz,
A. Adenis, C. Hennequin, B. Denis, and M. Ducreux, “Induction chemotherapy and dose intensification of the
radiation boost in locally advanced anal canal carcinoma: Final analysis of the randomized UNICANCER ACCORD 03
trial,” Journal of Clinical Oncology, vol. 30, no. 16, pp. 1941–1948, [2012].
G. Piessen, W. B. Robb, M. Messager, J. H. Lefevre, V. Pichot-Delhaye, A. Souadka, and C. Mariette, “Palliative
resection for Advanced Gastric and Junctional Adenocarcinoma (AGJA): which patients will benefit from surgery?,”
Gut, vol. 61, no. 2, p. A364, [2012].
S. Postel-Vinay, E. Vanhecke, K. A. Olaussen, C. J. Lord, A. Ashworth, and J.-C. Soria, “The potential of exploiting
DNA-repair defects for optimizing lung cancer treatment,” Nature Reviews Clinical Oncology, vol. 9, no. 3,
pp. 144–155, [2012].
I. Ray-Coquard, J.-Y. Blay, A. Italiano, A. Le Cesne, N. Penel, J. Zhi, F. Heil, R. Rueger, B. Graves, M. Ding, D. Geho,
S. A. Middleton, L. T. Vassilev, G. L. Nichols, and B. N. Bui, “Effect of the MDM2 antagonist RG7112 on the P53
pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proofof-mechanism study,” The Lancet Oncology, vol. 13, no. 11, pp. 1133–1140, [2012].
W. B. Robb, C. Mariette, L. Dahan, E. Maillard, F. Mornex, B. Meunier, V. Boige, C. Genet, D. Pezet, P. A. Thomas,
and J. P. Triboulet, “Surgery alone vs chemoradiotherapy followed by surgery for stage I and II oesophageal cancer:
final analysis of a randomised controlled phase III trial-FFCD 9901,” Gut, vol. 61, no. 2, pp. A37–A38, [2012].
D. A. Rodriguez, S. Zamorano, F. Lisbona, D. Rojas-Rivera, H. Urra, J. R. Cubillos-Ruiz, R. Armisen,
D. R. Henriquez, E. H Cheng, M. Letek, T. Vaisar, T. Irrazabal, C. Gonzalez-Billault, A. Letai, F. X. Pimentel-Muiéos,
G. Kroemer, and C. Hetz, “BH3-only proteins are part of a regulatory network that control the sustained signalling of
the unfolded protein response sensor IRE1_,” EMBO Journal, vol. 31, no. 10, pp. 2322–2335, [2012].
S. Salas, A. Dufresne, B. Bui, J.-Y. Blay, P. Terrier, D. Ranchere-Vince, S. Bonvalot, E. Stoeckle, L. Guillou,
A. Le Cesne, O. Oberlin, V. Brouste, and J.-M. Coindre, “Reply to Y. Nishida et al,” Journal of Clinical Oncology,
vol. 30, no. 12, p. 1391, [2012].
S. Salas, A. Dufresne, B. Bui, J.-Y. Blay, P. Terrier, D. Ranchere-Vince, S. Bonvalot, E. Stoeckle, L. Guillou,
A. Le Cesne, O. Oberlin, V. Brouste, and J.-M. Coindre, “Is It Possible to Identify Clinically Useful Prognostic Groups
for Patients With Desmoid Tumors? Reply,” Journal of Clinical Oncology, vol. 30, no. 12, p. 1391, [2012].
H. Salmon, K. Franciszkiewicz, D. Damotte, M.-C. Dieu-Nosjean, P. Validire, A. Trautmann, F. Mami-Chouaib, and
E. Donnadieu, “Matrix architecture defines the preferential localization and migration of T cells into the stroma of
human lung tumors,” Journal of Clinical Investigation, vol. 122, no. 3, pp. 899–910, [2012].
E. Segura, J. Valladeau-Guilemond, M.-H. Donnadieu, X. Sastre-Garau, V. Soumelis, and S. Amigorena,
“Characterization of resident and migratory dendritic cells in human lymph nodes,” Journal of Experimental
Medicine, vol. 209, no. 4, pp. 653–660, [2012].
S. Shen, M. Niso-Santano, S. Adjemian, T. Takehara, S. A. Malik, H. Minoux, S. Souquere, G. Mariño, S. Lachkar,
L. Senovilla, L. Galluzzi, O. Kepp, G. Pierron, M. C. Maiuri, H. Hikita, R. Kroemer, and G. Kroemer, “Cytoplasmic
STAT3 Represses Autophagy by Inhibiting PKR Activity,” Molecular Cell, vol. 48, no. 5, pp. 667–680, [2012].
[65]
[66]
[67]
[68]
[69]
[70]
[71]
[72]
[73]
[74]
[75]
[76]
[77]
[78]
[79]
D. Sluik, B. Buijsse, R. Muckelbauer, R. Kaaks, B. Teucher, N. F. Johnsen, A. Tjønneland, K. Overvad,
J. N. Ostergaard, P. Amiano, E. Ardanaz, B. Bendinelli, V. Pala, R. Tumino, F. Ricceri, A. Mattiello, A. M. W.
Spijkerman, E. M. Monninkhof, A. M. May, P. W. Franks, P. M. Nilsson, P. Wennberg, O. Rolandsson, G. Fagherazzi,
M. C. Boutron-Ruault, F. Clavel-Chapelon, J. M. H. Castaño, V. Gallo, H. Boeing, and U. Nöthlings, “Physical Activity
and Mortality in Individuals With Diabetes Mellitus: A Prospective Study and Meta-analysis.,” Archives of internal
medicine, vol. 172, no. 17, pp. 1285–1295, [Aug. 2012].
E. Solary, “PHAGOCYTES & GRANULOCYTES When monocyte life hangs by a thread,” Blood, vol. 119, no. 12,
pp. 2699–2700, [Mar. 2012].
E. Soucie, K. Hanssens, T. Mercher, S. Georgin-Lavialle, G. Damaj, C. Livideanu, M. O. Chandesris, Y. Acin,
S. Létard, P. De Sepulveda, O. Hermine, O. A. Bernard, and P. Dubreuil, “In aggressive forms of mastocytosis, TET2
loss cooperates with c-KITD816V to transform mast cells,” Blood, vol. 120, no. 24, pp. 4846–4849, [2012].
A. S. Tarakhovsky and G. Kroemer, “Innate immunity,” Current Opinion in Immunology, vol. 24, no. 1, pp. 1–2, [2012].
C. Thiollier, C. K. Lopez, B. Gerby, C. Ignacimouttou, S. Poglio, Y. Duffourd, J. Guégan, P. Rivera-Munoz,
O. Bluteau, V. Mabialah, M. Diop, Q. Wen, A. Petit, A.-L. Bauchet, D. Reinhardt, B. Bornhauser, D. Gautheret,
Y. Lecluse, J. Landman-Parker, I. Radford, W. Vainchenker, N. Dastugue, S. de Botton, P. Dessen, J.-P. Bourquin,
J. D. Crispino, P. Ballerini, O. A. Bernard, F. Pflumio, and T. Mercher, “Characterization of novel genomic alterations
and therapeutic approaches using acute megakaryoblastic leukemia xenograft models,” Journal of Experimental
Medicine, vol. 209, no. 11, pp. 2017–2031, [2012].
M. Y. Tolstorukov, J. A. Goldman, C. Gilbert, V. Ogryzko, R. E. Kingston, and P. J. Park, “Histone Variant H2A.Bbd Is
Associated with Active Transcription and mRNA Processing in Human Cells,” Molecular Cell, vol. 47, no. 4,
pp. 596–607, [2012].
F. Touzot, L. Gaillard, N. Vasquez, T. Le Guen, Y. Bertrand, J. Bourhis, T. Leblanc, A. Fischer, J. Soulier, J.-P. De
Villartay, and P. Revy, “Heterogeneous telomere defects in patients with severe forms of dyskeratosis congenita,”
Journal of Allergy and Clinical Immunology, vol. 129, no. 2, pp. 473–482.e3, [2012].
K. Y. Urayama, R. F. Jarrett, H. Hjalgrim, A. Diepstra, Y. Kamatani, A. Chabrier, V. Gaborieau, A. Boland, A. Nieters,
N. Becker, L. Foretova, Y. Benavente, M. Maynadié, A. Staines, L. Shield, A. Lake, D. Montgomery, M. Taylor,
K. E. Smedby, R.-M. Amini, H.-O. Adami, B. Glimelius, B. Feenstra, I. M. Nolte, L. Visser, G. W. Van Imhoff,
T. Lightfoot, P. Cocco, L. Kiemeney, S. H. Vermeulen, I. Holcatova, L. Vatten, G. J. MacFarlane, P. Thomson,
D. I. Conway, S. Benhamou, A. Agudo, C. M. Healy, K. Overvad, A. Tjønneland, B. Melin, F. Canzian, K.-T. Khaw,
R. C. Travis, P. H. M. Peeters, C. A. González, J. R. Quirós, M.-J. Sánchez, J. M. Huerta, E. Ardanaz, M. Dorronsoro,
F. Clavel-Chapelon, H. B. Bueno-De-Mesquita, E. Riboli, E. Roman, P. Boffetta, S. De Sanjosé, D. Zelenika,
M. Melbye, A. Van Den Berg, M. Lathrop, P. Brennan, and J. D. McKay, “Genome-wide association study of classical
hodgkin lymphoma and epstein-barr virus status-defined subgroups,” Journal of the National Cancer Institute,
vol. 104, no. 3, pp. 240–253, [2012].
M. A. E. Van Der Kaaij, N. Heutte, P. Meijnders, E. Abeilard-Lemoisson, M. Spina, E. C. Moser, A. Allgeier,
B. Meulemans, A. H. M. Simons, P. J. Lugtenburg, B. M. P. Aleman, E. M. Noordijk, C. Fermé, J. Thomas,
A. Stamatoullas, C. Fruchart, P. Brice, I. Gaillard, S. Bologna, F. Ong, H. Eghbali, J. K. Doorduijn, F. Morschhauser,
C. Sebban, J. M. Roesink, M. Bouteloup, A. Van Hoof, J. M. M. Raemaekers, M. Henry-Amar, and H. C. KluinNelemans, “Premature ovarian failure and fertility in long-term survivors of Hodgkin’s lymphoma: A European
Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d’ÉTude des Lymphomes de
l’Adulte Cohort Study,” Journal of Clinical Oncology, vol. 30, no. 3, pp. 291–299, [2012].
M. A. E. Van Der Kaaij, N. Heutte, P. Meijnders, E. Abeilard-Lemoisson, M. Spina, L. C. Moser, A. Allgeier,
B. Meulemans, B. Dubois, A. H. M. Simons, P. J. Lugtenburg, B. M. P. Aleman, E. M. Noordijk, C. Fermé, J. Thomas,
A. Stamatoullas, C. Fruchart, P. Brice, I. Gaillard, J. K. Doorduijn, C. Sebban, W. G. J. M. Smit, S. Bologna,
J. M. Roesink, F. Ong, M. P. E. André, J. M. M. Raemaekers, M. Henry-Amar, and H. C. Kluin-Nelemans,
“Parenthood in survivors of Hodgkin lymphoma: An EORTC-GELA general population case-control study,” Journal of
Clinical Oncology, vol. 30, no. 31, pp. 3854–3863, [2012].
N. Vey, J.-H. Bourhis, N. Boissel, D. Bordessoule, T. Prebet, A. Charbonnier, A. Etienne, P. Andre, F. Romagne,
D. Benson, H. Dombret, and D. Olive, “A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete
remission,” Blood, vol. 120, no. 22, pp. 4317–4323, [2012].
S. A. Wells Jr., B. G. Robinson, R. F. Gagel, H. Dralle, J. A. Fagin, M. Santoro, E. Baudin, R. Elisei, B. Jarzab,
J. R. Vasselli, J. Read, P. Langmuir, A. J. Ryan, and M. J. Schlumberger, “Vandetanib in patients with locally
advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial,” Journal of Clinical
S. A. Wells Jr., B. G. Robinson, R. F. Gagel, H. Dralle, J. A. Fagin, M. Santoro, E. Baudin, R. Elisei, B. Jarzab,
J. R. Vasselli, J. S. Read, P. Langmuir, A. J. Ryan, and M. J. Schlumberger, “Reply to J.-F. Chatal et al. : Treatment
of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling
Time,” Journal of Clinical Oncology, vol. 30, no. 17, pp. 2166–2167, [2012].
Y. Zermati, S. Mouhamad, L. Stergiou, B. Besse, L. Galluzzi, S. Boehrer, A.-L. Pauleau, F. Rosselli, M. D’Amelio,
R. Amendola, M. Castedo, M. Hengartner, J.-C. Soria, F. Cecconi, and G. Kroemer, “Nonapoptotic role for apaf-1 in
the DNA damage checkpoint,” Molecular Cell, vol. 48, no. 2, pp. 322–324, [2012].
L. Zitvogel and F. Housseau, “IKDCs or B220+ NK cells are pre-mNK cells,” Blood, vol. 119, no. 19, pp. 4345–4346,
[2012].
ANNUAL REPORT 2012 / GUSTAVE ROUSSY
71
BY GUSTAVE ROUSSY
With an impact factor between 5 and 10 (415 publications in 2012)
[1]
Abanesi, Marcello, Mancardi, David A., Macdonald, Lynn E., Iannascoli, Bruno, Zitvogel, Laurence, Murphy,
Andrew J., Leusen, Jeanette H., and Bruhns, Pierre Cutting Edge : Fc gamma RIII (CD16) and Fc gamma R1
(CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic
B16 Melanoma. [2012] Journal of Immunology (189) 12 : 5513-5517. Impact factor : 5.520
[2]
Adam, Julien, Bollée, Guillaume, Fougeray, Sophie, Noël, Laure Hélène, Antignac, Corinne, Knebelman,
Bertrand, and Pallet, Nicolas Endoplasmic reticulum stress in UMOD-related kidney disease: a human pathologic
study. [2012] American journal of kidney diseases : the official journal of the National Kidney Foundation (59) 1 :
117-121. Impact factor : 5.294
[3]
Adinolfi, E., Raffaghello, L., Giuliani, A. L., Cavazzini, L., Capece, M., Chiozzi, P., Bianchi, G., Kroemer, G., Pistoia,
V., and Di Virgilio, F. Expression of P2X7 receptor increases in vivo tumor growth. [2012] Cancer Research (72) 12 :
2957-2969. Impact factor : 8.650
[4]
Ahluwalia, Namanjeet, Tondeur, Laura, Boutron, Marie Christine, and Clavel-Chaperon, Francoise Healthy
Mediterranean-like dietary pattern predicts reduced risk of acute myocardial infarction (MI) in women: The EpicFrance (E3N) prospective cohort study. [2012] FASEB Journal (26). Impact factor : 5.704
[5]
Al Batran, S. E., Ducreux, M., and Ohtsu, A. MTOR as a therapeutic target in patients with gastric cancer. [2012]
International Journal of Cancer (130) 3 : 491-496. Impact factor : 6.198
[6]
Al Nakouzi, N., Bawa, O., le Pape, A., Lerondel, S., Gaudin, C., Opolon, P., Gonin, P., Fizazi, K., and Chauchereau,
A. The IGR-CaP1 xenograft model recapitulates mixed osteolytic/ blastic bone lesions observed in metastatic prostate cancer. [2012] Neoplasia (14) 5 : 376-387. Impact factor : 5.470
[7]
Alapetite, Claire, Puget, Stephanie, Ruffier, Amandine, Habrand, Jean Louis, Bolle, Stephanie, Noel, Georges,
Nauraye, Catherine, De Marzy, Ludovic, Boddaert, Nathalie, Brisse, Herve, Sainte-Rose, Christian, Zerah,
Michel, Boetto, Sergio, Laffond, Christelle, Chevignard, Mathilde, Grill, Jacques, and Doz, Francois Protontherapy for craniopharyngioma in children: update of the Orsay proton center experience. [2012] Neuro-Oncology (14)
supplt 1 : 24-24. Impact factor : 6.180
[8]
Albanesi, M., Mancardi, D. A., Macdonald, L. E., Iannascoli, B., Zitvogel, L., Murphy, A. J., Leusen, J. H., and
Bruhns, P. Cutting edge: FcyRIII (CD16) and FcyRI (CD64) are responsible for anti-glycoprotein 75 monoclonal
antibody TA99 therapy for experimental metastatic B16 melanoma. [2012] Journal of Immunology (189) 12 : 55135517. Impact factor : 5.520
[9]
Albiges, L., Chamming’s, F., Duclos, B., Stern, M., Motzer, R. J., Ravaud, A., and Camus, P. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. [2012] Annals
of Oncology (23) 8 : 1943-1953. Impact factor : 7.384
[10]
Albiges, L., Le Moulec, S., Loriot, Y., Goupil, M. Gross, Rouge, T. De La Motte, Guillot, A., Fizazi, K., and Massard,
C. Reponse to Cabazitaxel in the Postchemotherapy Setting in CRPC Patients Previously Treated with Docetaxel and
Abiraterone Acetate. [2012] Annals of Oncology (23) 9 : 313-313. Impact factor : 7.384
[11]
Albiges, L., Riet, F., Massard, C., Le Moulec, S., Loriot, Y., Levy, A., Fizazi, K., and Escudier, B. Second line treatment in metastatic papillary renal cell carcinoma: retrospective analysis of a 48 patients cohort. [2012] Annals of
Oncology (23) 9 : 277-277. Impact factor : 7.384
[12]
Aleksandrova, K., Boeing, H., Jenab, M., Bueno-de-Mesquita, H. B., Jansen, E., Van duijnhoven, F. J., Fedirko,
V., Rinaldi, S., Romieu, I., Riboli, E., Romaguera, D., Westphal, S., Overvad, K., Tjonneland, A., Boutron-Ruault,
M. C., Clavel-Chapelon, F., Kaaks, R., Lukanova, A., Trichopoulou, A., Lagiou, P., Trichopoulos, D., Agnoli, C.,
Mattiello, A., Saieva, C., Vineis, P., Tumino, R., Peeters, P. H., Argüelles, M., Bonet, C., Sanchez, M., Dorronsoro,
M., Huerta, J., Barricarte, A., Palmqvist, R., Hallmans, G., Khaw, K., Wareham, N., Allen, N. E., Crowe, F. L., and
Pischon, T. Total and high-molecular weight adiponectin and risk of colorectal cancer: The European prospective
investigation into cancer and nutrition study. [2012] Carcinogenesis (33) 6 : 1211-1218. Impact factor : 5.635
[13]
Aleksandrova, K., Boeing, H., Jenab, M., Bueno-de-Mesquita, H. B., Jansen, E., Van Duijnhoven, F. J. B., Rinaldi,
S., Fedirko, V., Romieu, I., Riboli, E., Gunter, M. J., Westphal, S., Overvad, K., Tjonneland, A., Halkjaer, J.,
Racine, A., Boutron-Ruault, M. C., Clavel-Chapelon, F., Kaaks, R., Lukanova, A., Trichopoulou, A., Lagiou, P.,
Trichopoulos, D., Mattiello, A., Pala, V., Palli, D., Tumino, R., Vineis, P., Buckland, G., Sanchez, M. J., Amiano, P.,
Huerta, J. M., Barricarte, A., Menendez, V., Peeters, P. H., Soderberg, S., Palmqvist, R., Allen, N. E., Crowe, F.
L., Khaw, K. T., Wareham, N., and Pischon, T. Leptin and soluble leptin receptor in risk of colorectal cancer in the
European prospective investigation into cancer and nutrition cohort. [2012] Cancer Research (72) 20 : 5328-5337.
Impact factor : 8.650
[14]
Allard, D., Lacroix-Triki, M., Maillot, G., Mhamdi, L., Pierredon, S., Obrist, F., Goubar, A., Roche, H., Andre, F.,
and Vagner, S. A FEEDBACK REGULATORY LOOP BETWEEN MIR-125B AND BRMS1 LINKED TO BREAST TUMOR
PROGRESSION. [2012] Annals of Oncology (23) 2. Impact factor : 7.384
[15]
Andre, F., Conforti, R., Moeder, C. B., Mauguen, A., Arnedos, M., Berrada, N., Delaloge, S., Tomasic, G., Spielmann, M., Esteva, F. J., Rimm, D. L., and Michiels, S. Association between the nuclear to cytoplasmic ratio of p27
and the efficacy of adjuvant polychemotherapy in early breast cancer. [2012] Annals of Oncology (23) 8 : 20592064. Impact factor : 7.384
[16]
Andre, F. and Zielinski, C. C. Optimal strategies for the treatment of metastatic triple-negative breast cancer with
currently approved agents. [2012] Annals of Oncology (23) SUPPL. 6 : vi46-vi51. Impact factor : 7.384
[17]
Andre, F. Introduction: recent failures in drug development for TN MBC. [2012] Annals of Oncology (23) 9 : 29-29.
[18]
Andre, F., Nowak, F., Arnedos, M., Lacroix, L., Viens, P., and Calvo, F. Biomarker discovery, development, and implementation in France: A report from the French National Cancer Institute and Cooperative Groups. [2012] Clinical
Cancer Research (18) 6 : 1555-1560. Impact factor : 7.837
[19]
Andre, Fabrice, Dieci, Maria V., Dubsky, Peter, Sotiriou, Christos, Curigliano, Giuseppe, Denkert, Carsten, and
Loi, Sherene Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in
Breast Cancer. [2012] Clinical Cancer Research. Impact factor : 7.837
[20]
Angevin, E., Trillet-Lenoir, V., Isambert, N., Alexandre, J., Valleix, F., Podoll, T., Miyashita, I., Yamada, T.,
Kaneko, Y., and Morimoto, C. First-in-human phase 1 administration of YS110, a humanized monoclonal antibody
directed against the CD26 molecule in cancer patients. [2012] Annals of Oncology (23) 9 : 170-171. Impact factor :
7.384
[21]
Antoniou, Antonis C., Kuchenbaecker, Karoline B., Soucy, Penny, Beesley, Jonathan, Chen, Xiaoqing, McGuffog,
Lesley, Lee, Andrew, Barrowdale, Daniel, Healey, Sue, Sinilnikova, Olga M., Caligo, Maria A., Loman, Niklas,
Harbst, Katja, Lindblom, Annika, Arver, Brita, Rosenquist, Richard, Karlsson, Per, Nathanson, Kate, Domchek,
Susan, Rebbeck, Tim, Jakubowska, Anna, Lubinski, Jan, Jaworska, Katarzyna, Durda, Katarzyna, Zlowowcka-Perlowska, Elzbieta, Osorio, Ana, Duran, Mercedes, Andres, Raquel, Benitez, Javier, Hamann, Ute, Hogervorst, Frans B., van Os, Theo A., Verhoef, Senno, Meijers-Heijboer, Hanne E. J., Wijnen, Juul, Garcia, Encarna
B. G., Ligtenberg, Marjolijn J., Kriege, Mieke, Collee, Margriet, Ausems, Margreet G. E. M., Oosterwijk, Jan C.,
Peock, Susan, Frost, Debra, Ellis, Steve D., Platte, Radka, Fineberg, Elena, Evans, D. Gareth, Lalloo, Fiona, Jacobs, Chris, Eeles, Ros, Adlard, Julian, Davidson, Rosemarie, Cole, Trevor, Cook, Jackie, Paterson, Joan, Douglas, Fiona, Brewer, Carole, Hodgson, Shirley, Morrison, Patrick J., Walker, Lisa, Rogers, Mark T., Donaldson,
Alan, Dorkins, Huw, Godwin, Andrew K., Bove, Betsy, Stoppa-Lyonnet, Dominique, Houdayer, Claude, Buecher,
Bruno, de Pauw, Antoine, Mazoyer, Sylvie, Calender, Alain, Leone, Melanie, Bressac-de Paillerets, Brigitte, Caron, Olivier, Sobol, Hagay, Frenay, Marc, Prieur, Fabienne, Ferrer, Sandra Fert, Mortemousque, Isabelle, Buys,
Saundra, Daly, Mary, Miron, Alexander, Terry, Mary Beth, Hopper, John L., John, Esther M., Southey, Melissa,
Goldgar, David, Singer, Christian F., Fink-Retter, Anneliese, Tea, Muy Kheng, Kaulich, Daphne Geschwantler,
Hansen, Thomas V. O., Nielsen, Finn C., Barkardottir, Rosa B., Gaudet, Mia, Kirchhoff, Tomas, Joseph, Vijai,
Dutra-Clarke, Ana, Offit, Kenneth, Piedmonte, Marion, Kirk, Judy, Cohn, David, Hurteau, Jean, Byron, John,
Fiorica, James, Toland, Amanda E., Montagna, Marco, Oliani, Cristina, Imyanitov, Evgeny, Isaacs, Claudine,
Tihomirova, Laima, Blanco, Ignacio, Lazaro, Conxi, Teule, Alex, Del Valle, J., Gayther, Simon A., Odunsi, Kunle,
Gross, Jenny, Karlan, Beth Y., Olah, Edith, Teo, Soo Hwang, Ganz, Patricia A., Beattie, Mary S., Dorfling, Cecelia
M., van Rensburg, Elizabeth Jansen, Diez, Orland, Kwong, Ava, Schmutzler, Rita K., Wappenschmidt, Barbara,
Engel, Christoph, Meindl, Alfons, Ditsch, Nina, Arnold, Norbert, Heidemann, Simone, Niederacher, Dieter,
Preisler-Adams, Sabine, Gadzicki, Dorothea, Varon-Mateeva, Raymonda, Deissler, Helmut, Gehrig, Andrea,
Sutter, Christian, Kast, Karin, Fiebig, Britta, Schaefer, Dieter, Caldes, Trinidad, de la Hoya, Miguel, Nevanlinna,
Heli, Muranen, Taru A., Lesperance, Bernard, Spurdle, Amanda B., Neuhausen, Susan L., Ding, Yuan C., Wang,
Xianshu, Fredericksen, Zachary, Pankratz, Vernon S., Lindor, Noralane M., Peterlongo, Paolo, Manoukian,
Siranoush, Peissel, Bernard, Zaffaroni, Daniela, Bonanni, Bernardo, Bernard, Loris, Dolcetti, Riccardo, Papi,
Laura, Ottini, Laura, Radice, Paolo, Greene, Mark H., Loud, Jennifer T., Andrulis, Irene L., Ozcelik, Hilmi, Mulligan, Anna Marie, Glendon, Gord, Thomassen, Mads, Gerdes, Anne Marie, Jensen, Uffe B., Skytte, Anne Bine,
Kruse, Torben A., Chenevix-Trench, Georgia, Couch, Fergus J., Simard, Jacques, Easton, Douglas F., Collaborator, CIMBA Study, Collaborator, SWE BRCA Study, Collaborator, HEBON Study, Collaborator, EMBRACE Study,
Collaborator, GEMO Study, and Investigators, K. C. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365
are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. [2012] Breast Cancer Research
(14) 1. Impact factor : 5.872
[22]
[23]
Antony-Debré, I., Bluteau, D., Itzykson, R., Baccini, V., Renneville, A., Boehlen, F., Morabito, M., Droin, N.,
Deswarte, C., Chang, Y., Leverger, G., Solary, E., Vainchenker, W., Favier, R., and Raslova, H. MYH10 protein
expression in platelets as a biomarker of RUNX1 and FLI1 alterations. [2012] Blood (120) 13 : 2719-2722. Impact
factor : 9.060
Arnault, J. P., Mateus, C., Escudier, B., Tomasic, G., Wechsler, J., Hollville, E., Soria, J. C., Malka, D., Sarasin, A.,
Larcher, M., André, J., Kamsu-Kom, N., Boussemart, L., Lacroix, L., Spatz, A., Eggermont, A. M., Druillennec, S.,
Vagner, S., Eychène, A., Dumaz, N., and Robert, C. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway
activation and oncogenic mutations of HRAS, TP53, and TGFBR1. [2012] Clinical Cancer Research (18) 1 : 263-272.
[24]
Arnedos, M., Scott, V., Job, B., De La Cruz, J., Commo, F., Mathieu, M. C., Wolp-Diniz, R., Richon, C., Campone,
M., Bachelot, T., Dalenc, F., Dessen, P., Lacroix, L., Lazar, V., Soria, J. C., Delaloge, S., and Andre, F. Array CGH
and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with
metastatic breast cancer. [2012] European Journal of Cancer (48) 15 : 2293-2299. Impact factor : 5.061
[25]
Arnedos, Monica, André, Fabrice, Farace, Françoise, Lacroix, Ludovic, Besse, Benjamin, Robert, Caroline,
Soria, Jean Charles, and Eggermont, Alexander M. M. The challenge to bring personalized cancer medicine from
clinical trials into routine clinical practice: The case of the Institut Gustave Roussy. [2012] Molecular Oncology (6) 2 :
[26]
Auvray, C., Delahaye, A., Pflumio, F., Haddad, R., Amsellem, S., Miri-Nezhad, A., Broix, L., Yacia, A., Bulle, F.,
Fichelson, S., and Vigon, I. HOXC4 homeoprotein efficiently expands human hematopoietic stem cells and triggers
similar molecular alterations as HOXB4. [2012] Haematologica (97) 2 : 168-178. Impact factor : 5.935
[27]
Ayala-Ramirez, M., Chougnet, C. N., Habra, M. A., Palmer, J. L., Leboulleux, S., Cabanillas, M. E., Caramella,
C., Anderson, P., Al Ghuzlan, A., Waguespack, S. G., Deandreis, D., Baudin, E., and Jimenez, C. Treatment with
sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. [2012]
Journal of Clinical Endocrinology and Metabolism (97) 11 : 4040-4050. Impact factor : 6.430
[28]
Azim, Hatem A., Michiels, Stefan, Bedard, Philippe L., Singhal, Sandeep K., Criscitiello, Carmen, Ignatiadis, Michail, Haibe-Kains, Benjamin, Piccart, Martine J., Sotiriou, Christos, and Loi, Sherene Elucidating prognosis and
biology of breast cancer arising in young women using gene expression profiling. [2012] Clinical cancer research :
an official journal of the American Association for Cancer Research (18) 5 : 1341-1351. Impact factor : 7.837
[29]
Azizi, Amedeo A., Fox, Richard, Grill, Jacques, Mirow, Cora, Gnekow, Astrid, Walker, David, Perilongo, Giorgio,
Opocher, Enrico, Wheatley, Keith, and van Meeteren, Antoinette Y. N. S. Children below the age of two treated for
optic pathway glioma- a multinational, retrospective multivariate analysis of risk factors. [2012] Neuro-Oncology
(14) supp 1 : i79-i79. Impact factor : 6.180
[30]
Bachelot, T., Ferrero, J., Cropet, C., Bourgier, C., Abadie-Lacourtoisie, S., Levy, C., Legouffe, E., Lortholary, A.,
Pujade-Lauraine, E., and Treilleux, I. Translational studies within the TAMRAD randomized GINECO trial: evidence
for TOR1 activation marker as a predictive factor for everolimus efficacy in metastatic breast cancer (MBC). [2012]
Annals of Oncology (23) 2. Impact factor : 7.384
[31]
Bachner, M., Loriot, Y., Gross-goupil, M., Zucali, P. A., Horwich, A., Germa-lluch, J. R., Kollmannsberger, C.,
Stoiber, F., Fléchon, A., Oechsle, K., Gillessen, S., Oldenburg, J., Cohn-cedermark, G., Daugaard, G., Morelli, F.,
Sella, A., Harland, S., Kerst, M., Gampe, J., Dittrich, C., Fizazi, K., and De Santis, M. 2-18fluoro-deoxy-D-glucose
positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: A retrospective validation of the sempet trial. [2012] Annals of Oncology (23) 1 : 59-64. Impact factor : 7.384
[32]
Barret, M., Dalban, C., Taieb, J., Malka, D., Mansourbakht, T., Latko, E., and Antoun, S. Sarcopenia affects treatment toxicity in metastatic colorectal cancer patients: results of a prospective multicenter study. [2012] Annals of
[33]
Basch, E., Ryan, C. J., Kheoh, T., Fizazi, K., Logothetis, C. J., Rathkopf, D. E., Smith, M. R., Mainwaring, P. N.,
Hao, Y., Griffin, T., Li, S., Meyers, M., Molina, A., and Cleeland, C. THE IMPACT OF ABIRATERONE ACETATE (AA)
THERAPY ON PATIENT-REPORTED PAIN AND FUNCTIONAL STATUS IN CHEMOTHERAPY-NAIVE PATIENTS WITH
PROGRESSIVE, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). [2012] Annals of Oncology
(23) 9 : 295-295. Impact factor : 7.384
[34]
Bastie, J. N., Aucagne, R., Droin, N., Solary, E., and Delva, L. Heterogeneity of molecular markers in chronic
myelomonocytic leukemia: A disease associated with several gene alterations. [2012] Cellular and Molecular Life
Sciences (69) 17 : 2853-2861. Impact factor : 5.615
[35]
Bazin, H., Andre, F., Mathieu, M., Ho-Pun-Cheung, A., Lopez-Crapez, E., Mathis, G., and Garnero, P. PREDICTION
OF DISEASE OUTCOME WITH QUANTITATIVE MEASUREMENT OF HER-2 RECEPTOR EXPRESSION AND DIMERIZATION IN PATIENTS WITH BREAST CANCER. [2012] Annals of Oncology (23) 9 : 84-84. Impact factor : 7.384
[36]
Beleoken, E., Sobesky, R., Le Caer, J. P., Roche, B., Mustapha, M. Z., Guettier, C., Sebagh, M., Johanet, C., Samuel, D., Bourhis, J. H., Duclos-Vallee, J. C., and Ballot, E. AUTOIMMUNE-LIKE HEPATITIS FOLLOWING ALLOGENIC BONE MARROW TRANSPLANTATION: A NEW ENTITY CHARACTERISED BY USING A PROTEOMIC APPROACH.
[2012] Journal of Hepatology (56) 2. Impact factor : 9.858
[37]
Bendell, J., Roda, D., Mateo, J., Hollebecque, A., Mattos-Arruda, L., Meng, R., Isakoff, S., Molife, L. R., Tabernero, J., and Cervantes Ruiperez, A. PHASE IB DOSE-ESCALATION STUDY OF THE AKT INHIBITOR GDC-0068 WITH
DOCETAXEL (D) OR MODIFIED FOLFOX6 (F) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS. [2012] Annals of
[38]
Benhamou, Ygal, Assie, Cyrielle, Boelle, Pierre Yves, Buffet, Marc, Grillberger, Rana, Malot, Sandrine, Wynckel, Alain, Presne, Claire, Choukroun, Gabriel, Poullin, Pascale, Provot, Francois, Gruson, Didier, Hamidou,
Mohamed, Bordessoule, Dominique, Pourrat, Jacques, Mira, Jean Paul, Le Guern, Veronique, Pouteil-Noble,
Claire, Daubin, Cedric, Vanhille, Philippe, Rondeau, Eric, Palcoux, Jean Bernard, Mousson, Christiane, Vigneau,
Cecile, Bonmarchand, Guy, Guidet, Bertrand, Galicier, Lionel, Azoulay, Elie, Rottensteiner, Hanspeter, Veyradier, Agnes, Coppo, Paul, and Refer, Thrombotic Microangiopathies Development and validation of a predictive
model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic
purpura: the French TMA Reference Center experience. [2012] Haematologica (97) 8 : 1181-1186. Impact
factor : 5.935
[39]
Bennetzen, M. V., Marino, G., Pultz, D., Morselli, E., Faergeman, N. J., Kroemer, G., and Andersen, J. S. Phosphoproteomic analysis of cells treated with longevity-related autophagy inducers. [2012] Cell Cycle (11) 9 : 18271840. Impact factor : 5.243
[40]
Bennouna, J., Ducreux, M., Asselain, B., Phelip, J., Andre, T., Senellart, H., and Commenges, B. EFFICACY AND
SAFETY OF BEVACIZUMAB COMBINED WITH CHEMOTHERAPY IN DAILY PRACTICE IN 765 FRENCH PATIENTS
WITH MCRC: THE CONCERT COHORT AT A MAXIMUM OF 24 MONTHS FOLLOW-UP. [2012] Annals of Oncology (23)
9 : 218-218. Impact factor : 7.384
[41]
Benusiglio, P. R., Malka, D., De Pauw, A., Buecher, B., Rouleau, E., Colas, C., Grandjouan, S., Blayau, M., Delaloge, S., and Caron, O. Germline mutations in cdh1 and the hereditary diffuse gastric and lobular breast cancer
syndrome. [2012] Annals of Oncology (23) 9 : 175-175. Impact factor : 7.384
[42]
Bergmann, L., Kube, U., Albiges, L., Eymard, J., Schmidinger, M., Bamias, A., Ktiouet, M., Fischer, G., Xanthaki,
D., and Guderian, G. Pooled analysis of non-interventional studies of everolimus in patients with metastatic renal
cell carcinoma (MRCC) refractory to anti-VEGF therapy. [2012] Annals of Oncology (23) 9 : 278-278. Impact
factor : 7.384
[43]
Bergthold, Guillaume, Piette, Caroline, Raquin, Marie Anne, Dufour, Christelle, Varlet, Pascale, Dhermain,
Frederic, Puget, Stephanie, Sainte-Rose, Christian, Abely, Michel, CANALE, Sandra, and Grill, Jacques Clinical
and radiological predictive factors of chemosensitivity in pediatric low grade gliomas: a single center study. [2012]
Neuro-Oncology (14) supp 1 : i76-i76. Impact factor : 6.180
[44]
Berruti, A., Baudin, E., Gelderblom, H., Haak, H. R., Porpiglia, F., Fassnacht, M., and Pentheroudakis, G. Adrenal
cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. [2012] Annals of Oncology (23)
SUPPL. 7 : vii131-vii138. Impact factor : 7.384
[45]
Bertrand, J., Despeaux, M., Joly, S., Bourogaa, E., Gallay, N., Demur, C., Bonnevialle, P., Louache, F., Maguer-Satta, V., Vergnolle, N., Payrastre, B., and Racaud-Sultan, C. Sex differences in the GSK3+Æ-mediated
survival of adherent leukemic progenitors. [2012] Oncogene (31) 6 : 694-705. Impact factor : 7.357
[46]
Besse, B., Le Moulec, S., Senellart, H., Mazieres, J., Barlesi, F., Dansin, E., Robinot, G., Perol, M., Moro-Sibilot,
D., and Soria, J. Phase II study of bevacizumab in combination with 1st-line chemotherapy or 2nd-line erlotinib
in non-squamous NSCLC (NS-NSCLC) patients with asymptomatic untreated brain metastases (ML21823). [2012]
Annals of Oncology (23) 9 : 426-427. Impact factor : 7.384
[47]
Besse, B. and Le chevalier, T. Developments in the treatment of early NSCLC: When to use chemotherapy. [2012]
Annals of Oncology (23) SUPPL. 10 : x52-x59. Impact factor : 7.384
[48]
Besse, B., Salgia, R., Solomon, B., Shaw, A., Kim, D., Schachar, R., Wilner, K., Reisman, A., Bartlett, C. H., and
Iyer, S. Visual disturbances in patients (PTS) with anaplastic lymphoma kinase (ALK)-positive advanced non-small
cell lung cancer (NSCLC) treated with crizotinib. [2012] Annals of Oncology (23) 9 : 416-416. Impact factor : 7.384
[49]
Bianchini, D., Loriot, Y., Ileana, E., Sandhu, S., Pezaro, C., Albiges, L., Attard, G., Fizazi, K., De Bono, J. S., and
Massard, C. Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100: a multicentre study. [2012] Annals of Oncology (23) 9 : 304-305. Impact factor : 7.384
[50]
Bidard, F., Ligthart, S. T., Bachelot, T., Delaloge, S., Brain, E., Campone, M., Viens, P., Pierga, J., and Terstappen,
L. W. M. M. Automated quantitative HER2 assessment in circulating tumor cells: discrepancies with primary tumor
in neoadjuvant and metastatic trials. [2012] Annals of Oncology (23) 2. Impact factor : 7.384
[51]
Bidard, F. C., Hajage, D., Bachelot, T., Delaloge, S., Brain, E., Campone, M., Cottu, P., Beuzeboc, P., Rolland,
E., Mathiot, C., and Pierga, J. Y. Assessment of circulating tumor cells and serum markers for progression-free
survival prediction in metastatic breast cancer: A prospective observational study. [2012] Breast Cancer Research
[52]
Blay, J. Y., Pérol, D., and Le Cesne, A. Imatinib rechallenge in patients with advanced gastrointestinal stromal
tumors. [2012] Annals of Oncology (23) 7 : 1659-1665. Impact factor : 7.384
[53]
Bluteau, D., Glembotsky, A. C., Raimbault, A., Balayn, N., Gilles, L., Rameau, P., Nurden, P., Alessi, M. C., Debili, N.,
Vainchenker, W., Heller, P. G., Favier, R., and Raslova, H. Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional
RUNX1 mutations is linked to myosin II deregulated expression. [2012] Blood (120) 13 : 2708-2718. Impact factor : 9.060
[54]
Boichard, A., Croux, L., Al Ghuzlan, A., Broutin, S., Dupuy, C., Leboulleux, S., Schlumberger, M., Bidart, J. M.,
and Lacroix, L. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid
carcinomas and extend to a previously unidentified exon. [2012] Journal of Clinical Endocrinology and Metabolism
(97) 10 : E2031-E2035. Impact factor : 6.430
[55]
Bonvalot, S., De Baere, T., Mendiboure, J., Paci, A., Farace, F., Drouard-Troalen, L., Bonnet, L., Hakime, A.,
Bonniaud, G., Raynard, B., Israel, P., Le Cesne, A., Eggermont, A. M., Laplanche, A., and Muret, J. Hyperthermic
pelvic perfusion with tumor necrosis factor-a for locally advanced cancers: Encouraging results of a phase II study.
[2012] Annals of Surgery (255) 2 : 281-286. Impact factor : 6.329
[56]
Bonvalot, S., Desai, A., Coppola, S., Le péchoux, C., Terrier, P., Dômont, J., and Le Cesne, A. The treatment of desmoid
tumors: A stepwise clinical approach. [2012] Annals of Oncology (23) SUPPL. 10 : x158-x166. Impact factor : 7.384
[57]
Bonvalot, S., Meeus, P., Stoeckle, E., Bui, B., Le Cesne, A., Penel, N., Ray-Coquard, I. L., Coindre, J., Chemin, C.,
Blay, J., and Network, Netsarc Natl Organisation of sarcoma patient management in reference centers in NETSARC
network: analysis of the quality of resection. [2012] Annals of Oncology (23) 9 : 482-482. Impact factor : 7.384
[58]
Borget, I., Cadranel, J., Pignon, J. P., Quoix, E., Coudert, B., Westeel, V., Dansin, E., Madelaine, J., Madroszyk, A.,
Friard, S., Daniel, C., Morin, F., and Chouaid, C. Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. [2012] EUROPEAN RESPIRATORY JOURNAL (39) 1 :
[59]
Borget, I., Perol, M., Perol, D., Lavole, A., Greillier, L., Gervais, R., Zalcman, G., Chabaud, S., Vergnenegre, A.,
and Chouaid, C. Cost-utility analysis of maintenance therapy with either gemcitabine or erlotinib versus observation
with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC:
IFCT-GFPC 0502-ECO phase III study. [2012] Annals of Oncology (23) 9 : 397-398. Impact factor : 7.384
[60]
Boubakour-Azzouz, I., Bertrand, P., Claes, A., Lopez, B. S., and Rougeon, F. Terminal deoxynucleotidyl transferase
requires KU80 and XRCC4 to promote N-addition at non-V(D)J chromosomal breaks in non-lymphoid cells. [2012]
Nucleic Acids Research (40) 17 : 8381-8391. Impact factor : 8.278
[61]
Bouche, O., Le Cesne, A., Rios, M., Chaigneau, L., Bui, B., Xavier, P., and Blay, J. Real-life management of advanced
gastrointestinal stromal tumors (GIST) treated with imatinib in France. [2012] Annals of Oncology (23) 9 : 236-236.
[62]
Bourgier, C., Levy, A., Vozenin, M. C., and Deutsch, E. Pharmacological strategies to spare normal tissues from
radiation damage: Useless or overlooked therapeutics? [2012] Cancer and Metastasis Reviews (31) 3-4 : 699-712.
[63]
Bracarda, S., Hutson, T. E., Porta, C., Figlin, R. A., Calvo, E., Grünwald, V., Ravaud, A., Motzer, R., Kim, D., Anak, O.,
Panneerselvam, A., and Escudier, B. Everolimus in metastatic renal cell carcinoma patients intolerant to previous
VEGFr-TKI therapy: A RECORD-1 subgroup analysis. [2012] British Journal of Cancer (106) 9 : 1475-1480. Impact
factor : 5.082
[64]
Braem, M. G. M., Onland-Moret, N. C., Schouten, L. J., Tjonneland, A., Hansen, L., Dahm, C. C., Overvad, K., Lukanova, A., Dossus, L., Floegel, A., Boeing, H., Clavel-Chapelon, F., Chabbert-Buffet, N., Fagherazzi, G., Trichopoulou, A., Benetou, V., Goufa, I., Pala, V., Galasso, R., Mattiello, A., Sacerdote, C., Palli, D., Tumino, R., Gram,
I. T., Lund, E., Gavrilyuk, O., Sanchez, M. J., Quiros, R., Gonzales, C. A., Dorronsoro, M., Huerta Castano, J. M.,
Gurrea, A. B., Idahl, A., Ohlson, N., Lundin, E., Jirstrom, K., Wirfalt, E., Allen, N. E., Tsilidis, K. K., Kaw, K. T., Bueno-de-Mesquita, H. B., Dik, V. K., Rinaldi, S., Fedirko, V., Norat, T., Riboli, E., Kaaks, R., and Peeters, P. H. M. Coffee
and tea consumption and the risk of ovarian cancer: A prospective cohort study and updated meta-analysis. [2012]
American Journal of Clinical Nutrition (95) 5 : 1172-1181. Impact factor : 6.504
[65]
Brennan, K., Garcia-Closas, M., Orr, N., Fletcher, O., Jones, M., Ashworth, A., Swerdlow, A., Thorne, H., Riboli, E.,
Vineis, P., Dorronsoro, M., Clavel-Chapelon, F., Panico, S., Onland-Moret, N. C., Trichopoulos, D., Kaaks, R., Khaw,
K. T., Brown, R., and Flanagan, J. M. Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast
cancer risk. [2012] Cancer Research (72) 9 : 2304-2313. Impact factor : 8.650
[66]
Bussone, Guillaume, Tamby, Mathieu C., Calzas, Cynthia, Kherbeck, Nada, Sahbatou, Younes, Sanson, Claire,
Ghazal, Khaldoun, Dib, Hanadi, Weksler, Babette B., Broussard, Cedric, Verrecchia, Franck, Yaici, Azzedine,
Witko-Sarsat, Veronique, Simonneau, Gerald, Guillevin, Loic, Humbert, Marc, and Mouthon, Luc IgG from patients
with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces
cell contraction. [2012] ANNALS OF THE RHEUMATIC DISEASES (71) 4 : 596-605. Impact factor : 9.111
[67]
Calvo, E., Escudier, B., Motzer, R. J., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Gr++nwald, V., Thompson, J.
A., Ravaud, A., Kim, D., Panneerselvam, A., Anak, O., and Figlin, R. A. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase
inhibitor therapies enrolled in the phase III RECORD-1 study. [2012] European Journal of Cancer (48) 3 : 333-339.
[68]
Cano, C. E., Sandi, M. J., Hamidi, T., Calvo, E. L., Turrini, O., Bartholin, L., Loncle, C., Secq, V., Garcia, S., Lomberk,
G., Kroemer, G., Urrutia, R., and Iovanna, J. L. Homotypic cell cannibalism, a cell-death process regulated by the
nuclear protein 1, opposes to metastasis in pancreatic cancer. [2012] EMBO Molecular Medicine (4) 9 : 964-979.
[69]
Cao, C., Yan, T. D., Deraco, M., Elias, D., Glehen, O., Levine, E. A., Moran, B. J., Morris, D. L., Chua, T. C., Piso, P.,
Sugarbaker, P. H., Baratti, D., Kusamura, S., Gilly, F. N., Shen, P., and Mohamed, F. Importance of gender in diffuse
malignant peritoneal mesothelioma. [2012] Annals of Oncology (23) 6 : 1494-1498. Impact factor : 7.384
[70]
Caputo, S., Benboudjema, L., Sinilnikova, O., Rouleau, E., Béroud, C., Lidereau, R., Sevenet, N., Bonnet, F., Longy,
M., Hardouin, A., Vaur, D., Krieger, S., Uhrhammer, N., Bignon, Y. J., Peyrat, J. P., Revillion, F., Fournier, J., Remenieras, A., Mazoyer, S., léone, M., Sobol, H., Noguchi, T., Bourdon, V., Rey, J. M., Bronner, M., Jonveaux, P., Philippe, C., Delnatte, C., Coulet, F., Castera, L., Caux-Moncoutier, V., Houdayer, C., Stoppa-Lyonnet, D., Delvincourt,
C., Gorisse, M. C., Bièche, I., Lefol, C., Muller, D., Abecassis, J., Toulas, C., Guillaud-Bataille, M., and Paillerets, B.
B. D. Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in
the UMD-BRCA1/BRCA2 databases. [2012] Nucleic Acids Research (40) D1 : D992-D1002. Impact factor : 8.278
[71]
Cardoso, F., Loibl, S., Pagani, O., Graziottin, A., Panizza, P., Martincich, L., Gentilini, O., Peccatori, F., Fourquet, A.,
Delaloge, S., Marotti, L., Penault-Llorca, F., Kotti-Kitromilidou, A. M., Rodger, A., and Harbeck, N. The European
Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer.
[2012] European Journal of Cancer (48) 18 : 3355-3377. Impact factor : 5.061
[72]
Carmona-Gutierrez, D., Sommer, C., Andryushkova, A., Kroemer, G., and Madeo, F. A higher spirit: Avoiding yeast
suicide during alcoholic fermentation. [2012] Cell Death and Differentiation (19) 6 : 913-914. Impact factor : 8.371
[73]
Carson, C., Omolo, B., Chu, H., Zhou, Y., Sambade, M. J., Peters, E. C., Tompkins, P., Simpson, D. A., Thomas, N. E.,
Fan, C., Sarasin, A., Dessen, P., Shields, J. M., Ibrahim, J. G., and Kaufmann, W. K. A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines. [2012] Pigment Cell and Melanoma Research (25)
4 : 514-526. Impact factor : 5.839
[74]
Carson, C., Omolo, B., Chu, H., Zhou, Y., Tompkins, P., Simpson, D., Fan, C., Sarasin, A., Dessen, P., Ibrahim, J.,
Kaufmann, W., and Thomas, N. Using a gene signature to predict metastases in melanoma patients. [2012] Journal of
investigative dermatology (132) 1 : S27-S27. Impact factor : 6.193
[75]
Casali, P. G., Reichardt, P., Kang, Y., Blay, J., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., Badalamenti, G., Blackstein, M., Le Cesne, A., Schoffski, P., Maki, R., Xu, J., Nishida, T., Kuss,
I., Laurent, D., and Demetri, G. D. Clinical benefit with regorafenib across subgroups and post-progression in patients
with advanced gastrointestinal stromal tumor (GIST) after progression on imatinib (IM) and sunitinib (SU): phase 3
grid trial update. [2012] Annals of Oncology (23) 9 : 478-479. Impact factor : 7.384
[76]
Cassier, P. A., Gelderblom, H., Stacchiotti, S., Thomas, D., Maki, R. G., Kroep, J. R., Van Der Graaf, W. T., Italiano,
A., Seddon, B., D+¦mont, J., Bompas, E., Wagner, A. J., and Blay, J. Y. Efficacy of imatinib mesylate for the treatment
of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. [2012] Cancer
(118) 6 : 1649-1655. Impact factor : 5.201
[77]
Castedo, M., Senovilla, L., Vitale, I., and Kroemer, G. Tetraploid cancer cell precursors in ovarian carcinoma. [2012]
Cell Cycle (11) 17 : 3157-3158. Impact factor : 5.243
[78]
Cella, D., Kaiser, K., Beaumont, J., Diaz, J., McCann, L., Mehmud, F., Lata, S., Bono, P., Porta, C., and Escudier, B.
Quality of life (QOL) among renal cell carcinoma (RCC) patients in a randomized double blind cross-over patient preference study of pazopanib (P) versus sunitinib (S). [2012] Annals of Oncology (23) 9 : 261-262. Impact factor : 7.384
[79]
Colin, C., De Vathaire, F., Noël, A., Charlot, M., Devic, C., Foray, N., and Valette, P. J. Updated relevance of mammographic screening modalities in women previously treated with chest irradiation for hodgkin disease. [2012] Radiology
(265) 3 : 669-676. Impact factor : 6.339
[80]
Coppo, Paul and VEYRADIER, Agnès Microangiopathies thrombotiques : référentiels hémostase/Société française
d’hématologie (Thrombotic microangiopathic syndromes: SFH recommendations]. [2012] Hématologie (18) 4 : 221232. Impact factor : 5.935
[81]
Coriat, Romain, Nicco, Carole, Chéreau, Christiane, Mir, Olivier, Alexandre, J., Ropert, Stanislas, Weill, Bernard,
Chaussade, Stanislas, Goldwasser, François, and Batteux, Frédéric Sorafenib-induced hepatocellular carcinoma
cell death depends on reactive oxygen species production in vitro and in vivo. [2012] Molecular cancer therapeutics
(11) 10 : 2284-2293. Impact factor : 5.599
[82]
Cortés, J., Caralt, M., Delaloge, S., Cortes-Funes, H., Pierga, J. Y., Pritchard, K. I., Bollag, D. T., and Miles, D. W.
Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. [2012] European Journal of Cancer
(48) 4 : 475-481. Impact factor : 5.061
[83]
Cosnefroy, O., Tocco, A., Lesbats, P., Thierry, S., Calmels, C., Wiktorowicz, T., Reigadas, S., Kwon, Y., De Cian, A.,
Desfarges, S., Bonot, P., San Filippo, J., Litvak, S., Le Cam, E., Rethwilm, A., Fleury, H., Connell, P. P., Sung, P., Delelis, O., Andréola, M. L., and Parissi, V. Stimulation of the human RAD51 nucleofilament restricts HIV-1 integration
in vitro and in infected cells. [2012] Journal of Virology (86) 1 : 513-526. Impact factor : 5.076
[84]
Cousin, S., Hollebecque, A., Koscielny, S., Varga, A., Baracos, V., Soria, J., and Antoun, S. BODY COMPOSITION IS
LINKED TO TOXICITY AND OUTCOME IN PATIENTS (PTS) INCLUDED IN PHASE I TRIALS. [2012] Annals of Oncology
(23) 9 : 168-169. Impact factor : 7.384
[85]
Criollo, A., Chereau, F., Malik, S. A., Niso-Santano, M., Marino, G., Galluzzi, L., Maiuri, M. C., Baud, V., and Kroemer, G. Autophagy is required for the activation of NF+¦B. [2012] Cell Cycle (11) 1 : 194-199. Impact factor : 5.243
[86]
Criollo, A., Chereau, F., Malik, S. A., Niso-Santano, M., Marino, G., Galluzzi, L., Maiuri, M. C., Baud, V., and Kroemer, G. Autophagy is required for the activation of NFkB (erratum : Cell Cycle 11, 1 (194-199)). [2012] Cell Cycle (11)
24 : 4673-4673. Impact factor : 5.243
[87]
Cufer, T., Cardoso, F., Werutsky, G., Bonnefoi, H., Brain, E., Cataliotti, L., Dal Lago, L., Delaloge, S., Jassem, J., van
Tienhoven, G., Van’t Veer, L., Westenberg, H., Marreaud, S., Bogaerts, J., Rutgers, E., and Cameron, D. The EORTC
Breast Cancer Group: Major achievements of 50 years of research and future directions. [2012] European Journal
of Cancer, Supplement (10) 1 : 27-33. Impact factor : 5.061
[88]
Daboussi, F., Zaslavskiy, M., Poirot, L., Loperfido, M., Gouble, A., Guyot, V., Leduc, S., Galetto, R., Grizot, S.,
Oficjalska, D., Perez, C., Delacôte, F., Dupuy, A., Chion-Sotinel, I., Le Clerre, D., Lebuhotel, C., Danos, O., Lemaire,
F., Oussedik, K., Cédrone, F., Epinat, J. C., Smith, J., Yanez-Munoz, R. J., Dickson, G., Popplewell, L., Koo, T.,
Vandendriessche, T., Chuah, M. K., Duclert, A., Duchateau, P., and Pâques, F. Chromosomal context and epigenetic
mechanisms control the efficacy of genome editing by rare-cutting designer endonucleases. [2012] Nucleic Acids
Research (40) 13 : 6367-6379. Impact factor : 8.278
[89]
Dalmay, C., De Menorval, M. A., Français, O., Mir, L. M., and Le Pioufle, B. A microfluidic device with removable packaging for the real time visualisation of intracellular effects of nanosecond electrical pulses on adherent cells. [2012]
Lab on a Chip - Miniaturisation for Chemistry and Biology (12) 22 : 4709-4715. Impact factor : 5.697
[90]
Damm, F., Kosmider, O., Gelsi-Boyer, V., Renneville, A., Carbuccia, N., Hidalgo-Curtis, C., Della Valle, V., Couronné,
L., Scourzic, L., Chesnais, V., Guerci-Bresler, A., Slama, B., Beyne-Rauzy, O., Schmidt-Tanguy, A., Stamatoullas-Bastard, A., Dreyfus, F., Prébet, T., De Botton, S., Vey, N., Morgan, M. A., Cross, N. C. P., Preudhomme, C., Birnbaum, D.,
Bernard, O. A., and Fontenay, M. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate
with patient outcome in myelodysplastic syndromes. [2012] Blood (119) 14 : 3211-3218. Impact factor : 9.060
[91]
David, M., Petit, D., and Bertoglio, J. Cell cycle regulation of Rho signaling pathways. [2012] Cell Cycle (11) 16 : 30033010. Impact factor : 5.243
[92]
de Lara, C. Tunon, Giard, S., Baron, M., Le Bouedec, G., Garbay, J. R., Blanchot, J., Mollard, J., Charitansky, H., Martin-Francoise, S., and Macgrogan, G. Sentinel Node Biopsy in Extensive Ductal Carcinoma in Situ (DCIS) Results of the
French Prospective Trial CINNAMOME. [2012] European Journal of Cancer (48) 1 : S190-S191. Impact factor : 5.061
[93]
de Leval, L., Bonnet, C., Copie-Bergman, C., Seidel, L., Baia, M., Bri+¿re, J., Molina, T. J., Fabiani, B., Petrella, T.,
Bosq, J., Gisselbrecht, C., Siebert, R., Tilly, H., Haioun, C., Fillet, G., and Gaulard, P. Diffuse large B-cell lymphoma
of waldeyer’s ring has distinct clinicopathologic features: A GELA study. [2012] Annals of Oncology (23) 12 : 3143-3151.
[94]
De Masson, A., Bouaziz, J. D., De Latour, R. P., Wittnebel, S., Ribaud, P., Rubio, M. T., Micol, J. B., Suarez, F.,
Nguyen, S., Dalle, J. H., Yakouben, K., Robin, M., Xhaard, A., Adès, L., Bourhis, J. H., Rybojad, M., Bagot, M., and
Socié, G. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.
[2012] Blood (120) 25 : 5089-5090. Impact factor : 9.060
[95]
De Ruysscher, D., Ramaekers, B. L. T., Joore, M. A., Lueza, B., Bonastre, J., Mauguen, A., Pignon, J., Le Pechoux,
C., Grutters, J. P., and Grp, Mar LC Collaborative MODIFIED FRACTIONATION RADIOTHERAPY VERSUS CONVENTIONAL RADIOTHERAPY FOR UNRESECTED NON-SMALL CELL LUNG CANCER PATIENTS: A COST-EFFECTIVENESS
ANALYSIS. [2012] Annals of Oncology (23) 9 : 397-397 . Impact factor : 7.384
[96]
Decorsière, A., Toulas, C., Fouque, F., Tilkin-Mariamé, A. F., Selves, J., Guimbaud, R., Chipoulet, E., Delmas, C., Rey,
J. M., Pujol, P., Favre, G., Millevoi, S., and Vagner, S. Decreased efficiency of MSH6 mRNA polyadenylation linked to a
20-base-pair duplication in Lynch syndrome families. [2012] Cell Cycle (11) 13 : 2578-2580. Impact factor : 5.243
[97]
Delbaldo, C., Michiels, S., Rolland, E., Syz, N., Soria, J. C., Le chevalier, T., and Pignon, J. P. WITHDRAWN: Second
or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. [2012]
Cochrane database of systematic reviews (4). Impact factor : 5.703
[98]
Demetri, G. D., Garrett, C. R., Schöffski, P., Shah, M. H., Verweij, J., Leyvraz, S., Hurwitz, H. I., Pousa, A. L., Le
Cesne, A., Goldstein, D., Paz-Ares, L., Blay, J. Y., McArthur, G. A., Xu, Q., Huang, X., Harmon, C. S., Tassell, V.,
Cohen, D. P., and Casali, P. G. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of
sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. [2012] Clinical Cancer Research
(18) 11 : 3170-3179. Impact factor : 7.837
[99]
Demetri, G. D., Le Cesne, A., Chawla, S. P., Brodowicz, T., Maki, R. G., Bach, B. A., Smethurst, D. P., Bray, S., Hei,
Y. J., and Blay, J. Y. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with
conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study.
[100]
Deutsch, E., Rivera, C., and Rivera, S. NEW DRUGS ON THE HORIZON TARGETING STEM CELLS IN NSCLC. [2012]
[101]
Dib, Hanadi, Tamby, Mathieu C., Bussone, Guillaume, Regent, Alexis, Berezne, Alice, Lafine, Claudine, Broussard,
Cedric, Simonneau, Gerald, Guillevin, Loic, Witko-Sarsat, Veronique, Humbert, Marc, and Mouthon, Luc Targets
of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. [2012] EUROPEAN RESPIRATORY
JOURNAL (39) 6 : 1405-1414. Impact factor : 6.355
[102]
Dienstmann, R., Andre, F., Soria, J., Tabernero, J., De Braud, F. G. M., Cereda, R., Bahleda, R., Hollebecque, A.,
Delmonte, A., and Camboni, M. G. SIGNIFICANT ANTITUMOR ACTIVITY OF E-3810, A NOVEL FGFR AND VEGFR
INHIBITOR, IN PATIENTS WITH FGFR1 AMPLIFIED BREAST CANCER. [2012] Annals of Oncology (23) 9 : 116-117.
[103]
Dogan, S., Goubar, A., Arnedos, M., Delaloge, S., and Andre, F. EVOLUTION AND LANDSCAPE OF CLINICAL TRIALS
FOR BREAST CANCER PATIENTS. [2012] Annals of Oncology (23) 2. Impact factor : 7.384
[104]
DRAKE, C. G., EGGERMONT, Alexander M., FINN, Olivera J., and KERR, D. J. Combination immunotherapy
approaches. [2012] Annals of Oncology (23) SUP8 - Advances in Immuno-oncology. Impact factor : 7.384
[105]
Dromain, C., Thibault, F., Diekmann, F., Fallenberg, E. M., Jong, R. A., Koomen, M., Hendrick, R. E., Tardivon, A.,
and Toledano, A. Dual-energy contrast-enhanced digital mammography: Initial clinical results of a multireader,
multicase study. [2012] Breast Cancer Research (14) 3. Impact factor : 5.872
[106]
Ducreux, M., Lievre, A., Artru, P., Guiu, M., Merlin, J., Sabourin, J. C., Viguier, J., Bastie, A., Seronde, A., and
LAURENT-PUIG, P. REVIEW OF THE CURRENT STATUS OF KRAS MUTATION TESTING IN FRANCE IN 2011: THE
FLASH-KRAS STUDY. [2012] Annals of Oncology (23) 9 : 85-85. Impact factor : 7.384
[107]
Ducreux, Michel, Davidenko, Irina, Propper, David, Cardellino, Giovanni Gerardo, Garin, Avgust, Bridgewater,
John, Jain, Minesh, Kupcinskas, Limas, Safina, Sufiya, Fittipaldo, Alberto, Bordogna, Walter, Hillenbach, Carina,
and Klughammer, Barbara EXPLORATORY SERUM BIOMARKER ANALYSES FROM BO21129, A PHASE II STUDY
OF ERLOTINIB IN SECOND-LINE PANCREATIC CANCER: POTENTIAL ROLE OF AMPHIREGULIN? [2012] Annals of
[108]
Ducreux, Michel, Peeters, Marc, Siena, Salvatore, Douillard, Jean Yves, Punt, Cornelis, Braun, Stephan, Rong,
Alan, and Sidhu, Roger BENEFIT OF ADDING PANITUMUMAB (PMAB) TO 1ST/2ND-LINE CHEMOTHERAPY IN
PATIENTS WITH KRAS WT MCRC: A NUMBER-NEEDED-TO-TREAT (NNT) ANALYSIS. [2012] Annals of Oncology (23)
4 : 26-27. Impact factor : 7.384
[109]
Duell, E. J., Sala, N., Travier, N., Munoz, X., Boutron-Ruault, M. C., Clavel-Chapelon, F., Barricarte, A., Arriola, L.,
Navarro, C., Sanchez-Cantalejo, E., Quiros, J. R., Krogh, V., Vineis, P., Mattiello, A., Tumino, R., Khaw, K., Wareham,
N., Allen, N. E., Peeters, P. H., Numans, M. E., Bueno-de-Mesquita, H. B., Van Oijen, M. G. H., Bamia, C., Benetou,
V., Trichopoulos, D., Canzian, F., Kaaks, R., Boeing, H., Bergmann, M. M., Lund, E., Ehrnström, R., Johansen, D.,
Hallmans, G., Stenling, R., Tjonneland, A., Overvad, K., Ostergaard, J. N., Ferrari, P., Fedirko, V., Jenab, M., Nesi, G.,
Riboli, E., and Gonzalez, C. A. Genetic variation in alcohol dehydrogenase (ADH1A, ADH1B, ADH1C, ADH7) and aldehyde
dehydrogenase (ALDH2), alcohol consumption and gastric cancer risk in the European Prospective Investigation into
Cancer and nutrition (EPIC) Cohort. [2012] Carcinogenesis (33) 2 : 361-367. Impact factor : 5.635
[110]
[111]
[112]
[113]
[114]
[115]
[116]
[117]
[118]
[119]
[120]
[121]
Duffaud, F., Huynh, T., Cassier, P., Boucher, E., Bouche, O., Le Cesne, A., Landi, B., Mancini, J., Marchal, F., and
Blay, J. FINAL RESULTS OF A FRENCH SARCOMA GROUP (FSG) RETROSPECTIVE REVIEW OF 110 PATIENTS
WITH PRIMARY LOCALIZED GASTROINTESTINAL STROMAL TUMORS (GIST) OF THE DUODENUM. [2012] Annals of
Dufour, C., Beaugrand, A., Le Deley, M. C., Bourdeaut, F., André, N., Leblond, P., Bertozzi, A. I., Frappaz, D.,
Rialland, X., Fouyssac, F., Edan, C., Grill, J., Quidot, M., and Varlet, P. Clinicopathologic prognostic factors in
childhood atypical teratoid and rhabdoid tumor of the central nervous system: A multicenter study. [2012] Cancer
(118) 15 : 3812-3821. Impact factor : 5.201
Dunet, Vincent, Rossier, Christine, Buck, Alfred, Stupp, Roger, and Prior, John O. Performance of 18F-fluoro-ethyltyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis.
[2012] Journal of nuclear medicine : official publication, Society of Nuclear Medicine (53) 2 : 207-214. Impact factor :
5.774
Durand, J. P., Deplanque, G., Montheil, V., Gornet, J. M., Scotte, F., Mir, O., Cessot, A., Coriat, R., Raymond,
E., Mitry, E., Herait, P., Yataghene, Y., and Goldwasser, F. Efficacy of venlafaxine for the prevention and relief of
oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III
trial. [2012] Annals of oncology : official journal of the European Society for Medical Oncology / ESMO (23) 1 : 200205. Impact factor : 7.384
Dutertre, Charles Antoine, Amraoui, Sonia, DeRosa, Annalisa, Jourdain, Jean Pierre, Vimeux, Lene, Goguet,
Matthieu, Degrelle, Severine, Feuillet, Vincent, Liovat, Anne Sophie, Mueller-Trutwin, Michaela, Decroix, Nipa,
Deveau, Christiane, Meyer, Laurence, Goujard, Cecile, Loulergue, Pierre, Launay, Odile, Richard, Yolande, and
Hosmalin, Anne Pivotal role of M-DC8(+) monocytes from viremic HIV-infected patients in TNF alpha overproduction
in response to microbial products. [2012] Blood (120) 11 : 2259-2268. Impact factor : 9.060
Dutta, B., Pusztai, L., Qi, Y., André, F., Lazar, V., Bianchini, G., Ueno, N., Agarwal, R., Wang, B., Shiang, C. Y.,
Hortobagyi, G. N., Mills, G. B., Symmans, W. F., and Bal+ízsi, G. A network-based, integrative study to identify core
biological pathways that drive breast cancer clinical subtypes. [2012] British Journal of Cancer (106) 6 : 1107-1116.
Edeline, J., Loriot, Y., Culine, S., Massard, C., Albiges, L., Blesius, A., Escudier, B., and Fizazi, K. Accelerated MVAC
chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen.
Eggermont, A. M. M. Can immuno-oncology offer a truly pan-tumour approach to therapy? [2012] Annals of Oncology
(23) SUPPL.8 : viii53-viii57. Impact factor : 7.384
Eggermont, A. M. M., Suciu, S., Testori, A., Kruit, W. H., Marsden, J., Punt, C. J., Santinami, M., Sals, F.,
Schadendorf, D., Patel, P., Dummer, R., Robert, C., Keilholz, U., Yver, A., and Spatz, A. Ulceration and stage are
predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
Elias, D. WHEN TO THINK OF SURGERY PLUS OR MINUS HIPEC FOR PERITONEAL CARCINOMATOSIS. [2012] Annals
of Oncology (23) 9 : 35-35. Impact factor : 7.384
Ernoult-Lange, M., Baconnais, S., Harper, M., Minshall, N., Souquere, S., Boudier, T., Bénard, M., Andrey, P.,
Pierron, G., Kress, M., Standart, N., Le Cam, E., and Weil, D. Multiple binding of repressed mRNAs by the P-body
protein Rck/p54. [2012] RNA (18) 9 : 1702-1715. Impact factor : 5.088
Escudier, B., Eisen, T., Porta, C., Patard, J. J., Khoo, V., Algaba, F., Mulders, P., and Kataja, V. Renal cell carcinoma:
ESMO clinical practice guidelines for diagnosis, treatment and follow-up. [2012] Annals of Oncology (23) SUPPL. 7 :
vii65-vii71. Impact factor : 7.384
[122]
Escudier, B., Albiges, L., Massard, C., Loriot, Y., and Fizazi, K. How to select amongst available options for the
treatment of advanced RCC? [2012] Annals of Oncology (23) SUPPL. 10 : x309-x312. Impact factor : 7.384
[123]
Escudier, B., Osanto, S., Ljungberg, B., Porta, C., Wagstaff, J., Mulders, P., Gore, M., Bex, A., Bellmunt, J., Bracarda, S.,
Franklin, A., Honoré, P. H., Ravaud, A., Steijn, J. V., Aziz, Z., and Akaza, H. Multidisciplinary management of metastatic renal
cell carcinoma in the era of targeted therapies. [2012] Cancer Treatment Reviews (38) 2 : 127-132. Impact factor : 6.024
[124]
Escudier, B. Emerging immunotherapies for renal cell carcinoma. [2012] Annals of Oncology (23) SUPPL.8 :
viii35-viii40. Impact factor : 7.384
[125]
Escudier, B., Steelman, L., Cesic, D., and Berkenblit, A. PATIENT PREFERENCE FOR TIVOZANIB
HYDROCHLORIDE OR SUNITINIB IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC): TAURUS
STUDY. [2012] Annals of Oncology (23) 9 : 293-293. Impact factor : 7.384
[126]
Escudier, B., Bracarda, S., Maroto, J. P., Szczylik, C., Nathan, P., Negrier, S., Slimane, K., May, C., Porta, C., and
Gruenwald, V. OPEN-LABEL PHASE II TRIAL OF FIRST-LINE EVEROLIMUS MONOTHERAPY IN PATIENTS WITH
ADVANCED PAPILLARY RENAL CELL CARCINOMA: RAPTOR INTERIM ANALYSIS. [2012] Annals of Oncology (23) 9 :
[127]
Fabre, C., Koscielny, S., Mohty, M., Fegueux, N., Blaise, D., Maillard, N., Tabrizi, R., Michallet, M., Société, G.,
Yakoub-Agha, I., Garban, F., Uzunov, M., François, S., Contentin, N., Lapusan, S., and Bourhis, J. H. Younger
donor’s age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients
treated by tandem autologous-allogeneic stem cell transplantation: A retrospective study from the société
française de greffe de moelle. [2012] Haematologica (97) 4 : 482-490. Impact factor : 5.935
[128]
Fadoukhair, Z., Lefeuvre, D., Hofert, K., Lanoy, E., Rahhali, R., Mathieu, M., Mazouni, C., and Delaloge, S.
PROFESSIONAL ATTITUDES TOWARDS TREATMENT OF RARE HISTOLOGICAL SUBTYPES OF CARCINOMAS OF
THE BREAST: AN INTERNATIONAL PRACTICE SURVEY (PARIS STUDY). [2012] Annals of Oncology (23) 9 : 110-110.
[129]
Fagherazzi, G., Chabbert-Buffet, N., Fabre, A., Guillas, G., Boutron-Ruault, M. C., Mesrine, S., and ClavelChapelon, F. Hip circumference is associated with the risk of premenopausal ER-/PR breast cancer. [2012]
International Journal of Obesity (36) 3 : 431-439. Impact factor : 5.221
[130]
Farace, F., Le Moulec, S., Mazieres, J., Senellart, H., Dansin, E., Madroszyk, A., Quantin, X., Berard, H., and
Besse, B. CIRCULATING ENDOTHELIAL CELLS (CEC), CIRCULATING ENDOTHELIAL PROGENITORS (CEP)
AND CIRCULATING TUMOUR CELLS (CTC) AS MARKERS FOR RESPONSE TO BEVACIZUMAB/CARBOPLATIN/
PACLITAXEL (B plus CP) OR BEVACIZUMAB/ERLOTINIB (B plus E) IN ADVANCED NON-SQUAMOUS NON-SM.
[2012] Annals of Oncology (23) 9 : 406-407. Impact factor : 7.384
[131]
Farace, F. F., Lombard-Bohas, C., Mitry, E., Ychou, M., Bengrine-Lefevre, L., Lecomte, T., Joly, K., Ducreux,
M., and Baudin, E. PREDICTIVE VALUE OF CIRCULATING ENDOTHELIAL CELL (CEC) LEVELS IN METASTATIC OR
LOCALLY ADVANCED NEUROENDOCRINE DIGESTIVE TUMOR PATIENTS TREATED WITH CHEMOTHERAPY AND
BEVACIZUMAB. [2012] Annals of Oncology (23) 9 : 85-85. Impact factor : 7.384
[132]
Fauvet, R., Brzakowski, M., Morice, P., Resch, B., Marret, H., Graesslin, O., and Daraï, E. Borderline ovarian
tumors diagnosed during pregnancy exhibit a high incidence of aggressive features: Results of a French
multicenter study. [2012] Annals of Oncology (23) 6 : 1481-1487. Impact factor : 7.384
[133]
Felip, E., Carcereny, E., Barlesi, F., Gandhi, L., Sequist, L. V., Kim, S. W., Groen, H. J. M., Besse, B., Kim, D. W.,
Smit, E., Akimov, M., Avsar, E., Bailey, S., Ofosu-Appiah, W., and Garon, E. B. PHASE II ACTIVITY OF THE HSP90
INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NONSMALL CELL LUNG CANCER (NSCLC). [2012] Annals of Oncology (23) 9 : 152-152. Impact factor : 7.384
[134]
Ferme, Christophe, CHAIBI, Pascal, and ROCHAND, Henri Les modalités des traitements spécifiques du
lymphome de Hodgkin des sujets âgés. Prise en charge des hémopathies malignes du sujet âgés. Seconde partie.
[2012] Hématologie (18) SUP2 : 19-22. Impact factor : 5.935
[135]
Ferrand, F. R., Gourzones, C., Verillaud, B., Saada, E., Lang, P., Schneider, V., Amiel, C., Guigay, J., and Busson,
P. PLASMATIC EPSTEIN-BARR VIRUS MICRO-RNA-BART-17 IN NASOPHARYNGEAL CARCINOMAS PATIENTS:
HIGH POTENTIAL AS A TUMOR BIOMARKER ASSOCIATED TO EBV DNA CONCENTRATION. [2012] Annals of
[136]
Ferrari, A., De Salvo, G. L., Oberlin, O., Casanova, M., De Paoli, A., Rey, A., Minard, V., Orbach, D., Carli, M.,
Brennan, B., Vannoesel, M. M., Morosi, C., Stevens, M. C., and Bisogno, G. Synovial sarcoma in children and
adolescents: A critical reappraisal of staging investigations in relation to the rate of metastatic involvement at
diagnosis. [2012] European Journal of Cancer (48) 9 : 1370-1375. Impact factor : 5.061
[137]
Ferreira, Celine, Dieffenbach, Geoffrey, Barbosa, Carmela, Cuny, Pascale, and Grill, Jacques ANTI-TUMORAL
EFFECT OF THE HDACi SAHA ON PEDIATRIC GLIAL TUMORS. [2012] Neuro-Oncology (14) supplt 1 : 39-39. Impact
factor : 6.180
[138]
Fizazi, K., De Bono, J. S., Flechon, A., Heidenreich, A., Voog, E., Davis, N. B., Qi, M., Bandekar, R., Vermeulen, J. T.,
Cornfeld, M., and Hudes, G. R. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. [2012] European Journal of Cancer (48) 1 : 85-93. Impact factor : 5.061
[139]
Fizazi, K., Lesaunier, F., Delva, R., Gravis, G., Rolland, F., Priou, F., Ferrero, J. M., Houedé, N., Mourey, L.,
Theodore, C., Krakowski, I., Berdah, J. F., Baciuchka, M., Laguerre, B., Fléchon, A., Ravaud, A., Cojean-Zelek, I.,
Oudard, S., Labourey, J. L., Lagrange, J. L., Chinet-Charrot, P., Linassier, C., Deplanque, G., Beuzeboc, P., Geneve,
J., Davin, J. L., Tournay, E., and Culine, S. A phase III trial of docetaxel-estramustine in high-risk localised prostate
cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial. [2012] European Journal of
Cancer (48) 2 : 209-217. Impact factor : 5.061
[140]
Fizazi, K., Albiges, L., Massard, C., Escudier, B., and Loriot, Y. Novel and bone-targeted agents for CRPC. [2012]
Annals of Oncology (23) SUPPL. 10 : x264-x267. Impact factor : 7.384
[141]
Fizazi, K., Scher, H. I., Saad, F., Sternberg, C. N., Miller, K., Mulders, P., Chi, K., Basch, E., Hirmand, M., and De
Bono, J. S. IMPACT OF ENZALUTAMIDE, AN ANDROGEN RECEPTOR SIGNALING INHIBITOR, ON TIME TO FIRST
SKELETAL RELATED EVENT (SRE) AND PAIN IN THE PHASE 3 AFFIRM STUDY. [2012] Annals of Oncology (23) 9 :
[142]
Fizazi, K., Brown, J. E., Carducci, M., Shore, N. D., Sieber, P., Kueppers, F., Karsh, L., Wei, R., and Goessl, C.
DENOSUMAB IN PATIENTS WITH METASTATIC PROSTATE CANCER PREVIOUSLY TREATED WITH DENOSUMAB OR
ZOLEDRONIC ACID: 2-YEAR OPEN-LABEL EXTENSION PHASE RESULTS FROM THE PIVOTAL PHASE 3 STUDY. [2012]
[143]
Fouret, R., Laffaire, J., Hofman, P., Beau-Faller, M., Mazieres, J., Validire, P., Girard, P., Camilleri-Bröet, S.,
Vaylet, F., Leroy-Ladurie, F., Soria, J. C., and Fouret, P. A comparative and integrative approach identifies ATPase
Family, AAA Domain Containing 2 as a likely driver of cell proliferation in lung adenocarcinoma. [2012] Clinical Cancer
Research (18) 20 : 5606-5616. Impact factor : 7.837
[144]
Franciszkiewicz, Katarzyna, Boissonnas, Alexandre, Boutet, Marie, Combadière, Christophe, and Mami-Chouaib,
Fathia Role of Chemokines and Chemokine Receptors in Shaping the Effector Phase of the Antitumor Immune Response. [2012] Cancer Research (72) 24 : 6325-6332. Impact factor : 8.650
[145]
Frisan, E., Vandekerckhove, J., De Thonel, A., Pierre-Eugène, C., Sternberg, A., Arlet, J. B., Floquet, C., Gyan, E.,
Kosmider, O., Dreyfus, F., Gabet, A. S., Courtois, G., Vyas, P., Ribeil, J. A., Zermati, Y., Lacombe, C., Mayeux, P., Solary, E., Garrido, C., Hermine, O., and Fontenay, M. Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. [2012] Blood (119) 6 : 1532-1542. Impact factor : 9.060
[146]
Galluzzi, L., Kepp, O., and Kroemer, G. Reverse Warburg: Straight to cancer. [2012] Cell Cycle (11) 6 : 1059-1060.
[147]
Galluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., Dawson, T. M., Dawson,
V. L., El Deiry, W. S., Fulda, S., Gottlieb, E., Green, D. R., Hengartner, M. O., Kepp, O., Knight, R. A., Kumar, S.,
Lipton, S. A., Lu, X., Madeo, F., Malorni, W., Mehlen, P., Néez, G., Peter, M. E., Piacentini, M., Rubinsztein, D. C.,
Shi, Y., Simon, H. U., Vandenabeele, P., White, E., Yuan, J., Zhivotovsky, B., Melino, G., and Kroemer, G. Molecular
definitions of cell death subroutines: Recommendations of the Nomenclature Committee on Cell Death 2012. [2012]
Cell Death and Differentiation (19) 1 : 107-120. Impact factor : 8.371
[148]
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., and Kroemer, G. Molecular
mechanisms of cisplatin resistance. [2012] Oncogene (31) 15 : 1869-1883. Impact factor : 7.357
[149]
Galluzzi, L., Vitale, I., Senovilla, L., Eisenberg, T., Carmona-Gutierrez, D., Vacchelli, E., Robert, T., Ripoche, H.,
Jägemann, N., Paccard, C., Servant, N., Hupé, P., Lazar, V., Dessen, P., Barillot, E., Zischka, H., Madeo, F., and
Kroemer, G. Independent transcriptional reprogramming and apoptosis induction by cisplatin. [2012] Cell Cycle (11)
18 : 3472-3480. Impact factor : 5.243
[150]
Galluzzi, L., Kepp, O., and Kroemer, G. Enlightening the impact of immunogenic cell death in photodynamic cancer
therapy. [2012] EMBO Journal (31) 5 : 1055-1057. Impact factor : 9.822
[151]
Galluzzi, L., Kepp, O., and Kroemer, G. Caspase-3 and prostaglandins signal for tumor regrowth in cancer therapy.
[2012] Oncogene (31) 23 : 2805-2808. Impact factor : 7.357
[152]
Galluzzi, L., Kepp, O., Trojel-Hansen, C., and Kroemer, G. Non-apoptotic functions of apoptosis-regulatory
proteins. [2012] EMBO Reports (13) 4 : 322-330. Impact factor : 7.189
[153]
Galluzzi, Lorenzo, Marsili, Sabrina, Vitale, Ilio, Senovilla, Laura, Michels, Judith, Garcia, Pauline, Vacchelli,
Erika, Chatelut, Etienne, Castedo, Maria, and Kroemer, Guido Vitamin B6 metabolism influences the intracellular
accumulation of cisplatin. [2012] Cell Cycle (12) 3. Impact factor : 5.243
[154]
Garbay, D., Le Cesne, A., Penel, N., Chevreau, C., Marec-Berard, P., Blay, J. Y., Debled, M., Isambert, N., Thyss, A.,
Bompas, E., Collard, O., Salas, S., Coindre, J. M., Bui, B., and Italiano, A. Chemotherapy in patients with desmoid tumors:
A study from the French Sarcoma Group (FSG). [2012] Annals of Oncology (23) 1 : 182-186. Impact factor : 7.384
[155]
Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Spatz, A., Grob, J. J., Malvehy, J., Newton-Bishop,
J., Stratigos, A., Pehamberger, H., and Eggermont, A. M. Diagnosis and treatment of melanoma. European
consensus-based interdisciplinary guideline - Update 2012. [2012] European Journal of Cancer (48) 15 : 23752390. Impact factor : 5.061
[156]
Gaspar, N., Rey, A., Bérard, P. M., Michon, J., Gentet, J. C., Tabone, M. D., Roché, H., Defachelles, A. S., Lejars,
O., Plouvier, E., Schmitt, C., Bui, B., Boutard, P., Taque, S., Munzer, M., Vannier, J. P., Plantaz, D., Enz-Werlé, N.,
and Oberlin, O. Risk adapted chemotherapy for localised Ewing’s sarcoma of bone: The French EW93 study. [2012]
European Journal of Cancer (48) 9 : 1376-1385. Impact factor : 5.061
[157]
Gauler, T. C., Besse, B., Mauguen, A., Meric, J. B., Gounant, V., Fischer, B., Overbeck, T. R., Krissel, H., Laurent, D.,
Tiainen, M., Commo, F., Soria, J. C., and Eberhardt, W. E. E. Phase II trial of ptk787/zk 222584 (vatalanib) administered
orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage
iiib/iv non-small-cell lung cancer (nsclc). [2012] Annals of Oncology (23) 3 : 678-687. Impact factor : 7.384
[158]
Gautier, E. F., Picard, M., Laurent, C., Marty, C., Villeval, J. L., Demur, C., Delhommeau, F., Hexner, E., Giraudier,
S., Bonnevialle, N., Ducommun, B., Récher, C., Laurent, G., Manenti, S., and Mansat-De Mas, V. The cell cycle
regulator CDC25A is a target for JAK2 V617F oncogene. [2012] Blood (119) 5 : 1190-1199. Impact factor : 9.060
[159]
Geoerger, B., Kieran, M. W., Grupp, S., Perek, D., Clancy, J., Krygowski, M., Ananthakrishnan, R., Boni, J. P.,
Berkenblit, A., and Spunt, S. L. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma
and rhabdomyosarcoma. [2012] European Journal of Cancer (48) 2 : 253-262. Impact factor : 5.061
[160]
Geoerger, B., Estlin, E. J., Aerts, I., Kearns, P., Gibson, B., Corradini, N., Doz, F., Lardelli, P., Miguel, B. D., Soto,
A., Prados, R., and Vassal, G. A phase 1 and pharmacokinetic study of plitidepsin in children with advanced solid
tumours: An Innovative Therapies for Children with Cancer (ITCC) study. [2012] European Journal of Cancer (48) 3 :
289-296 . Impact factor : 5.061
[161]
Ghesquières, H., Cartron, G., Seymour, J. F., Delfau-Larue, M. H., Offner, F., Soubeyran, P., Perrot, A., Brice, P.,
Bouabdallah, R., Sonet, A., Dupuis, J., Casasnovas, O., Catalano, J. V., Delmer, A., Jardin, F., Verney, A., Dartigues, P.,
and Salles, G. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study
is not affected by FCGR3A and FCGR2A polymorphisms. [2012] Blood (120) 13 : 2650-2657. Impact factor : 9.060
[162]
Gibault, L., Ferreira, C., Pérot, G., Audebourg, A., Chibon, F., Bonnin, S., Lagarde, P., Vacher-Lavenu, M.
C., Terrier, P., Coindre, J. M., and Aurias, A. From PTEN loss of expression to RICTOR role in smooth muscle
differentiation: Complex involvement of the mTOR pathway in leiomyosarcomas and pleomorphic sarcomas. [2012]
Modern Pathology (25) 2 : 197-211. Impact factor : 5.253
[163]
Gnekow, Astrid K., Falkenstein, Fabian, Walker, David, Perilongo, Giorgio, Picton, Sue, Grill, Jacques, Kortmann, Rolf
Dieter, Stokland, Tore, van Meeteren, Antoinette Schouten, Slavc, Irene, Faldum, Andreas, de Salvo, Gian Luca, and
Worki, SIOP-Europe Low Grade Glioma SIOP-LGG 2004-COHORT DESCRIPTION OF A COMPREHENSIVE TREATMENT
STRATEGY FOR LOW GRADE GLIOMA IN CHILDREN AND ADOLESCENTS INCLUDING A RANDOMISED CHEMOTHERAPY
TRIAL AND A RADIOTHERAPY TRIAL. [2012] Neuro-Oncology (14) supplt 1 : 74-74. Impact factor : 6.180
[164]
Goere, D., Flament, C., Chaput-Gras, N., and Zitvogel, L. CONTRIBUTION OF IMMUNOGENIC CELL DEATH (ICD) TO
THE ANTI-TUMOR ACTIVITY OF CATUMAXOMAB (ANTI-EPCAM X ANTI-CD3). [2012] Annals of Oncology (23) 9 : 169170. Impact factor : 7.384
[165]
Gomez-Roca, C. A., Lacroix, L., Massard, C., De Baere, T., Deschamps, F., Pramod, R., Bahleda, R., Deutsch, E.,
Bourgier, C., Angevin, E., Lazar, V., Ribrag, V., Koscielny, S., Chami, L., Lassau, N., Dromain, C., Robert, C., Routier,
E., Armand, J. P., and Soria, J. C. Sequential research-related biopsies in phase I trials: Acceptance, feasibility and
safety. [2012] Annals of Oncology (23) 5 : 1301-1306. Impact factor : 7.384
[166]
Gonzales, Emmanuel, Grosse, Brigitte, Cassio, Doris, Davit-Spraul, Anne, Fabre, Monique, and Jacquemin, Emmanuel Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial
intrahepatic cholestasis type 2. [2012] Journal of Hepatology (57) 3 : 695-698. Impact factor : 9.858
[167]
Gonzalez, C. A., Lujan-Barroso, L., Bueno-de-Mesquita, H. B., Jenab, M., Duell, E. J., Agudo, A., Tjonneland, A.,
Boutron-Ruault, M. C., Clavel-Chapelon, F., Touillaud, M., Teucher, B., Kaaks, R., Boeing, H., Steffen, A., Trichopoulou, A., Roukos, D., Karapetyan, T., Palli, D., Tagliabue, G., Mattiello, A., Tumino, R., Ricceri, F., Siersema, P.
D., Numans, M. E., Peeters, P. P. H., Parr, C. L., Skeie, G., Lund, E., Quiros, J. R., Sanchez-Cantalejo, E., Navarro,
C., Barricarte, A., Dorronsoro, M., Ehrnström, R., Regner, S., Khaw, K. T., Wareham, N., Key, T. J., Crowe, F. L.,
Blaker, H., Romieu, I., and Riboli, E. Fruit and vegetable intake and the risk of gastric adenocarcinoma: A reanalysis
of the european prospective investigation into cancer and nutrition (EPIC-EURGAST) study after a longer follow-up.
[2012] International Journal of Cancer (131) 12 : 2910-2919. Impact factor : 6.198
[168]
Gonzàlez, C. A., Megraud, F., Buissonniere, A., Lujan Barroso, L., Agudo, A., Duell, E. J., Boutron-Ruault, M. C.,
Clavel-Chapelon, F., Palli, D., Krogh, V., Mattiello, A., Tumino, R., Sacerdote, C., Quiros, J. R., Sanchez-Cantalejo,
E., Navarro, C., Barricarte, A., Dorronsoro, M., Khaw, K. T., Wareham, N., Allen, N. E., Tsilidis, K. K., Bas Bueno-De-Mesquita, H., Jeurnink, S. M., Numans, M. E., Peeters, P. H. M., Lagiou, P., Valanou, E., Trichopoulou, A.,
Kaaks, R., Lukanova-McGregor, A., Bergman, M. M., Boeing, H., Manjer, J., Lindkvist, B., Stenling, R., Hallmans,
G., Mortensen, L. M., Overvad, K., Olsen, A., Tjonneland, A., Bakken, K., Dumeaux, V., Lund, E., Jenab, M., Romieu,
I., Michaud, D., Mouw, T., Carneiro, F., Fenge, C., and Riboli, E. Helicobacter pylori infection assessed by ELISA and
by immunoblot and noncardia gastric cancer risk in a prospective study: The Eurgast-EPIC project. [2012] Annals of
[169]
Gore, M. E., Bellmunt, J., Eisen, T., Escudier, B., Mickisch, G., Patard, J., Porta, C., Ravaud, A., Schmidinger,
M., Schöffski, P., Sternberg, C. N., Szczylik, C., De Nigris, E., Wheeler, C., and Kirpekar, S. Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated
semi-quantitative RAND corporation/University of California, Los Angeles methodology. [2012] European Journal of
[170]
Goss, G., Lu, S., Felip, E., Ardizzoni, A., Georgoulias, V., Gadgeel, S., Chand, V., Gu, Y., Olivo, Y. S., and Soria, J.
LUX-LUNG 8: A RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF AFATINIB VS. ERLOTINIB IN PATIENTS WITH
ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG AS SECOND-LINE THERAPY FOLLOWING FIRST-LINE
PLATINUM-BASED CHEMOTHERAPY. [2012] Annals of Oncology (23) 9 : 174-174. Impact factor : 7.384
[171]
Gourzones, C., Barjon, C., and Busson, P. Host-tumor interactions in nasopharyngeal carcinomas. [2012] Seminars
in Cancer Biology (22) 2 : 127-136. Impact factor : 7.436
[172]
Gourzones, C., Jimenez, A. S., and Busson, P. Author reply : Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. [2012] Cancer (118) 18 : 4634-4634. Impact factor : 5.201
[173]
Graf, N., Van Tinteren, H., Bergeron, C., Pein, F., Heuvel-Eibrink, M. M., Sandstedt, B., Schenk, J. P., Godzinski,
J., Oldenburger, F., Furtwängler, R., and De Kraker, J. Characteristics and outcome of stage II and III non-anaplastic Wilms’ tumour treated according to the SIOP trial and study 93-01. [2012] European Journal of Cancer (48) 17 :
3240-3248. Impact factor : 5.061
[174]
Gram, I. T., Lukanova, A., Brill, I., Braaten, T., Lund, E., Lundin, E., Overvad, K., Tjonneland, A., Clavel-Chapelon, F.,
Chabbert-Buffet, N., Bamia, C., Trichopoulou, A., Zylis, D., Masala, G., Berrino, F., Galasso, R., Tumino, R., Sacerdote,
C., Gavrilyuk, O., Kristiansen, S., Rodriguez, L., Bonet, C., Huerta, J. M., Barricarte, A., Sanchez, M. J., Dorronsoro,
M., Jirström, K., Almquist, M., Idahl, A., Bueno-de-Mesquita, H. B., Braem, M., Onland-Moret, C., Tsilidis, K. K.,
Allen, N. E., Fedirko, V., Riboli, E., and Kaaks, R. Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. [2012] International Journal of Cancer (130) 9 : 2204-2210. Impact factor : 6.198
[175]
Gravis, G., Fizazi, K., Lobbedez, F. Joly, Oudard, S., Priou, F., Latorzeff, I., Delva, R., Krakowski, I., Laguerre,
B., Rolland, F., Theodore, C., Deplanque, G., Ferrero, J. M., Pouessel, D., Mourey, L., Beuzeboc, P., Zanetta, S.,
Esterni, B., Habibian, M., and Soulie, M. SURVIVAL ANALYSIS OF A RANDOMIZED PHASE III TRIAL COMPARING
ANDROGEN DEPRIVATION THERAPY (ADT) PLUS DOCETAXEL VERSUS ADT ALONE IN HORMONE-SENSITIVE
METASTATIC PROSTATE CANCER (GETUG-AFU 15/0403). [2012] Annals of Oncology (23) 9 : 294-294. Impact
factor : 7.384
[176]
Gronchi, A., Bui, B. N., Bonvalot, S., Pilotti, S., Ferrari, S., Hohenberger, P., Hohl, R. J., Demetri, G. D., Le Cesne,
A., Lardelli, P., Pérez, I., Nieto, A., Tercero, J. C., Alfaro, V., Tamborini, E., and Blay, J. Y. Phase II clinical trial of
neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. [2012] Annals of Oncology (23) 3
: 771-776. Impact factor : 7.384
[177]
Gross-goupil, M., Fourcade, A., Blot, E., Penel, N., Négrier, S., Culine, S., Chaigneau, L., Lesimple, T., Priou, F.,
Lortholary, A., Kaminsky, M. C., Provencal, J., Voog, E., Bouzy, J., Laplanche, A., and Fizazi, K. Cisplatin alone or
combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial. [2012]
[178]
Grote, V. A., Kaaks, R., Nieters, A., Tjonneland, A., Halkjaer, J., Overvad, K., Skjelbo Nielsen, M. R., BoutronRuault, M. C., Clavel-Chapelon, F., Racine, A., Teucher, B., Becker, S., Pischon, T., Boeing, H., Trichopoulou,
A., Cassapa, C., Stratigakou, V., Palli, D., Krogh, V., Tumino, R., Vineis, P., Panico, S., Rodriguez, L., Duell, E.
J., Sanchez, M. J., Dorronsoro, M., Navarro, C., Gurrea, A. B., Siersema, P. D., Peeters, P. H. M., Ye, W., Sund,
M., Lindkvist, B., Johansen, D., Khaw, K. T., Wareham, N., Allen, N. E., Travis, R. C., Fedirko, V., Jenab, M.,
Michaud, D. S., Chuang, S. C., Romaguera, D., Bueno-de-Mesquita, H. B., and Rohrmann, S. Inflammation
marker and risk of pancreatic cancer: A nested case-control study within the EPIC cohort. [2012] British Journal
of Cancer (106) 11 : 1866-1874. Impact factor : 5.082
[179]
Grote, Verena A., Rohrmann, Sabine, Dossus, Laure, Nieters, Alexandra, Halkjaer, Jytte, Tjonneland, Anne,
Overvad, Kim, Stegger, Jakob, Chabbert-Buffet, Nathalie, Boutron-Ruault, Marie Christine, Clavel-Chapelon,
Françoise, Teucher, Birgit, Becker, Susen, Montonen, Jukka, Boeing, Heiner, Trichopoulou, Antonia, Lagiou,
Pagona, Trichopoulos, Dimitrios, Palli, Domenico, Sieri, Sabina, Tumino, Rosario, Vineis, Paolo, Mattiello,
Amalia, Argüelles, Marcial, Duell, Eric J., Molina-Montes, Esther, Larranaga, Nerea, Chirlaque, Maria Dolores,
Gurrea, Aurelio Barricarte, Jeurnink, Suzanne M., Peeters, Petra Hm, Ye, Weimin, Sund, Malin, Lindkvist,
Björn, Johansen, Dorthe, Khaw, Kay Tee, Wareham, Nick, Crowe, Francesca L., Romieu, Isabelle, Rinaldi,
Sabina, Jenab, Mazda, Romaguera, Dora, Michaud, Dominique S., Riboli, Elio, Bas Bueno-De-Mesquita, H., and
Kaaks, Rudolf The association of circulating adiponectin levels with pancreatic cancer risk: a study within the
prospective EPIC cohort. [2012] International Journal of Cancer (130) 10 : 2428-2437. Impact factor : 6.198
[180]
Guiu, B., Deschamps, F., Aho, S., Munck, F., Dromain, C., Boige, V., Malka, D., Leboulleux, S., Ducreux, M.,
Schlumberger, M., Baudin, E., and De Baere, T. Liver/biliary injuries following chemoembolisation of endocrine
tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads. [2012] Journal of Hepatology (56) 3 : 609617. Impact factor : 9.858
[181]
Guiu, S., Michiels, S., André, F., Cortes, J., Denkert, C., Di Leo, A., Hennessy, B. T., Sorlie, T., Sotiriou, C., Turner,
N., Van de Vijver, M., Viale, G., Loi, S., and Reis-Filho, J. S. Molecular subclasses of breast cancer: How do we
define them? The IMPAKT 2012 working group statement. [2012] Annals of Oncology (23) 12 : 2997-3006. Impact
factor : 7.384
[182]
Hadj-Rabia, S., Oriot, D., Soufir, N., Dufresne, H., Taieb, A., Sarasin, A., and Bodemer, C. Unexpected
extradermatological findings in 31 Xeroderma Pigmentosum type C patients. [2012] Journal of investigative
dermatology (132) 2 : S96-S96. Impact factor : 6.193
[183]
Hainaut, P., Ma, X., Lacas, B., Tsao, M., Douillard, J., Rousseau, V., Dunant, A., Seymour, L., Filipits, M., Graziano,
S., and Grp, LACE Bio Study LACE-BIO POOLED ANALYSIS OF THE PROGNOSTIC AND PREDICTIVE VALUE OF TP53
MUTATIONS IN COMPLETELY RESECTED NON SMALL CELL LUNG CANCER (NSCLC). [2012] Annals of Oncology
(23) 9 : 389-389. Impact factor : 7.384
[184]
Hannani, D., Ma, Y., Yamazaki, T., Déchanet-Merville, J., Kroemer, G., and Zitvogel, L. Harnessing yo T cells in
anticancer immunotherapy. [2012] Trends in Immunology (33) 5 : 199-206. Impact factor : 9.486
[185]
Hartl, D. M., Bahleda, R., Hollebecque, A., Bosq, J., Massard, C., and Soria, J. C. Bevacizumab-induced laryngeal
necrosis. [2012] Annals of Oncology (23) 1 : 276-278. Impact factor : 7.384
[186]
Hartl, D. M., Leboulleux, S., Al Ghuzlan, A., Baudin, E., Chami, L., Schlumberger, M., and Travagli, J. P. Optimization
of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. [2012]
Annals of Surgery (255) 4 : 777-783. Impact factor : 6.329
[187]
Hebert, G., Netzer, F., Fourcade, A., Ducreux, M., Minvielle, E., and Lemare, F. IATRIGGER PROJECT: DEVELOPMENT
AND VALIDATION OF A TOOL TO EVALUATE ADVERSE DRUGS EVENTS IN ONCOLOGY PATIENTS. [2012] Annals of
[188]
Helissey, C., Vedrine, L., Ceccaldi, B., Houlgatte, A., Mullot, H., Bauduceau, O., Chargari, C., Massard, C., Fizazi, K.,
and Le Moulec, S. CONTINUOUS INFUSION BLEOMYCIN IN THE BEP REGIMEN: A THERAPEUTIC ALTERNATIVE IN THE
MANAGEMENT OF PATIENTS WITH GERM-CELL TUMORS? [2012] Annals of Oncology (23) 9 : 285-285. Impact factor : 7.384
[189]
Hofman, P., Ilie, M., Hofman, V., Roux, S., Valent, A., Bernheim, A., Alifano, M., Leroy-Ladurie, F., Vaylet, F.,
Rouquette, I., Validire, P., Beau-Faller, M., Lacroix, L., Soria, J. C., and Fouret, P. Immunohistochemistry to identify
egfr mutations or ALK rearrangements in patients with lung adenocarcinoma. [2012] Annals of Oncology (23) 7 : 17381743. Impact factor : 7.384
[190]
Hollebecque, A., Houede, N., Cohen, E. E. W., Italiano, A., Yuan, Z., Westwood, P., Bumgardner, W., Benhadji, K. A.,
and Soria, J. C. A PHASE 1 STUDY OF LY2584702, A P70S6 KINASE INHIBITOR, WITH ERLOTINIB OR EVEROLIMUS IN
PATIENT WITH ADVANCED SOLID TUMORS. [2012] Annals of Oncology (23) 1 : 16-16. Impact factor : 7.384
[191]
HOOS, A., EGGERMONT, Alexander M., FINN, Olivera J., and KERR, D. J. Evolution of end points for cancer immunotherapy
trials (English). [2012] Annals of Oncology (23) SUP8 - Advances in Immuno-oncology. Impact factor : 7.384
[192]
Houdayer, C., Caux-Moncoutier, V., Krieger, S., Barrois, M., Bonnet, F., Bourdon, V., Bronner, M., Buisson, M., Coulet,
F., Gaildrat, P., Lefol, C., léone, M., Mazoyer, S., Muller, D., Remenieras, A., Révillion, F., Rouleau, E., Sokolowska,
J., Vert, J. P., Lidereau, R., Soubrier, F., Sobol, H., Sevenet, N., Bressac-de Paillerets, B., Hardouin, A., Tosi, M.,
Sinilnikova, O. M., and Stoppa-Lyonnet, D. Guidelines for splicing analysis in molecular diagnosis derived from a set
of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. [2012] Human Mutation (33) 8 : 1228-1238.
[193]
Hüsing, A., Canzian, F., Beckmann, L., Garcia-Closas, M., Diver, W. R., Thun, M. J., Berg, C. D., Hoover, R. N., Ziegler,
R. G., Figueroa, J. D., Isaacs, C., Olsen, A., Viallon, V., Boeing, H., Masala, G., Trichopoulos, D., Peeters, P. H. M., Lund,
E., Ardanaz, E., Khaw, K. T., Lenner, P., Kolonel, L. N., Stram, D. O., Le Marchand, L., McCarty, C. A., Buring, J. E., Lee,
I. M., Zhang, S., Lindström, S., Hankinson, S. E., Riboli, E., Hunter, D. J., Henderson, B. E., Chanock, S. J., Haiman,
C. A., Kraft, P., and Kaaks, R. Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor
status. [2012] Journal of Medical Genetics (49) 9 : 601-608. Impact factor : 5.703
[194]
Ilie, S. M., Ruginescu, I., Saada, E., Ferrand, F. R., Schilf, A., Janot, F., and Guigay, J. THE USEFULNESS OF G8
EVALUATION IN THERAPEUTIC DECISION AND PREDICTION OF TOLERANCE IN LOCALLY ADVANCED OR METASTATIC
SQUAMOUS CELL HEAD AND NECK CANCER (SCCHN) PATIENTS OLDER THAN 65 YEARS. [2012] Annals of Oncology
(23) 9 : 345-345. Impact factor : 7.384
[195]
Ilie, S. M., Ruginescu, I., Saada, E., Ferrand, F. R., Schilf, A., Janot, F., and Guigay, J. THE TOLERANCE OF TPF
CHEMOTHERAPY REGIME STANDARD OR MODIFIED IN HEAD NECK CANCER PATIENTS OVER 65 YEARS OLD. [2012]
[196]
Italiano, A., Garbay, D., Cioffi, A., Maki, R. G., and Bui, B. Advanced pleomorphic liposarcomas: Clinical outcome and
impact of chemotherapy. [2012] Annals of Oncology (23) 8 : 2205-2206. Impact factor : 7.384
[197]
Italiano, A., Toulmonde, M., Cioffi, A., Penel, N., Isambert, N., Bompas, E., Duffaud, F., Patrikidou, A., Lortal, B., Le
Cesne, A., Blay, J.-Y., Maki, R. G., Schwartz, G. K., Antonescu, C. R., Singer, S., Coindre, J.-M., and Bui, B. Advanced
well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. [2012] Annals of Oncology (23) 6 :
1601-1601. Impact factor : 7.384
[198]
Italiano, A., Cioffi, A., Penel, N., Levra, M. G., Delcambre, C., Kalbacher, E., Chevreau, C., Bertucci, F., Isambert, N.,
Blay, J. Y., Bui, B., Antonescu, C., D’Adamo, D. R., Maki, R. G., and Keohan, M. L. Comparison of doxorubicin and weekly
paclitaxel efficacy in metastatic angiosarcomas. [2012] Cancer (118) 13 : 3330-3336. Impact factor : 5.201
[199]
Itzykson, R., Droin, N., and Solary Les progrès récents dans la leucémie myélomonocytaire chronique [Recent
advances in chronic myelomonocytic leukemia]. [2012] Hématologie (18) 1 : 24-36. Impact factor : 5.935
[200]
Jabbour, Elias, Mathisen, Michael S., and O’Brien, Susan 10 Years of Progress in Chronic Myelogenous Leukemia.
[2012] JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (10) 9 : 1049-1053. Impact
factor : 5.112
[201]
Jacquel, A., Obba, S., Boyer, L., Dufies, M., Robert, G., Gounon, P., Lemichez, E., Luciano, F., Solary, E., and
Auberger, P. Autophagy is required for CSF-1-induced macrophagic differentiation and acquisition of phagocytic
functions. [2012] Blood (119) 19 : 4527-4531. Impact factor : 9.060
[202]
Jaeger, D., Guo, J., Korbenfeld, E., Zemanova, M., Leonhartsberger, N., Stauch, K., Boeckenhoff, A., Yu, J.,
Mardiak, J., and Escudier, B. SORAFENIB IN PATIENTS WITH RENAL CELL CARCINOMA (RCC) AND BASELINE
HYPERTENSION OR DIABETES: SUBANALYSIS OF THE NON-INTERVENTIONAL PREDICT STUDY. [2012] Annals of
[203]
Jakszyn, Paula, Agudo, Antonio, Lujan-Barroso, Leila, Bueno-de-Mesquita, H. Bas, Jenab, Mazda, Navarro, Carmen,
Palli, Domenico, Boeing, Heiner, Manjer, Jonas, Numans, Mattijs E., Igali, Laszlo, Boutron-Ruault, Marie Christine,
Clavel-Chapelon, Francoise, Morois, Sophie, Grioni, Sara, Panico, C. S., Tumino, Rosario, Sacerdote, Carlotta, Ramon
Quiros, J., Molina-Montes, Esther, Huerta Castano, Jose Ma, Barricarte, Aurelio, Amiano, Pilar, Khaw, Kay Tee,
Wareham, Nicholas, Allen, Naomi E., Key, Timothy J., Jeurnink, Suzanne M., Peeters, Petra H. M., Bamia, Christina,
Valanou, Elisabeth, Trichopoulou, Antonia, Kaaks, Rudolf, Lukanova, Annekatrin, Bergmann, Manuela M., Lindkvist,
Bjorn, Stenling, Roger, Johansson, Ingegerd, Dahm, Christina C., Overvad, Kim, Olsen, Anja, Tjonneland, Anne,
Skeie, Guri, Ragnhild Broderstad, Ann, Lund, Eiliv, Michaud, Dominique S., Mouw, Traci, Riboli, Elio, and Gonzalez,
Carlos A. Dietary intake of heme iron and risk of gastric cancer in the European prospective investigation into cancer and
nutrition study. [2012] International Journal of Cancer (130) 11 : 2654-2663. Impact factor : 6.198
[204]
Janne, P. A., Shepherd, F. A., Domerg, C., Le Teuff, G., Kratzke, R., Hainaut, P., Pignon, J., Rosell, R., Soria, J.,
and Tsao, M. PROGNOSTIC AND PREDICTIVE VALUES OF KRAS IN EGFR-BASED SUBGROUPS AND COMBINED
WITH P53 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER (NSCLC): A LACE-BIO STUDY. [2012]
[205]
Jemaá, M., Vitale, I., Kepp, O., Berardinelli, F., Galluzzi, L., Senovilla, L., Marino, G., Malik, S. A., Rello-Varona, S.,
Lissa, D., Antoccia, A., Tailler, M., Schlemmer, F., Harper, F., Pierron, G., Castedo, M., and Kroemer, G. Selective
killing of p53-deficient cancer cells by SP600125. [2012] EMBO Molecular Medicine (4) 6 : 500-514. Impact factor :
7.795
[206]
Jemaá, M., Galluzzi, L., Kepp, O., Boilève, A., Lissa, D., Senovilla, L., Harper, F., Pierron, G., Berardinelli, F.,
Antoccia, A., Castedo, M., Vitale, I., and Kroemer, G. Preferential killing of p53-deficient cancer cells by reversine.
[2012] Cell Cycle (11) 11 : 2149-2158. Impact factor : 5.243
[207]
Jerusalem, G., Marinsek, N., Ricci, J., Etchberger, J., Degun, R., Benelli, G., Saletan, S., and Andre, F. PATTERNS
OF CLINICAL MANAGEMENT AND RESOURCE UTILIZATION FOR POSTMENOPAUSAL HORMONE-RECEPTORPOSITIVE HER2-NEGATIVE (HR+HER2-) ADVANCED BREAST CANCER (ABC) IN EUROPE. [2012] Annals of
[208]
Jeurnink, S. M., Büchner, F. L., Bueno-de-Mesquita, H. B., Siersema, P. D., Boshuizen, H. C., Numans, M. E.,
Dahm, C. C., Overvad, K., Tjonneland, A., Roswall, N., Clavel-Chapelon, F., Boutron-Ruault, M. C., Morois, S.,
Kaaks, R., Teucher, B., Boeing, H., Buijsse, B., Trichopoulou, A., Benetou, V., Zylis, D., Palli, D., Sieri, S., Vineis,
P., Tumino, R., Panico, S., Ocké, M. C., Peeters, P. H. M., Skeie, G., Brustad, M., Lund, E., Sànchez-cantalejo,
E., Navarro, C., Amiano, P., Ardanaz, E., Ramon Quiro, J., Hallmans, G., Johansson, I., Lindkvist, B., Regnér,
S., Khaw, K. T., Wareham, N., Key, T. J., Slimani, N., Norat, T., Vergnaud, A. C., Romaguera, D., and Gonzalez,
C. A. Variety in vegetable and fruit consumption and the risk of gastric and esophageal cancer in the European
prospective investigation into cancer and nutrition. [2012] International Journal of Cancer (131) 6 : E963-E973.
[209]
Johansson, C. Hertzman, Azimi, A., Pernemalm, M., Pawitan, Y., Stolt, M. Frostvik, Lazar, V., Lundeberg, J.,
Lehtio, J., Egyhazi, S., and Hansson, J. PROTEOMICS AND GENE EXPRESSION PROFILING OF MELANOMA
CHEMOTHERAPY RESPONSE IN TUMORS. [2012] Annals of Oncology (23) 5 : 27-27. Impact factor : 7.384
[210]
Julian-Reynier, C., Fabre, R., Coupier, I., Stoppa-Lyonnet, D., Lasset, C., Caron, O., Mouret-Fourme, E., Berthet,
P., Faivre, L., Frenay, M., Gesta, P., Gladieff, L., Bouhnik, A. D., Protière, C., and Noguès, C. BRCA1/2 carriers:
Their childbearing plans and theoretical intentions about having preimplantation genetic diagnosis and prenatal
diagnosis. [2012] Genetics in Medicine (14) 5 : 527-534. Impact factor : 5.560
[211]
Julien, S., Merino-Trigo, A., Lacroix, L., Pocard, M., Goéré, D., Mariani, P., Landron, S., Bigot, L., Nemati, F.,
Dartigues, P., Weiswald, L. B., Lantuas, D., Morgand, L., Pham, E., Gonin, P., Dangles-Marie, V., Job, B., Dessen, P.,
Bruno, A., Pierré, A., De Thé, H., Soliman, H., Nunes, M., Lardier, G., Calvet, L., Demers, B., Prévost, G., Vrignaud,
P., Roman-Roman, S., Duchamp, O., and Berthet, C. Characterization of a large panel of patient-derived tumor
xenografts representing the clinical heterogeneity of human colorectal cancer. [2012] Clinical Cancer Research (18)
19 : 5314-5328. Impact factor : 7.837
[212]
Jung, K. O., Khan, A. M., Tan, B. Y. L., Hu, Y., Simon, G. G., Nascimento, E. J. M., Lemonnier, F., Brusic, V., Miotto,
O., Tan, T. W., Marques, E. T. A., Dhalia, R., Salmon, J., and August, J. T. West nile virus T-cell ligand sequences
shared with other flaviviruses: A multitude of variant sequences as potential altered peptide ligands. [2012] Journal
of Virology (86) 14 : 7616-7624. Impact factor : 5.076
[213]
Kazma, R., Babron, M. C., Gaborieau, V., Génin, E., Brennan, P., Hung, R. J., Mclaughlin, J. R., Krokan, H. E.,
Elvestad, M. B., Skorpen, F., Anderssen, E., Vooder, T., Välk, K., Metspalu, A., Field, J. K., Lathrop, M., Sarasin, A.,
and Benhamou, S. Lung cancer and DNA repair genes: Multilevel association analysis from the international lung
cancer consortium. [2012] Carcinogenesis (33) 5 : 1059-1064. Impact factor : 5.635
[214]
Kharaziha, P., Rodriguez, P., Li, Q., Rundqvist, H., Björklund, A. C., Augsten, M., Ullén, A., Egevad, L., Wiklund,
P., Nilsson, S., Kroemer, G., Grander, D., and Panaretakis, T. Targeting of distinct signaling cascades and cancerassociated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. [2012] Cell Death and Disease
[215]
Kieffer, V., Dellatolas, G., Chevignard, M., Puget, S., Dhermain, F., Grill, J., and Dufour, C. Neurocognitive outcome
and academic achievement in adult survivors of childhood medulloblastoma. [2012] Neuro-Oncology (14) suuplt 3 :
[216]
Kieffer, Virginie, Dellatolas, Georges, Chevignard, Mathilde, Puget, Stephanie, Dhermain, Frederic, Grill,
Jacques, and Dufour, Christelle Neurocognitive outcome and academic achievement in adult survivors of childhood
medulloblastoma. [2012] Neuro-Oncology (14) supplt 1 : 129-129. Impact factor : 6.180
[217]
Kieusseian, A., de la Grange, P. B., Burlen-Defranoux, O., Godin, I., and Cumano, A. Immature hematopoietic stem
cells undergo maturation in the fetal liver. [2012] Development (Cambridge) (139) 19 : 3521-3530. Impact factor : 6.208
[218]
Kilday, J. P., Mitra, B., Domerg, C., Ward, J., Andreiuolo, F., Osteso-Ibanez, T., Mauguen, A., Varlet, P., Le Deley, M.
C., Lowe, J., Ellison, D. W., Gilbertson, R. J., Coyle, B., Grill, J., and Grundy, R. G. Copy number gain of 1q25 predicts
poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: A
prospective european clinical trial cohort analysis on behalf of the Children’s Cancer Leukaemia Group (CCLG. [2012]
Clinical Cancer Research (18) 7 : 2001-2011. Impact factor : 7.837
[219]
Kilday, John Paul, Mitra, Biswaroop, Domerg, Caroline, Ward, Jennifer, Andreiuolo, Felipe, Osteso-Ibanez,
Teresa, Mauguen, Audrey, Varlet, Pascale, Le Deley, Marie Cecile, Lowe, James, Ellison, David W., Gilbertson,
Richard J., Coyle, Beth, Grill, Jacques, and Grundy, Richard G. GAIN OF 1q25 PREDICTS POOR PROGRESSIONFREE SURVIVAL FOR PEDIATRIC INTRACRANIAL EPENDYMOMAS AND ENABLES PATIENT RISK STRATIFICATION: A
EUROPEAN CLINICAL TRIAL COHORT ANALYSIS ON BEHALF OF CCLG, SFOP AND SIOP. [2012] Neuro-Oncology (14)
suuplt 1 : 37-37. Impact factor : 6.180
[220]
Kirkwood, J. M., Bastholt, L., Robert, C., Sosman, J., Larkin, J., Hersey, P., Middleton, M., Cantarini, M., Zazulina,
V., Kemsley, K., and Dummer, R. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as
monotherapy versus temozolomide in patients with advanced melanoma. [2012] Clinical Cancer Research (18) 2 :
[221]
Kraeber-Bodéré, F., Carlier, T., Naegelen, V. M., Shochat, E., Lumbroso, J., Trampal, C., Nagarajah, J., Chua, S.,
Hugonnet, F., Stokkel, M., Gleeson, F., and Tessier, J. Differences in the biologic activity of 2 novel MEK inhibitors
revealed by18F-FDG PET: Analysis of imaging data from 2 phase I trials. [2012] Journal of Nuclear Medicine (53) 12 :
1836-1846. Impact factor : 5.774
[222]
Ladoire, S., Mignot, G., Dalban, C., Chevriaux, A., Arnould, L., Rébé, C., Apetoh, L., Boidot, R., Penault-Llorca,
F., Fumoleau, P., Roché, H., Spielmann, M., Levy, C., Lortholary, A., Eichler, F., Mesleard, C., Bonnetain, F., and
Ghiringhelli, F. FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer
treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. [2012] Annals of Oncology (23) 10 :
2552-2561. Impact factor : 7.384
[223]
Ladroue, C., Hoogewijs, D., Gad, S., Carcenac, R., Storti, F., Barrois, M., Gimenez-Roqueplo, A. P., Leporrier, M.,
Casadevall, N., Hermine, O., Kiladjian, J. J., Baruchel, A., Fakhoury, F., Bressac-de Paillerets, B., Feunteun,
J., Mazure, N., Pouysségur, J., Wenger, R. H., Richard, S., and Gardie, B. Distinct deregulation of the hypoxia
inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. [2012] Haematologica
(97) 1 : 9-14. Impact factor : 5.935
[224]
Lainey, E., Sebert, M., Thépot, S., Scoazec, M., Bouteloup, C., Leroy, C., De Botton, S., Galluzzi, L., Fenaux, P.,
and Kroemer, G. Erlotinib antagonizes ABC transporters in acute myeloid leukemia. [2012] Cell Cycle (11) 21 :
4079-4092. Impact factor : 5.243
[225]
Lajous, M., Tondeur, L., Fagherazzi, G., Lauzon-Guillain, B., Boutron-Ruaualt, M. C., and Clavel-Chapelon, F.
Processed and unprocessed red meat consumption and incident type 2 diabetes among French women. [2012]
Diabetes Care (35) 1 : 128-130. Impact factor : 7.735
[226]
Lamperti, M., Bodenham, A. R., Pittiruti, M., Blaivas, M., Augoustides, J. G., Elbarbary, M., Pirotte, T.,
Karakitsos, D., Ledonne, J., Doniger, S., Scoppettuolo, G., Feller-Kopman, D., Schummer, W., Biffi, R.,
Desruennes, E., Melniker, L. A., and Verghese, S. T. International evidence-based recommendations on
ultrasound-guided vascular access. [2012] Intensive Care Medicine (38) 7 : 1105-1117. Impact factor : 5.258
[227]
Lassau, N., Chapotot, L., Benatsou, B., Vilgrain, V., Kind, M., Lacroix, J., Cuinet, M., Taieb, S., Aziza, R., Sarran,
A., Labbe, C., Gallix, B., Lucidarme, O., Ptak, Y., Rocher, L., Caquot, L. M., Chagnon, S., Marion, D., Luciani, A.,
Uzan-Augui, J., and Koscielny, S. Standardization of dynamic contrast-enhanced ultrasound for the evaluation of
antiangiogenic therapies: The french multicenter support for innovative and expensive techniques study. [2012]
Investigative Radiology (47) 12 : 711-716. Impact factor : 5.460
[228]
Laulier, C. and Lopez, B. S. The secret life of Bcl-2: Apoptosis-independent inhibition of DNA repair by Bcl-2 family
members. [2012] Mutation Research - Reviews in Mutation Research (751) 2 : 247-257 . Impact factor : 6.426
[229]
Laurent-Matha, V., Huesgen, P. F., Masson, O., Derocq, D., Prébois, C., Gary-Bobo, M., Lecaille, F., Rebière,
B., Meurice, G., Oréar, C., Hollingsworth, R. E., Abrahamson, M., Lalmanach, G., Overall, C. M., and LiaudetCoopman, E. Proteolysis of cystatin C by cathepsin D in the breast cancer microenvironment. [2012] FASEB Journal
(26) 12 : 5172-5181 . Impact factor : 5.704
[230]
Le Cesne, Axel, Cresta, Sara, Maki, Robert G., Blay, Jean Yves, Verweij, Jaap, Poveda, Andrés, Casali, Paolo
G., Balana, Carme, Schöffski, Patrick, Grosso, Federica, Lardelli, Pilar, Nieto, Antonio, Alfaro, Vicente, and
Demetri, George D. A retrospective analysis of antitumour activity with trabectedin in translocation-related
sarcomas. [2012] European Journal of Cancer (48) 16 : 3036-3044. Impact factor : 5.061
[231]
Lebbe, C., Robert, C., Ricard, S., Sassolas, B., Grange, F., Saiag, P., Lhomel, C., and Mortier, L. Evolution of sun protection
measures in children in France. [2012] Journal of investigative dermatology (132) 2 : S71-S71. Impact factor : 6.193
[232]
Leblond, Pierre, Lansiaux, Amelie, Rialland, Xavier, Gentet, Jean Claude, Geoerger, Birgit, Frappaz, Didier,
Aerts, Isabelle, and Bernier-Chastagner, Valerie MULTICENTRIC PHASE I STUDY OF CILENGITIDE (CGT) IN
COMBINATION WITH RADIATION THERAPY IN CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE
GLIOMA: PRELIMINARY RESULTS. [2012] Neuro-Oncology (14) supplt 1 : 29-29. Impact factor : 6.180
[233]
Lecarpentier, J., Noguès, C., Mouret-Fourme, E., Gauthier-Villars, M., Lasset, C., Fricker, J. P., Caron, O.,
Stoppa-Lyonnet, D., Berthet, P., Faivre, L., Bonadona, V., Buecher, B., Coupier, I., Gladieff, L., Gesta, P., Eisinger,
F., Frénay, M., Luporsi, E., Lortholary, A., Colas, C., Dugast, C., Longy, M., Pujol, P., Tinat, J., Lidereau, R., and
Andrieu, N. Variation in breast cancer risk associated with factors related to pregnancies according to truncating
mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO). [2012] Breast
Cancer Research (14) 4. Impact factor : 5.872
[234]
Leenders, M., Chuang, S. C., Dahm, C. C., Overvad, K., Ueland, P. M., Midttun, O., Vollset, S. E., Tjonneland, A.,
Halkjaer, J., Jenab, M., Clavel-Chapelon, F., Boutron-Ruault, M. C., Kaaks, R., Canzian, F., Boeing, H., Weikert,
C., Trichopoulou, A., Bamia, C., Naska, A., Palli, D., Pala, V., Mattiello, A., Tumino, R., Sacerdote, C., Van
Duijnhoven, F. J. B., Peeters, P. H. M., Van Gils, C. H., Lund, E., Rodriguez, L., Duell, E. J., Pérez, M. J. S., MolinaMontes, E., Castano, J. M. H., Barricarte, A., Larranaga, N., Johansen, D., Lindkvist, B., Sund, M., Ye, W., Khaw,
K. T., Wareham, N. J., Michaud, D. S., Riboli, E., Xun, W. W., Allen, N. E., Crowe, F. L., Bueno-de-Mesquita, H. B.,
and Vineis, P. Plasma cotinine levels and pancreatic cancer in the EPIC cohort study. [2012] International Journal of
[235]
Lefebvre, J. L., Andry, G., Chevalier, D., Luboinski, B., Collette, L., Traissac, L., De raucourt, D., Langendijk, J. A.,
Rame, J. P., Crispino, S., Chiamenti, C., van den Beek, J. M. H., David, J. M., and Bernier, J. Laryngeal preservation
with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891.
[236]
Lemonnier, F., Couronné, L., Parrens, M., Jaïs, J. P., Travert, M., Lamant, L., Tournillac, O., Rousset, T., Fabiani,
B., Cairns, R. A., Mak, T., Bastard, C., Bernard, O. A., de Leval, L., and Gaulard, P. Recurrent TET2 mutations in
peripheral T-cell lymphomas correlate with T FH-like features and adverse clinical parameters. [2012] Blood (120) 7
: 1466-1469. Impact factor : 9.060
[237]
Leufkens, A. M., Van Duijnhoven, F. J. B., Boshuizen, H. C., Siersema, P. D., Kunst, A. E., Mouw, T., Tjonneland,
A., Olsen, A., Overvad, K., Boutron-Ruault, M. C., Clavel-Chapelon, F., Morois, S., Krogh, V., Tumino, R., Panico,
S., Polidoro, S., Palli, D., Kaaks, R., Teucher, B., Pischon, T., Trichopoulou, A., Orfanos, P., Goufa, I., Peeters, P.
H. M., Skeie, G., Braaten, T., Rodriguez, L., Lujan-Barroso, L., Sànchez-Pérez, M. J., Navarro, C., Barricarte,
A., Zackrisson, S., Almquist, M., Hallmans, G., Palmqvist, R., Tsilidis, K. K., Khaw, K. T., Wareham, N., Gallo, V.,
Jenab, M., Riboli, E., and Bueno-de-Mesquita, H. B. Educational level and risk of colorectal cancer in EPIC with
specific reference to tumor location. [2012] International Journal of Cancer (130) 3 : 622-630. Impact factor : 6.198
[238]
Levi, F., Boige, V., Rougier, P., Hebbar, M., Smith, D., Focan, C., Guimbaud, R., Carvalho, C., Bouchahda, M., and
Ducreux, M. SAFETY AND EFFICACY OF INTRAVENOUS CETUXIMAB (CET) AND HEPATIC ARTERY INFUSION OF
IRINOTECAN, 5-FLUOROURACIL AND OXALIPLATIN IN PATIENTS WITH UNRESECTABLE LIVER METASTASES FROM
WT KRAS COLORECTAL CANCER (CRC): RESULTS FROM OPTILIV EUROPEAN PHASE II TRIAL. [2012] Annals of
[239]
Levy, L., Herrera, A., Devauchelle, P., Bonvalot, S., Deutsch, E., and Le Pechoux, C. NBTXR3 NANOPARTICLES FOR
RADIOENHANCEMENT: RATIONALE FOR THE FIRST-IN-MAN STUDY IN ADVANCED SOFT TISSUE SARCOMA. [2012]
[240]
Li, D., Duell, E. J., Yu, K., Risch, H. A., Olson, S. H., Kooperberg, C., Wolpin, B. M., Jiao, L., Dong, X., Wheeler, B.,
Arslan, A. A., Bueno-de-Mesquita, H. B., Fuchs, C. S., Gallinger, S., Gross, M., Hartge, P., Hoover, R. N., Holly, E. A.,
Jacobs, E. J., Klein, A. P., Lacroix, A., Mandelson, M. T., Petersen, G., Zheng, W., Agalliu, I., Albanes, D., BoutronRuault, M. C., Bracci, P. M., Buring, J. E., Canzian, F., Chang, K., Chanock, S. J., Cotterchio, M., Gaziano, J. M.,
Giovannucci, E. L., Goggins, M., Hallmans, G., Hankinson, S. E., Hoffman Bolton, J. A., Hunter, D. J., Hutchinson,
A., Jacobs, K. B., Jenab, M., Khaw, K. T., Kraft, P., Krogh, V., Kurtz, R. C., McWilliams, Robert R., Mendelsohn,
J. B., Patel, A. V., Rabe, K. G., Riboli, E., Shu, X. O., Tjonneland, A., Tobias, G. S., Trichopoulos, D., Virtamo, J.,
Visvanathan, K., Watters, J., Yu, H., Zeleniuch-Jacquotte, A., Amundadottir, L., and Stolzenberg-Solomon, R. Z.
Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility
factors for pancreatic cancer. [2012] Carcinogenesis (33) 7 : 1384-1390. Impact factor : 5.635
[241]
Li, Qian, Chuang, Shu Chun, Eluf-Neto, Jose, Menezes, Ana, Matos, Elena, Koifman, Sergio, Wünsch-Filho, Victor,
Fernandez, Leticia, Daudt, Alexander W., Curado, Maria Paula, Winn, Deborah M., Franceschi, Silvia, Herrero, Rolando,
Castellsague, Xavier, Morgenstern, Hal, Zhang, Zuo Feng, Lazarus, Philip, Muscat, Joshua, McClean, Michael, Kelsey,
Karl T., Hayes, Richard B., Purdue, Mark P., Schwartz, Stephen M., Chen, Chu, Benhamou, Simone, Olshan, Andrew
F., Yu, Guopei, Schantz, Stimson, Ferro, Gilles, Brennan, Paul, Boffetta, Paolo, and Hashibe, Mia Vitamin or mineral
supplement intake and the risk of head and neck cancer: pooled analysis in the INHANCE consortium. [2012] International
journal of cancer.Journal international du cancer (131) 7 : 1686-1699. Impact factor : 6.198
[242]
Liew, Aaron, Andre, Franck, De Menorval, Marie Amelie, O’Brien, Timothy, and Mir, Lluis Optimal Electrogene Transfer
Method for Human Mesenchymal Stem Cells. [2012] MOLECULAR THERAPY (20) supplt 1 : S242-S242. Impact factor : 7.041
[243]
Lipton, A., Fizazi, K., Stopeck, A. T., Henry, D. H., Brown, J. E., Yardley, D. A., Richardson, G. E., Siena, S., Maroto,
P., Clemens, M., Bilynskyy, B., Charu, V., Beuzeboc, P., Rader, M., Viniegra, M., Saad, F., Ke, C., Braun, A., and Jun,
S. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3
pivotal, randomised, phase 3 trials. [2012] European Journal of Cancer (48) 16 : 3082-3092. Impact factor : 5.061
[244]
Little, M. P., Azizova, T. V., Bazyka, D., Bouffler, S. D., Cardis, E. S. C., Chekin, S., Chumak, V. V., Cucinotta, F. A.,
De Vathaire, F., Hall, P., Harrison, J. D., Hildebrandt, G., Ivanov, V., Kashcheev, V. V., Klymenko, S. V., Kreuzer,
M., Laurent, O., Ozasa, K., Schneider, T., Tapio, S., Taylor, A. M., Tzoulaki, I., Vandoolaeghe, W. L., Wakeford, R.,
Zablotska, L. B., Zhang, W., and Lipshultz, S. E. Systematic review and meta-analysis of circulatory disease from
exposure to low-level ionizing radiation and estimates of potential population mortality risks. [2012] Environmental
Health Perspectives (120) 11 : 1503-1511. Impact factor : 7.260
[245]
Llovet, J. M., Decaens, T., Raoul, J.-L., Boucher, E., Kudo, M., Chang, C., Kang, Y.-K., Assenat, E., Lim, H.-Y.,
Boige, V., Mathurin, P., Fartoux, L., Lin, D.-Y., Bruix, J., Poon, R. T., Sherman, M., Blanc, J.-F., Finn, R., Tak, W.Y., Chao, Y., Ezzeddine, R., Liu, D., Walters, I., and Park, J.-W. BRIVANIB VERSUS PLACEBO IN PATIENTS WITH
ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS
FROM THE PHASE 3 BRISK-PS STUDY. [2012] Journal of Hepatology (56) 2. Impact factor : 9.858
[246]
Longaud-Vales, Audrey, Grill, Jacques, Puget, Stephanie, Sainte-Rose, Christian, Dufour, Christelle, Kieffer,
Virginie, and Dellatolas, Geoerges NEUROPSYCHOLOGICAL ASSESSMENT IN CHILDREN AND ADOLESCENTS
TREATED FOR FRONTAL LOBE TUMOURS. [2012] Neuro-Oncology (14) supplt 1 : 112-113. Impact factor : 6.180
[247]
Lordier, L., Pan, J., Naim, V., Jalil, A., Badirou, I., Rameau, P., Larghero, J., Debili, N., Rosselli, F., Vainchenker,
W., and Chang, Y. Presence of a defect in karyokinesis during megakaryocyte endomitosis. [2012] Cell Cycle (11)
23 : 4385-4389. Impact factor : 5.243
[248]
Loriot, Y., Massard, C., and Fizazi, K. Recent developments in treatments targeting castration-resistant prostate
cancer bone metastases. [2012] Annals of Oncology (23) 5 : 1085-1094. Impact factor : 7.384
[249]
Loulergue, Pierre, Mir, Olivier, and Sogni, Philippe Super-infection with genotype 4 hepatitis C virus in a patient
treated for genotype 3 acute hepatitis C. [2012] AIDS (London, England) (26) 5 : 655-656. Impact factor : 6.407
[250]
Lutz, M. P., Zalcberg, J. R., Ducreux, M., Ajani, J. A., Allum, W., Aust, D., Bang, Y. J., Cascinu, S., Hölscher, A.,
Jankowski, J., Jansen, E. P. M., Kisslich, R., Lordick, F., Mariette, C., Moehler, M., Oyama, T., Roth, A., Rueschoff,
J., Ruhstaller, T., Seruca, R., Stahl, M., Sterzing, F., Van Cutsem, E., Van Der Gaast, A., Van Lanschot, J.,
Ychou, M., and Otto, F. Highlights of the EORTC st. gallen international expert consensus on the primary therapy
of gastric, gastroesophageal and oesophageal cancer - Differential treatment strategies for subtypes of early
gastroesophageal cancer. [2012] European Journal of Cancer (48) 16 : 2941-2953. Impact factor : 5.061
[251]
Macfarlane, T. V., Macfarlane, G. J., Thakker, N. S., Benhamou, S., Bouchardy, C., Ahrens, W., Pohlabeln, H.,
Lagiou, P., Lagiou, A., Castellsague, X., Agudo, A., Slamova, A., Plzak, J., Merletti, F., Richiardi, L., Talamini, R.,
Barzan, L., Kjaerheim, K., Canova, C., Simonato, L., Conway, D. I., Mckinney, P. A., Thomson, P., Sloan, P., Znaor,
A., Healy, C. M., McCartan, B. E., Marron, M., and Brennan, P. Role of medical history and medication use in the
aetiology of upper aerodigestive tract cancers in Europe: The ARCAGE study. [2012] Annals of Oncology (23) 4 :
1053-1060. Impact factor : 7.384
[252]
Maibach, R., Roebuck, D., Brugieres, L., Capra, M., Brock, P., Dall’Igna, P., Otte, J. B., De Camargo, B., Zsiros,
J., Zimmermann, A., Aronson, D., Childs, M., Scopinaro, M., Morland, B., Plaschkes, J., Czauderna, P., and
Perilongo, G. Prognostic stratification for children with hepatoblastoma: The SIOPEL experience. [2012] European
Journal of Cancer (48) 10 : 1543-1549. Impact factor : 5.061
[253]
Maio, M., Bondarenko, I., Robert, C., Thomas, L., Garbe, C., Testori, A., Francis, S., Chin, K., and Wolchok, J.
FOUR-YEAR SURVIVAL UPDATE FOR METASTATIC MELANOMA (MM) PATIENTS (PTS) TREATED WITH IPILIMUMAB
(IPI) plus DACARBAZINE (DTIC) ON PHASE 3 STUDY CA184-024. [2012] Annals of Oncology (23) 9 : 367-367.
[254]
Malka, D., Boige, V., Faron, M., Caramella, C., Boucher, E., Rivera, P., De Baere, T., Goere, D., Pignon, J., and
Ducreux, M. HEPATIC ARTERIAL INFUSION (HAI) OF OXALIPLATIN PLUS INTRAVENOUS (IV) FLUOROURACIL
(FU), LEUCOVORIN (LV) AND CETUXIMAB FOR FIRST-LINE TREATMENT OF UNRESECTABLE COLORECTAL LIVER
METASTASES (CRLM): FINAL RESULTS OF A MULTICENTER PHASE 2 STUDY (CHOICE). [2012] Annals of Oncology
(23) 9 : 198-198. Impact factor : 7.384
[255]
Malka, D., Boige, V., Jacques, N., Vimond, N., Adenis, A., Boucher, E., Pierga, J. Y., Conroy, T., Chauffert, B.,
François, E., Guichard, P., Galais, M. P., Cvitkovic, F., Ducreux, M., and Farace, F. Clinical value of circulating
endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and
bevacizumab. [2012] Annals of Oncology (23) 4 : 919-927. Impact factor : 7.384
[256]
Malouf, G. G., Brugières, L., Le Deley, M. C., Faivre, S., Fabre, M., Paradis, V., Aerts, I., Le Tourneau, C., Dreyer,
C., Branchereau, S., Belghiti, J., and Raymond, E. Pure and mixed fibrolamellar hepatocellular carcinomas differ
in natural history and prognosis after complete surgical resection. [2012] Cancer (118) 20 : 4981-4990. Impact
factor : 5.201
[257]
Man, C. H., Wei-Man Lun, S., Hui, J. W. Y., To, K. F., Choy, K. W., Wing-Hung Chan, A., Chow, C., Tin-Yun Chung,
G., Tsao, S. W., Tak-Chun Yip, T., Busson, P., and Lo, K. W. Inhibition of NOTCH3 signalling significantly enhances
sensitivity to cisplatin in EBV-associated nasopharyngeal carcinoma. [2012] Journal of Pathology (226) 3 : 471-481.
[258]
Mangoni, M., Vozenin, M. C., Biti, G., and Deutsch, E. Normal tissues toxicities triggered by combined antiangiogenic and radiation therapies: hurdles might be ahead. [2012] British Journal of Cancer (107) 2 : 308-314.
[259]
Mardiak, J., Ma, J., Korbenfeld, E., Zemanova, M., Leonhartsberger, N., Stauch, K., Boeckenhoff, A., Yu, J.,
Escudier, B., and Jaeger, D. SORAFENIB IN PATIENTS WITH RENAL CELL CARCINOMA AND BRAIN, BONE OR LUNG
METASTASES: SUBANALYSIS OF THE NON-INTERVENTIONAL PREDICT STUDY. [2012] Annals of Oncology (23) 9 :
[260]
Marie, I., Guillevin, L., Menard, J. F., Hatron, P. Y., Cherin, P., Amoura, Z., Cacoub, P., Bachelez, H., Buzyn, A., Le Roux,
G., Ziza, J. M., Brice, P., Munck, J. N., Sarrot-Reynauld, F., Piette, J. C., and Larroche, C. Hematological malignancy
associated with polymyositis and dermatomyositis. [2012] Autoimmunity Reviews (11) 9 : 615-620. Impact factor : 7.975
[261]
Marron, M., Boffetta, P., Moller, H., Ahrens, W., Pohlabeln, H., Benhamou, S., Bouchardy, C., Lagiou, P., Lagiou, A.,
Slamova, A., Schejbalovà, M., Merletti, F., Richiardi, L., Kjaerheim, K., Agudo, A., Castellsague, X., Macfarlane,
T. V., Macfarlane, G. J., Talamini, R., Barzan, L., Canova, C., Simonato, L., Biggs, A. M., Thomson, P., Conway, D. I.,
Mckinney, P. A., Znaor, A., Healy, C. M., McCartan, B. E., Brennan, P., and Hashibe, M. Risk of upper aerodigestive
tract cancer and type of alcoholic beverage: A European multicenter case-control study. [2012] European Journal of
Epidemiology (27) 7 : 499-517. Impact factor : 5.118
[262]
Marthey, L., Sa-Cunha, A., Blanc, J. F., Cueff, A., Francois, E., Trouilloud, I., Malka, D., Bachet, J., Coriat, R.,
and Taieb, J. FOLFIRINOX FOR LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA. RESULTS OF AN AGEO
MULTICENTRIC PROSPECTIVE STUDY. [2012] Annals of Oncology (23) 9 : 238-238. Impact factor : 7.384
[263]
Martinez-Garcia, M., Banerji, U., Albanell, J., Bahleda, R., Dolly, S., Kraeber-Bodéré, F., Rojo, F., Routier, E.,
Guarin, E., Xu, Z. X., Rueger, R., Tessier, J. J. L., Shochat, E., Blotner, S., Naegelen, V. M., and Soria, J. C. First-inhuman, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a firstin-class dual MEK/RAF inhibitor in patients with solid tumors. [2012] Clinical Cancer Research (18) 17 : 4806-4819.
[264]
Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Séror, C., Métivier, D., Perfettinic, J.
L., Zitvogel, L., and Kroemer, G. Erratum: Chemotherapy induces ATP release from tumor cells (Cell Cycle (2009)
8:22 (3723-3728)). [2012] Cell Cycle (11) 20 : 3901-3901. Impact factor : 5.243
[265]
Martins, Isabelle, Tesniere, Antoine, Kepp, Oliver, Michaud, Mickael, Schlemmer, Frederic, Senovilla, Laura,
Séror, Claire, Métivier, Didier, Perfettinic, Jean Luc, Zitvogel, Laurence, and Kroemer, Guido Erratum to Martins I,
et al. Cell Cycle Volume 8, Issue 22; pp. 3723rÇô8. [2012] Cell Cycle (11) 20 : 3901-3901. Impact factor : 5.243
[266]
Massard, C., Borget, I., Deley, M. C. L., Taylor, M., Gomez-Roca, C., Soria, J. C., and Farace, F. Prognostic value
of circulating VEGFR2 + bone marrow-derived progenitor cells in patients with advanced cancer. [2012] European
[267]
Mathieu, M. C., Mazouni, C., Kesty, N. C., Zhang, Y., Scott, V., Passeron, J., Arnedos, M., Schnabel, C. A., Delaloge,
S., Erlander, M. G., and André, F. Breast cancer index predicts pathological complete response and eligibility for
breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy. [2012] Annals of
[268]
Mazieres, J., Peters, S., Cortot, A., Besse, B., Barlesi, F., Beau-Faller, M., Urban, T., Moro-Sibilot, D., Milia,
J., and Gautschi, O. LUNG CANCER HARBORING HER2 MUTATION: EPIDEMIOLOGICAL CHARACTERISTICS AND
THERAPEUTIC PERSPECTIVES. [2012] Annals of Oncology (23) 9 : 403-403. Impact factor : 7.384
[269]
Mazouni, C., Spyratos, F., Romain, S., Fina, F., Bonnier, P., Ouafik, L. H., and Martin, P. M. A nomogram to predict
individual prognosis in node-negative breast carcinoma. [2012] European Journal of Cancer (48) 16 : 2954-2961.
[270]
Meijnders, P., Carde, P., Girinsky, T., Kluin-Nelemans, J. C., Henry-Amar, M., Raemaekers, J. M. M., Karrasch,
M., and van der Maazen, R. Clinical achievements of the EORTC Lymphoma Group and aspects of future group
strategy. [2012] European Journal of Cancer, Supplement (10) 1 : 105-111. Impact factor : 5.061
[271]
Mendiola, C., Davidenko, I., Colombo, N., Korach, J., Selle, F., Gocze, P., Chmielowska, E., Pautier, P., Bollag,
D., and Oza, A. M. ROSIA: A SINGLE-ARM STUDY IN MORE THAN 1000 PATIENTS (PTS) RECEIVING FRONT-LINE
BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) FOR OVARIAN CANCER (OC). [2012] Annals of Oncology (23) 9 :
[272]
Merad, M., Chachaty, E., Gachot, B., Alibay, A. T., Dipalma, M., and Sami, A. EPIDEMIOLOGY, RESISTANCE
PROFILE AND ORIGIN OF BACTEREMIA IN NON-NEUTROPENIC PATIENTS WITH SOLID TUMOR. [2012] Annals of
[273]
Mercadal, L., Metzger, M., Casadevall, N., Haymann, J. P., Karras, A., Boffa, J. J., Flamant, M., Vrtovsnik, F.,
Stengel, B., and Froissart, M. Timing and determinants of erythropoietin deficiency in chronic kidney disease.
[2012] Clinical Journal of the American Society of Nephrology (7) 1 : 35-42. Impact factor : 5.068
[274]
Millevoi, S., Moine, H., and Vagner, S. G-quadruplexes in RNA biology. [2012] Wiley Interdisciplinary Reviews: RNA
(3) 4 : 495-507. Impact factor : 5.088
[275]
Minard-Colin, V., Ichante, J. L., Nguyen, L., Paci, A., Orbach, D., Bergeron, C., Defachelles, A. S., André, N.,
Corradini, N., Schmitt, C., Tabone, M. D., Blouin, P., Sirvent, N., Goma, G., Geoerger, B., and Oberlin, O. Phase II
study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or
refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma - A report from the
Société Française des Ca. [2012] European Journal of Cancer (48) 15 : 2409-2416. Impact factor : 5.061
[276]
Minois, N., Carmona-Gutierrez, D., Bauer, M. A., Rockenfeller, P., Eisenberg, T., Brandhorst, S., Sigrist, S.
J., Kroemer, G., and Madeo, F. Spermidine promotes stress resistance in Drosophila melanogaster through
autophagy-dependent and -independent pathways. [2012] Cell Death and Disease (3) 10. Impact factor : 6.044
[277]
Mir, O., Boudou-Rouquette, P., Larousserie, F., Babinet, A., Dumaine, V., Anract, P., and Goldwasser, F. Objective
response to sorafenib in advanced clear-cell sarcoma. [2012] Annals of oncology : official journal of the European
Society for Medical Oncology / ESMO (23) 3 : 807-809. Impact factor : 7.384
[278]
Mir, O., Coriat, R., Boudou-Rouquette, P., Durand, J. P., and Goldwasser, F. Sorafenib-induced diarrhea and
hypophosphatemia: mechanisms and therapeutic implications. [2012] Annals of oncology : official journal of the
European Society for Medical Oncology / ESMO (23) 1 : 280-281 . Impact factor : 7.384
[279]
Moniz, H., Gastou, M., Leblanc, T., Hurtaud, C., Cré Tien, A., Lécluse, Y., Raslova, H., Larghero, J., Croisille, L.,
Faubladier, M., Bluteau, O., Lordier, L., Tchernia, G., Vainchenker, W., Mohandas, N., and Da Costa, L. Primary
hematopoietic cells from DBA patients with mutations in RPL11 and RPS19 genes exhibit distinct erythroid
phenotype in vitro. [2012] Cell Death and Disease (3) 7. Impact factor : 6.044
[280]
Montemurro, M., DOMONT, J., Rutkowski, P., Roth, A. D., von Moos, R., Inauen, R., Dietrich, D., Biaggi, C., Prior, J.,
and Leyvraz, S. DASATINIB FIRST-LINE TREATMENT IN GASTROINTESTINAL STROMAL TUMORS. A MULTICENTER
PHASE II TRIAL OF THE SAKK (SAKK 56/07). [2012] Annals of Oncology (23) 9 : 480-480. Impact factor : 7.384
[281]
Mordant, P., Loriot, Y., Lahon, B., Castier, Y., Lesèche, G., Soria, J. C., Massard, C., and Deutsch, E. Minimal
residual disease in solid neoplasia: New frontier or red-herring? [2012] Cancer Treatment Reviews (38) 2 : 101110. Impact factor : 6.024
[282]
Morera, Solange, Grin, Inga, Vigouroux, Armelle, Couve, Sophie, Henriot, Veronique, Saparbaev, Murat, and
Ishchenko, Alexander A. Biochemical and structural characterization of the glycosylase domain of MBD4 bound
to thymine and 5-hydroxymethyuracil-containing DNA. [2012] Nucleic Acids Research (40) 19 : 9917-9926. Impact
factor : 8.278
[283]
Morice, P., Kane, A., Muller, E., Fauvet, R., Gouy, S., Pautier, P., Lhomme, C., Darai, E., Duvillard, P., and Uzan,
C. PROGNOSTIC FACTORS AFTER CONSERVATIVE TREATMENT OF A LARGE SERIES OF ``STAGE I{‘’} SEROUS
BORDERLINE OVARIAN TUMORS. [2012] Annals of Oncology (23) 9 : 322-322. Impact factor : 7.384
[284]
Morois, S., Fournier, A., Clavel-Chapelon, F., Mesrine, S., and Boutron-Ruault, M. C. Menopausal hormone therapy
and risks of colorectal adenomas and cancers in the French E3N prospective cohort: True associations or bias?
[2012] European Journal of Epidemiology (27) 6 : 439-452. Impact factor : 5.118
[285]
Moss, Robert, Grosse, Thibault, and Thomas, S. Randall Exploration of pressure-natriuresis mechanisms using a
lumped, two-nephron whole-kidney model. [2012] FASEB Journal (26). Impact factor : 5.704
[286]
Motzer, R. J., Escudier, B., Tomczak, P., Negrier, S., Gore, M. E., Tarazi, J., Hariharan, S., Rosbrook, B., Kim, S.,
and Rini, B. I. AXITINIB VS SORAFENIB FOR ADVANCED RENAL CELL CARCINOMA: PHASE III OVERALL SURVIVAL
RESULTS AND ANALYSIS OF PROGNOSTIC FACTORS. [2012] Annals of Oncology (23) 9 : 262-262. Impact factor : 7.384
[287]
Nakatake, M., Monte-Mor, B., Debili, N., Casadevall, N., Ribrag, V., Solary, E., Vainchenker, W., and Plo, I. JAK2
V617F negatively regulates p53 stabilization by enhancing MDM2 via la expression in myeloproliferative neoplasms.
[288]
Natrajan, Rachael, Mackay, Alan, Wilkerson, Paul M., Lambros, Maryou B., Wetterskog, Daniel, Arnedos, Monica,
Shiu, Kai Keen, Geyer, Felipe C., Langerod, Anita, Kreike, Bas, Reyal, Fabien, Horlings, Hugo M., van de Vijver,
Marc J., Palacios, Jose, Weigelt, Britta, and Reis-Filho, Jorge S. Functional characterization of the 19q12 amplicon
in grade III breast cancers. [2012] Breast cancer research : BCR (14) 2 : R53-R53. Impact factor : 5.872
[289]
Nault, Jean Charles, Fabre, Monique, Couchy, Gabrielle, Pilati, Camilla, Jeannot, Emmanuelle, Tran Van Nhieu,
Jeanne, Saint-Paul, Marie Christine, De Muret, Anne, Redon, Marie José, Buffet, Catherine, Salenave, Sylvie,
Balabaud, Charles, Prevot, Sophie, Labrune, Philippe, Bioulac-Sage, Paulette, Scoazec, Jean Yves, Chanson,
Philippe, and Zucman-Rossi, Jessica GNAS-activating mutations define a rare subgroup of inflammatory liver
tumors characterized by STAT3 activation. [2012] Journal of Hepatology (56) 1 : 184-191. Impact factor : 9.858
[290]
Negretti, L., Blanchard, P., Couanet, D., Kieffer, V., Goma, G., Habrand, J. L., Dhermain, F., Valteau-Couanet,
D., Grill, J., and Dufour, C. Pseudoprogression after high-dose busulfan-thiotepa with autologous stem cell
transplantation and radiation therapy in children with brain tumors: Impact on survival. [2012] Neuro-Oncology (14)
11 : 1413-1421. Impact factor : 6.180
[291]
Nelson, J. B., Fizazi, K., Miller, K., Higano, C., Moul, J. W., Akaza, H., Morris, T., McIntosh, S., Pemberton, K., and
Gleave, M. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant
prostate cancer metastatic to bone. [2012] Cancer (118) 22 : 5709-5718. Impact factor : 5.201
[292]
Nguyen, L., Paci, A., and Vassal, G. Author reply : Population pharmacokinetics of busulfan in children-letter. [2012]
Clinical Cancer Research (18) 9 : 2715-2716. Impact factor : 7.837
[293]
Nishida, T., Casali, P. G., Reichardt, P., Kang, Y.-K., Blay, J.-Y., Joensuu, H., Maki, R. G., Rutkowski, P.,
Hohenberger, P., Gelderblom, H., Leahy, M. G., von Mehren, M., Schoffski, P., Blackstein, M. E., Cesne,
A. L., Badalamenti, G., Xu, J.-M., Laurent, D., Kuss, I., Demetri, G. D., and Investigators, G. R. I. D.
RANDOMIZED PHASE 3 TRIAL OF REGORAFENIB IN PATIENTS (PATIENTS) WITH METASTATIC AND/OR
UNRESECTABLE GASTROINTESTINAL STROMAL TUMOR (GIST) PROGRESSING DESPITE PRIOR TREATMENT
WITH AT LEAST IMATINIB (IM) AND SUNITINIB (SU) : GRID TRIAL. [2012] Annals of Oncology (23) 11 : 20-20.
[294]
Noman, Muhammad Zaeem, Buart, Stéphanie, Romero, Pedro, Ketari, Sami, Janji, Bassam, Mari, Bernard, MamiChouaib, Fathia, and Chouaib, Salem Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis
by cytotoxic T cells. [2012] Cancer Research (72) 18 : 4629-4641. Impact factor : 8.650
[295]
Nunes, M., Roman-Roman, S., Dessen, P., Bigot, L., Blot, L., Demers, B., Berthet, C., Dangles-Marie, V., Vriganud,
P., and Lacroix, L. TRANSLATIONAL RELEVANCE OF PATIENT-DERIVED COLON TUMOR XENOGRAFTS (PDX) TO
CORRELATE PATHWAYS ABNORMALITIES WITH RESPONSE TO ANTI-EGFR THERAPY. [2012] Annals of Oncology
(23) 1 : 41-42. Impact factor : 7.384
[296]
Olmos, D., Ang, J. E., Gomez-Roca, C., Morales-Barrera, R., Vulink, A. J., Massard, C., and Kaye, S. Pitfalls and
limitations of a single-centre, retrospectively derived prognostic score for Phase i oncology trial participants - Reply
to Fussenich et al.: A new, simple and objective prognostic score for Phase i cancer patients. [2012] European
[297]
Ong, M., Del Conte, G., Bahleda, R., Perotti, A., Damian, S., Lassau, N., Farace, F., Gennaro, D., Stimpson, S.,
Tinariu, N., Gianni, L., Sessa, C., Micallef, S., Demers, B., Oprea, C., Molife, L. R., and Soria, J. C. A PHASE I
STUDY OF OMBRABULIN (O) COMBINED WITH BEVACIZUMAB (B) IN PATIENTS WITH ADVANCED SOLID TUMORS PRELIMINARY RESULTS. [2012] Annals of Oncology (23) 1 : 19-19. Impact factor : 7.384
[298]
Opocher, Enrico, de Salvo, Gian Luca, De Paoli, Angela, Simmons, Ian, Sehested, Astrid, Walker, David A.,
Picton, Susan V., Gnekow, Astrid, Grill, Jacques, Driever, Pablo Hernaiz, Azizi, Amedeo A., Viscardi, Elisabetta,
and Perilongo, Giorgio VISUAL OUTCOME OF CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 AND PROGRESSIVE
OPTIC PATHWAY GLIOMA TREATED WITH CHEMOTHERAPY: PRELIMINARY REPORT FROM THE SIOP-LGG 2004
STUDY. [2012] Neuro-Oncology (14) supplt 1 : 72-72. Impact factor : 6.180
[299]
Ost, P., Cozzarini, C., Bossi, A., and Meerleer, G. D. Author reply : Salvage radiotherapy: A plea for dose-escalation
with intensity-modulated radiotherapy. [2012] European Journal of Cancer (48) 9 : 1415-1416. Impact factor :
5.061
[300]
Ott, Alban, Idali, Anouar, Marchais, Antonin, and Gautheret, Daniel NAPP: the Nucleic Acid Phylogenetic Profile
Database. [2012] Nucleic Acids Research (40) Database issue : D205-D209. Impact factor : 8.278
[301]
Oudard, S., Escudier, B., Thompson, J., Gruenwald, V., Conte, P. F., Bracarda, S., Panneerselvam, A., Gogov,
S., Chen, D., and Motzer, R. J. BIOMARKERS OF EVEROLIMUS EFFICACY IN PATIENTS WITH METASTATIC RENAL
CELL CARCINOMA (MRCC): ANALYSIS OF THE PHASE III RECORD-1 TRIAL. [2012] Annals of Oncology (23) 9 : 278279. Impact factor : 7.384
[302]
Pallud, J., Llitjos, J. F., Dhermain, F., Varlet, P., Dezamis, E., Devaux, B., Souillard-Scémama, R., Sanai, N.,
Koziak, M., Page, P., Schlienger, M., Daumas-Duport, C., Meder, J. F., Oppenheim, C., and Roux, F. X. Dynamic
imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas. [2012]
Neuro-Oncology (14) 4 : 496-505. Impact factor : 6.180
[303]
Park, A. K., Lee, S. J., Phi, J. H., Wang, K. C., Kim, D. G., Cho, B. K., Haberler, C., Fattet, S., Dufour, C., Puget,
S., Sainte-Rose, C., Bourdeaut, F., Grill, J., Delattre, O., Kim, S. K., and Park, W. Y. Prognostic classification of
pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway
activation. [2012] Neuro-Oncology (14) 2 : 203-214. Impact factor : 6.180
[304]
Patel, Pinal S., Forouhi, Nita G., Kuijsten, Anneleen, Schulze, Matthias B., van Woudenbergh, Geertruida J.,
Ardanaz, Eva, Amiano, Pilar, Arriola, Larraitz, Balkau, Beverley, Barricarte, Aurelio, Beulens, Joline W. J.,
Boeing, Heiner, Buijsse, Brian, Crowe, Francesca L., Lauzon-Guillan, Blandine, Fagherazzi, Guy, Franks, Paul
W., Gonzalez, Carlos, Grioni, Sara, Halkjaer, Jytte, Huerta, José Maria, Key, Timothy J., Kühn, Tilman, Masala,
Giovanna, Nilsson, Peter, Overvad, Kim, Panico, Salvatore, Quiros, Jose Ramon, Rolandsson, Olov, Sacerdote,
Carlotta, Sanchez, Maria José, Schmidt, Erik B., Slimani, Nadia, Spijkerman, Annemieke M. W., Teucher, Birgit,
Tjonneland, Anne, Tormo, Maria Jose, Tumino, Rosario, Van Der, A., van der Schouw, Yvonne T., Sharp, Stephen
J., Langenberg, Claudia, Feskens, Edith J. M., Riboli, Elio, and Wareham, Nicholas J. The prospective association
between total and type of fish intake and type 2 diabetes in 8 European countries: EPIC-InterAct Study. [2012]
American Journal of Clinical Nutrition (95) 6 : 1445-1453. Impact factor : 6.504
[305]
Patrikidou, A., Chabaud, S., Ray-Coquard, I., Bui, B. N., Adenis, A., Rios, M., Bertucci, F., Duffaud, F., Chevreau,
C., Cupissol, D., DOMONT, J., Pérol, D., Blay, J. Y., and Le Cesne, A. Influence of imatinib interruption and
rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French
Sarcoma Group randomised, phase III trial. [2012] Annals of oncology : official journal of the European Society for
Medical Oncology / ESMO. Impact factor : 7.384
[306]
Pautier, P., Lobbedez, F. Joly, Melichar, B., Kutarska, E., Hall, G., and Reed, N. A PHASE II MULTICENTER
RANDOMIZED OPEN-LABEL STUDY OF ORAL STEROID SULPHATASE (STS) INHIBITOR IROSUSTAT (BN83495)
VERSUS MEGESTROL ACETATE (MA) IN WOMEN WITH ADVANCED/RECURRENT ENDOMETRIAL CANCER (EC).
[307]
Pecquet, C., Diaconu, C. C., Staerk, J., Girardot, M., Marty, C., Royer, Y., Defour, J. P., Dusa, A., Besancenot, R.,
Giraudier, S., Villeval, J. L., Knoops, L., Courtoy, P. J., Vainchenker, W., and Constantinescu, S. N. Thrombopoietin
receptor down-modulation by JAK2 V617F: Restoration of receptor levels by inhibitors of pathologic JAK2 signaling
and of proteasomes. [2012] Blood (119) 20 : 4625-4635. Impact factor : 9.060
[308]
Perez-Moreno, P., Brambilla, E., Thomas, R., and Soria, J. C. Squamous cell carcinoma of the lung: Molecular
subtypes and therapeutic opportunities. [2012] Clinical Cancer Research (18) 9 : 2443-2451 . Impact factor : 7.837
[309]
Pernemalm, A., Branca, M., Petris, D. E., Forshed, J., Lewensohn, R., Besse, B., Lazar, V., den Oord, J., Pawitan,
Y., and Lehtio, J. PROTEOMICS ANCHORED SYSTEMS BIOLOGY ANALYSIS OF PROGNOSTIC FACTORS IN PRIMARY
LUNG ADENOCARCINOMA TUMOURS. [2012] Annals of Oncology (23) 5 : 38-38. Impact factor : 7.384
[310]
Pernot, E., Hall, J., Baatout, S., Benotmane, M. A., Blanchardon, E., Bouffler, S., El Saghire, H., Gomolka, M.,
Guertler, A., Harms-Ringdahl, M., Jeggo, P., Kreuzer, M., Laurier, D., Lindholm, C., Mkacher, R., Quintens, R.,
Rothkamm, K., Sabatier, L., Tapio, S., De Vathaire, F., and Cardis, E. Ionizing radiation biomarkers for potential
use in epidemiological studies. [2012] Mutation Research - Reviews in Mutation Research (751) 2 : 258-286.
[311]
Peters, Susan, Kromhout, Hans, Olsson, Ann C., Wichmann, Heinz Erich, Brüske, Irene, Consonni, Dario,
Landi, Maria Teresa, Caporaso, Neil, Siemiatycki, Jack, Richiardi, Lorenzo, Mirabelli, Dario, Simonato,
Lorenzo, Gustavsson, Per, Plato, Nils, Jöckel, Karl Heinz, Ahrens, Wolfgang, Pohlabeln, Hermann, Boffetta,
Paolo, Brennan, Paul, Zaridze, David, Cassidy, Adrian, Lissowska, Jolanta, Szeszenia-Dabrowska, Neonila,
Rudnai, Peter, Fabianova, Eleonora, Forastiere, Francesco, Bencko, Vladimir, Foretova, Lenka, Janout,
Vladimir, Stücker, Isabelle, Dumitru, Rodica Stanescu, Benhamou, Simone, Bueno-de-Mesquita, Bas,
Kendzia, Benjamin, Pesch, Beate, Straif, Kurt, Brüning, Thomas, and Vermeulen, Roel Occupational exposure
to organic dust increases lung cancer risk in the general population. [2012] Thorax (67) 2 : 111-116. Impact
factor : 8.376
[312]
Petit, A., Ragu, C., Soler, G., Ottolenghi, C., Schluth, C., Radford-Weiss, I., Schneider-Maunoury, S., Callebaut,
I., Dastugue, N., Drabkin, H. A., Bernard, O. A., Romana, S., and Penard-Lacronique, V. Functional analysis of the
NUP98-CCDC28A fusion protein. [2012] Haematologica (97) 3 : 379-387. Impact factor : 5.935
[313]
Pécuchet, N., Lebbe, C., Mir, O., Billemont, B., Blanchet, B., Franck, N., Viguier, M., Coriat, R., Tod, M., Avril, M. F.,
and Goldwasser, F. Sorafenib in advanced melanoma: a critical role for pharmacokinetics? [2012] British Journal of
[314]
Pierceall, W. E., Olaussen, K. A., Rousseau, V., Brambilla, E., Sprott, K. M., Andre, F., Pignon, J. P., Le chevalier,
T., Pirker, R., Jiang, C., Filipits, M., Chen, Y., Kutok, J. L., Weaver, D. T., Ward, B. E., and Soria, J. C. Cisplatin
benefit is predicted by immunohistochemical analysis of dna repair proteins in squamous cell carcinoma but not
adenocarcinoma: Theranostic modeling by nsclc constituent histological subclasses. [2012] Annals of Oncology (23)
9 : 2245-2252. Impact factor : 7.384
[315]
Pierga, J. Y., Hajage, D., Bachelot, T., Delaloge, S., Brain, E., Campone, M., Diéras, V., Rolland, E., Mignot, L.,
Mathiot, C., and Bidard, F. C. High independent prognostic and predictive value of circulating tumor cells compared
with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer
patients. [2012] Annals of Oncology (23) 3 : 618-624. Impact factor : 7.384
[316]
Pietrocola, F., Marino, G., Lissa, D., Vacchelli, E., Malik, S. A., Niso-Santano, M., Zamzami, N., Galluzzi, L., Maiuri,
M. C., and Kroemer, G. Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. [2012] Cell Cycle
(11) 20 : 3851-3860. Impact factor : 5.243
[317]
Planchard, D., Rahal, A., Lacroix, L., Ngocamus, M., Auger, N., Saulnier, P., Dorfmuller, P., Le chevalier, T., Soria,
J., and Besse, B. UPFRONT GENOMIC TESTING FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
RECEIVING FIRST-LINE PLATINUM-BASED REGIMEN: PRELIMINARY RESULT OF THE MSN STUDY. [2012] Annals of
Oncology (7) 6, Supplt 1 : S31-S31. Impact factor : 7.384
[318]
Planchard, D., Lueza, B., Rahal, A., Lacroix, L., Ngocamus, M., Auger, N., Saulnier, P., Dorfmuller, P., Le chevalier,
T., Celebic, A., Pignon, J. P., Soria, J. C., and Besse, B. UPFRONT GENOMIC TESTING FOR PATIENTS WITH NONSMALL CELL LUNG CANCER RECEIVING FIRST-LINE PLATINUM-BASED REGIMEN: PRELIMINARY RESULT OF THE
MSN STUDY. [2012] Annals of Oncology (23) 5 : 13-13. Impact factor : 7.384
[319]
Planchard, D., Camara-Clayette, V., Dorvault, N., Soria, J. C., and Fouret, P. P38 mitogen-activated protein kinase
signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients. [2012] Cancer
(118) 20 : 5015-5025. Impact factor : 5.201
[320]
Ploquin, A., Olmos, D., Lacombe, D., A’Hern, R., Duhamel, A., Twelves, C., Marsoni, S., Morales-Barrera, R.,
Soria, J. C., Verweij, J., Voest, E. E., Schöffski, P., Schellens, J. H., Kramar, A., Kristeleit, R. S., Arkenau, H. T.,
Kaye, S. B., and Penel, N. Prediction of early death among patients enrolled in phase i trials: Development and
validation of a new model based on platelet count and albumin. [2012] British Journal of Cancer (107) 7 : 10251030. Impact factor : 5.082
[321]
Rahal, Arslane, Boige, Valerie, David, Malka, Rahal, Chahinez, Burtin, Pascal, Sinapi, Isabelle, Elias,
Dominique, Goere, Diane, Lacas, Benjamin, and Ducreux, Michel MODIFIED FOLFIRI (MFOLFIRI) AS SECOND
LINE CHEMOTHERAPY IN ADVANCED GASTRIC CANCER (AGC). [2012] Annals of Oncology (23) 4 : 38-38. Impact
factor : 7.384
[322]
Rahal, C., Cioffi, A., DOMONT, J., Bonvalot, S., Le Pechoux, C., Vilcot, L., Terrier, P., Fayard, F., Rahal, A., and
Lecesne, A. VINORELBINE IS AN ACTIVE DRUG IN DESMOID TUMORS/AGGRESSIVE FIBROMATOSIS: INSTITUT
GUSTAVE ROUSSY EXPERIENCE. [2012] Annals of Oncology (23) 9 : 486-486 . Impact factor : 7.384
[323]
Raphael, J., Hollebecque, A., Le Teuff, G., Massard, C., Bahleda, R., Margery, J., Besse, B., Soria, J., and
Planchard, D. EFFICACY AND TOXICITY OBSERVED IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS TREATED
IN PHASE I TRIALS AT A SINGLE INSTITUTION. [2012] Annals of Oncology (23) 9 : 496-496. Impact factor : 7.384
[324]
Raphael, J., Massard, C., Farace, F., Le Teuff, G., Margery, J., Billiot, F., Besse, B., Hollebecque, A., Soria, J.,
and Planchard, D. DETECTION OF CIRCULATING TUMOUR CELLS IN PERIPHERAL BLOOD OF PATIENTS WITH
MALIGNANT PLEURAL MESOTHELIOMA. [2012] Annals of Oncology (23) 9 : 94-94. Impact factor : 7.384
[325]
Ravaud, A., Oudard, S., De Fromont, M., Chevreau, C., Gravis, G., Zanetta, S., Theodore, C., Jimenez, M., Sevin,
E., and Escudier, B. FIRST LINE SUNITINIB IN TYPE I AND II PAPILLARY RENAL CELL CARCINOMA (PRCC):
SUPAP- A PHASE II STUDY OF THE FRENCH GENITO-URINARY GROUP (GETUG) AND THE GROUP OF EARLY
PHASE TRIALS (GEP). [2012] Annals of Oncology (23) 9 : 263-263. Impact factor : 7.384
[326]
Ray-Coquard, I. and Le Cesne, A. A role for maintenance therapy in managing sarcoma. [2012] Cancer Treatment
Reviews (38) 5 : 368-378. Impact factor : 6.024
[327]
Ray-Coquard, I., Pautier, P., Alexandre, J., Vacher-Lavenu, M., Fabbro, M., Floquet, A., Selle, F., Ferron, G.,
Chiannilkulchai, N., and Pujade-Lauraine, E. FROM A WEBSITE TO A NATIONAL AND REGIONAL REFERENCE
CENTRE NETWORK: THE FRENCH EXPERIENCE FOR RARE OVARIAN TUMORS. [2012] Annals of Oncology (23) 9 :
[328]
Rebouissou, S., Hérault, A., Letouzé, E., Neuzillet, Y., Laplanche, A., Ofualuka, K., Maillé, P., Leroy, K., Riou, A.,
Lepage, M. L., Vordos, D., De La Taille, A., Denoux, Y., Sibony, M., Guyon, F., Lebret, T., Benhamou, S., Allory, Y.,
and Radvanyi, F. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial
bladder carcinoma. [2012] Journal of Pathology (227) 3 : 315-324. Impact factor : 7.585
[329]
Reichardt, P., Blay, J. Y., Boukovinas, I., Brodowicz, T., Broto, J. M., Casali, P. G., Decatris, M., Eriksson, M.,
Gelderblom, H., Kosmidis, P., Le Cesne, A., Pousa, A. L., Schlemmer, M., Verweij, J., and Joensuu, H. Adjuvant
therapy in primary GIST: State-of-the-art. [2012] Annals of Oncology (23) 11 : 2776-2781. Impact factor : 7.384
[330]
Reiman, T., Lai, R., Veillard, A. S., Paris, E., Soria, J. C., Rosell, R., Taron, M., Graziano, S., Kratzke, R.,
Seymour, L., Shepherd, F. A., Pignon, J. P., and Sève, P. Cross-validation study of class III beta-tubulin as a
predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: Analysis of four
randomized trials. [2012] Annals of Oncology (23) 1 : 86-93. Impact factor : 7.384
[331]
Rello-Varona, S., Lissa, D., Shen, S., Niso-Santano, M., Senovilla, L., Marino, G., Vitale, I., Jemaá, M., Harper, F.,
Pierron, G., Castedo, M., and Kroemer, G. Autophagic removal of micronuclei. [2012] Cell Cycle (11) 1 : 170-176.
[332]
Réguerre, Y., Martelli, H., Rey, A., Rogers, T., Gaze, M., Arush, M. W. B., Devalck, C., Oberlin, O., Stevens, M., and
Orbach, D. Local therapy is critical in localised pelvic rhabdomyosarcoma: Experience of the International Society
of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP-MMT) committee. [2012] European Journal of Cancer
(48) 13 : 2020-2027. Impact factor : 5.061
[333]
Richiardi, L., Corbin, M., Marron, M., Ahrens, W., Pohlabeln, H., Lagiou, P., Minaki, P., Agudo, A., Castellsague, X.,
Slamova, A., Schejbalova, M., Kjaerheim, K., Barzan, L., Talamini, R., Macfarlane, G. J., Macfarlane, T. V., Canova,
C., Simonato, L., Conway, D. I., Mckinney, P. A., Sneddon, L., Thomson, P., Znaor, A., Healy, C. M., McCartan, B. E.,
Benhamou, S., Bouchardy, C., Hashibe, M., Brennan, P., and Merletti, F. Occupation and risk of upper aerodigestive tract
cancer: The ARCAGE study. [2012] International Journal of Cancer (130) 10 : 2397-2406. Impact factor : 6.198
[334]
Rinaldi, S., Lise, M., Clavel-Chapelon, F., Boutron-Ruault, M. C., Guillas, G., Overvad, K., Tjonneland, A., Halkjaer,
J., Lukanova, A., Kaaks, R., Bergmann, M. M., Boeing, H., Trichopoulou, A., Zylis, D., Valanou, E., Palli, D., Agnoli, C.,
Tumino, R., Polidoro, S., Mattiello, A., Bas Bueno-De-Mesquita, H., Peeters, P. H., Weiderpass, E., Lund, E., Skeie, G.,
Rodriguez, L., Travier, N., Sanchez, M. J., Amiano, P., Huerta, J. M., Ardanaz, E., Rasmuson, T., Hallmans, G., Almquist,
M., Manjer, J., Tsilidis, K. K., Allen, N. E., Khaw, K. T., Wareham, N., Byrnes, G., Romieu, I., Riboli, E., and Franceschi,
S. Body size and risk of differentiated thyroid carcinomas: Findings from the EPIC study. [2012] International Journal of
Cancer (131) 6 : E1004-E1014 . Impact factor : 6.198
[335]
Rini, B., Szczylik, C., Tannir, N. M., Koralewski, P., Tomczak, P., Deptala, A., Dirix, L. Y., Fishman, M., Ramlau, R.,
Ravaud, A., Rogowski, W., Kracht, K., Sun, Y. N., Bass, M. B., Puhlmann, M., and Escudier, B. AMG 386 in combination
with sorafenib in patients with metastatic clear cell carcinoma of the kidney: A randomized, double-blind, placebocontrolled, phase 2 study. [2012] Cancer (118) 24 : 6152-6161. Impact factor : 5.201
[336]
Ritte, R., Lukanova, A., Berrino, F., Dossus, L., Tjonneland, A., Olsen, A., Overvad, T. F., Overvad, K., Clavel-Chapelon,
F., Fournier, A., Fagherazzi, G., Rohrmann, S., Teucher, B., Boeing, H., Aleksandrova, K., Trichopoulou, A., Lagiou, P.,
Trichopoulos, D., Palli, D., Sieri, S., Panico, S., Tumino, R., Vineis, P., Quiros, J. R., Buckland, G., Sanchez, M. J., Amiano,
P., Chirlaque, M. D., Ardanaz, E., Sund, M., Lenner, P., Bueno-De-Mesquita, B., Van Gils, C. H., Peeters, P. H. M., KrumHansen, S., Gram, I. T., Lund, E., Khaw, K. T., Wareham, N., Allen, N. E., Key, T. J., Romieu, I., Rinaldi, S., Siddiq, A., Cox,
D., Riboli, E., and Kaaks, R. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone
receptor status: A large prospective cohort study. [2012] Breast Cancer Research (14) 3. Impact factor : 5.872
[337]
Rodriguez, D. A., Zamorano, S., Lisbona, F., Rojas-Rivera, D., Urra, H., Cubillos-Ruiz, J. R., Armisen, R., Henriquez,
D. R., Cheng, H., Letek, M., Vaisar, T., Irrazabal, T., Gonzalez-Billault, C., Letai, A., Pimentel-Muiéos, F. X., Kroemer,
G., and Hetz, C. BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded
protein response sensor IRE1a. [2012] EMBO Journal (31) 10 : 2322-2335. Impact factor : 9.822
[338]
Rohrmann, S., Grote, V. A., Becker, S., Rinaldi, S., Tjonneland, A., Roswall, N., Gronbaek, H., Overvad, K., BoutronRuault, M. C., Clavel-Chapelon, F., Racine, A., Teucher, B., Boeing, H., Drogan, D., Dilis, V., Lagiou, P., Trichopoulou, A.,
Palli, D., Tagliabue, G., Tumino, R., Vineis, P., Mattiello, A., Rodriguez, L., Duell, E. J., Molina-Montes, E., Dorronsoro,
M., Huerta, J. M., Ardanaz, E., Jeurnink, S., Peeters, P. H. M., Lindkvist, B., Johansen, D., Sund, M., Ye, W., Khaw,
K. T., Wareham, N. J., Allen, N. E., Crowe, F. L., Fedirko, V., Jenab, M., Michaud, D. S., Norat, T., Riboli, E., Buenode-Mesquita, H. B., and Kaaks, R. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European
Prospective Investigation into Cancer and Nutrition. [2012] British Journal of Cancer (106) 5 : 1004-1010. Impact factor :
5.082
[339]
Romaguera, D., Vergnaud, A. C., Peeters, P. H., Van Gils, C. H., Chan, D. S. M., Ferrari, P., Romieu, I., Jenab, M., Slimani,
N., Clavel-Chapelon, F., Fagherazzi, G., Perquier, F., Kaaks, R., Teucher, B., Boeing, H., Von Rüsten, A., Tjonneland,
A., Olsen, A., Dahm, C. C., Overvad, K., Quiros, J. R., Gonzalez, C. A., Sanchez, M. J., Navarro, C., Barricarte, A.,
Dorronsoro, M., Khaw, K. T., Wareham, N. J., Crowe, F. L., Key, T. J., Trichopoulou, A., Lagiou, P., Bamia, C., Masala, G.,
Vineis, P., Tumino, R., Sieri, S., Panico, S., May, A. M., Bueno-de-Mesquita, H. B., Büchner, F. L., Wirfält, E., Manjer, J.,
Johansson, I., Hallmans, G., Skeie, G., Borch, K. B., Parr, C. L., Riboli, E., and Norat, T. Is concordance with World Cancer
Research Fund/American Institute for Cancer Research guidelines for cancer prevention related to subsequent risk of
cancer? Results from the EPIC study. [2012] American Journal of Clinical Nutrition (96) 1 : 150-163. Impact factor : 6.504
[340]
Romieu, I., Ferrari, P., Rinaldi, S., Slimani, N., Jenab, M., Olsen, A., Tjonneland, A., Overvad, K., Boutron-Ruault,
M. C., Lajous, M., Kaaks, R., Teucher, B., Boeing, H., Trichopoulou, A., Naska, A., Vasilopoulo, E., Sacerdote, C.,
Tumino, R., Masala, G., Sieri, S., Panico, S., Bueno-de-Mesquita, H. B., Van Der, A., Van Gils, C. H., Peeters, P. H.
M., Lund, E., Skeie, G., Asli, L. A., Rodriguez, L., Navarro, C., Amiano, P., Sanchez, M. J., Barricarte, A., Buckland,
G., Sonestedt, E., Wirf+ñlt, E., Hallmans, G., Johansson, I., Key, T. J., Allen, N. E., Khaw, K. T., Wareham, N. J.,
Norat, T., Riboli, E., and Clavel-Chapelon, F. Dietary glycemic index and glycemic load and breast cancer risk in the
European Prospective Investigation into Cancer and Nutrition (EPIC). [2012] American Journal of Clinical Nutrition
(96) 2 : 345-355. Impact factor : 6.504
[341]
Ros, M. M., Bas Bueno-De-Mesquita, H., Kampman, E., Buchner, F. L., Aben, K. K. H., Egevad, L., Overvad, K.,
Tjonneland, A., Roswall, N., Clavel-Chapelon, F., Boutron-Ruault, M. C., Morois, S., Kaaks, R., Teucher, B.,
Weikert, S., Ruesten, A. V., Trichopoulou, A., Naska, A., Benetou, V., Saieva, C., Pala, V., Ricceri, F., Tumino, R.,
Mattiello, A., Peeters, P. H. M., Van Gils, C. H., Gram, I. T., Engeset, D., Chirlaque, M. D., Ardanazx, E., Rodriguez,
L., Amanio, P., Gonzalez, C. A., Sanchez, M. J., Ulmert, D., Ernström, R., Ljungberg, B., Allen, N. E., Key, T. J.,
Khaw, K. T., Wareham, N., Slimani, N., Romieu, I., Kiemeney, L. A., and Riboli, E. Fruit and vegetable consumption
and risk of aggressive and non-aggressive urothelial cell carcinomas in the European Prospective Investigation into
Cancer and Nutrition. [2012] European Journal of Cancer (48) 17 : 3267-3277. Impact factor : 5.061
[342]
Ros, M. M., Bueno-de-Mesquita, H. B., Kampman, E., Aben, K. K. H., Buchner, F. L., Jansen, E. H. J. M., Van Gils, C.
H., Egevad, L., Overvad, K., Tjonneland, A., Roswall, N., Boutron-Ruault, M. C., Kvaskoff, M., Perquier, F., Kaaks,
R., Chang-Claude, J., Weikert, S., Boeing, H., Trichopoulou, A., Lagiou, P., Dilis, V., Palli, D., Pala, V., Sacerdote,
C., Tumino, R., Panico, S., Peeters, P. H. M., Gram, I. T., Skeie, G., Huerta, J. M., Barricarte, A., Quiros, J. R.,
Sanchez, M. J., Buckland, G., Larranaga, N., Ehrnström, R., Wallström, P., Ljungberg, B., Hallmans, G., Key, T. J.,
Allen, N. E., Khaw, K. T., Wareham, N., Brennan, P., Riboli, E., and Kiemeney, L. A. Plasma carotenoids and vitamin
C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and
Nutrition. [2012] American Journal of Clinical Nutrition (96) 4 : 902-910. Impact factor : 6.504
[343]
Rossier, Christine, Dunet, Vincent, Tissot, Frederic, Aubry-Rozier, Bereng+ re, Marchetti, Oscar, Marchetti,
Olivier, and Boubaker, Ariane Voriconazole-induced periostitis. [2012] European journal of nuclear medicine and
molecular imaging (39) 2 : 375-376. Impact factor : 5.114
[344]
Rouanne, M., Massard, C., Hollebecque, A., Rousseau, V., Varga, A., Gazzah, A., Neuzillet, Y., Lebret, T., and
Soria, J. EVALUATION OF SEXUALITY, QUALITY-OF-LIFE AND DEPRESSION IN ADVANCED CANCER PATIENTS
TREATED IN A DRUG DEVELOPMENT UNIT. [2012] Annals of Oncology (23) 9 : 474-474. Impact factor : 7.384
[345]
Rousseau, B., Loulergue, P., Mir, O., Krivine, A., Kotti, S., Viel, E., Simon, T., de Gramont, A., Goldwasser, F.,
Launay, O., and Tournigand, C. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients
treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. [2012] Annals of oncology : official
journal of the European Society for Medical Oncology / ESMO (23) 2 : 450-457. Impact factor : 7.384
[346]
Saad, F., Brown, J. E., Van Poznak, C., Ibrahim, T., Stemmer, S. M., Stopeck, A. T., Diel, I. J., Takahashi, S., Shore,
N., Henry, D. H., Barrios, C. H., Facon, T., Senecal, F., Fizazi, K., Zhou, L., Daniels, A., Carrière, P., and Dansey, R.
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded activecontrolled phase III trials in cancer patients with bone metastases. [2012] Annals of Oncology (23) 5 : 1341-1347.
[347]
Saada, E., Ferrand, F. R., Fekih, M., Hamdan, D., Janot, F., Temam, S., Julieron, M., Leridant, A. M., Schilf,
A., and Guigay, J. DOCETAXEL, CARBOPLATIN AND FLUORO-URACIL (TCF) INDUCTION THERAPY IN LOCALLY
ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) PATIENTS WITH CONTRAINDICATION FOR
CISPLATIN BASED COMBINATION (TPF). [2012] Annals of Oncology (23) 9 : 340-340. Impact factor : 7.384
[348]
Sacerdote, Carlotta, Ricceri, Fulvio, Rolandsson, Olov, Baldi, Ileana, Chirlaque, Maria Dolores, Feskens, Edith,
Bendinelli, Benedetta, Ardanaz, Eva, Arriola, Larraitz, Balkau, Beverley, Bergmann, Manuela, Beulens, Joline
W. J., Boeing, Heiner, Clavel-Chapelon, Françoise, Crowe, Francesca, Lauzon-Guillain, Blandine, Forouhi,
Nita, Franks, Paul W., Gallo, Valentina, Gonzalez, Carlos, Halkjaer, Jytte, Illner, Anne Kathrin, Kaaks, Rudolf,
Key, Timothy, Khaw, Kay Tee, Navarro, Carmen, Nilsson, Peter M., Dal Ton, Susanne Oksbjerg, Overvad, Kim,
Pala, Valeria, Palli, Domenico, Panico, Salvatore, Polidoro, Silvia, Quiros, J. Ramon, Romieu, Isabelle, Sanchez,
Maria José, Slimani, Nadia, Sluijs, Ivonne, Spijkerman, Annemieke, Teucher, Birgit, Tjonneland, Anne, Tumino,
Rosario, Van Der, A., Vergnaud, Anne Claire, Wennberg, Patrik, Sharp, Stephen, Langenberg, Claudia, Riboli,
Elio, Vineis, Paolo, and Wareham, Nicholas Lower educational level is a predictor of incident type 2 diabetes
in European countries: the EPIC-InterAct study. [2012] International journal of epidemiology (41) 4 : 1162-1173.
[349]
Sadanandam, A., Sidhu, S. S., Wullschleger, S., Singh, S., Varney, M. L., Yang, C. S., Ashour, A. E., Batra, S. K.,
and Singh, R. K. Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and
endothelial cell proliferation. [2012] British Journal of Cancer (107) 3 : 501-507. Impact factor : 5.082
[350]
Sadeghi, S., Albiges, L., Wood, L. S., Black, S. L., Gilligan, T. D., Dreicer, R., Garcia, J. A., Escudier, B. J., and
Rini, B. I. Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell
carcinoma: Feasibility and clinical outcome. [2012] Cancer (118) 13 : 3277-3282. Impact factor : 5.201
[351]
Saiag, P., Sassolas, B., Mortier, L., Grange, F., Robert, C., Lhomel, C., and Lebbe, C. Knowledge and attitudes
on melanoma prevention and diagnosis among the French population in 2011. [2012] Journal of investigative
dermatology (132) 2 : S71-S71. Impact factor : 6.193
[352]
Sala, N., Munoz, X., Travier, N., Agudo, A., Duell, E. J., Moreno, V., Overvad, K., Tjonneland, A., Boutron-Ruault,
M. C., Clavel-Chapelon, F., Canzian, F., Kaaks, R., Boeing, H., Meidtner, K., Trichopoulos, A., Tsiotas, K., Zylis, D.,
Vineis, P., Panico, S., Palli, D., Krogh, V., Tumino, R., Lund, E., Bueno-de-Mesquita, H. B., Numans, M. E., Peeters,
P. H. M., Quiros, J. R., S+ínchez, M. J., Navarro, C., Ardanaz, E., Dorronsoro, M., Hallmans, G., Stenling, R., Manjer,
J., Allen, N. E., Travis, R. C., Khaw, K. T., Jenab, M., Offerhaus, G. J. A., Riboli, E., and Gonzalez, C. A. Prostate
stem-cell antigen gene is associated with diffuse and intestinal gastric cancer in Caucasians: Results from the EPICEURGAST study. [2012] International Journal of Cancer (130) 10 : 2417-2427. Impact factor : 6.198
[353]
Samy, M., Gattolliat, C. H., Pendino, F., Hillion, J., Nguyen, E., Bombard, S., Douc-Rasy, S., Bénard, J., and SégalBendirdjian, E. Loss of the malignant phenotype of human neuroblastoma cells by a catalytically inactive dominantnegative hTERT mutant. [2012] Molecular cancer therapeutics (11) 11 : 2384-2393. Impact factor : 5.599
[354]
Santen, G. W. E., Sun, Y., Gijsbers, A. C. J., Carré, A., Holvoet, M., van Haeringen, A., Lesnik Oberstein, S. A. J.,
Tomoda, A., Mabe, H., Polak, M., Devriendt, K., Ruivenkamp, C. A. L., and Bijlsma, E. K. Further delineation of
the phenotype of chromosome 14q13 deletions: (Positional) involvement of FOXG1 appears the main determinant of
phenotype severity, with no evidence for a holoprosencephaly locus. [2012] Journal of Medical Genetics (49) 6 : 366372. Impact factor : 5.703
[355]
Scagliotti, G., Stahel, R. A., Rosell, R., Thatcher, N., and Soria, J. C. ALK translocation and crizotinib in non-small
cell lung cancer: An evolving paradigm in oncology drug development. [2012] European Journal of Cancer (48) 7 :
[356]
Scagliotti, G. V., Kim, D.-W., Shaw, A. T., Ou, S.-H. I., Riely, G. J., Gettinger, N., Besse, B., Thomas, M., Salgia, R.,
Wilner, K., Bartlett, C. H., Polli, A., and Gandara, D. R. A Large Retrospective Analysis Of The Activity Of Pemetrexed
(Pem) In Patients (Patients) With Alk Plus Nsclc Before Crizotinib (Criz). [2012] Annals of Oncology (23) 11 : 33-33.
[357]
Scher, H. I., Fizazi, K., Saad, F., Chi, K., Taplin, M., Sternberg, C. N., Armstrong, A. J., Hirmand, M., Selby, B., and
De Bono, J. S. ASSOCIATION OF BASELINE CORTICOSTEROID WITH OUTCOMES IN A MULTIVARIATE ANALYSIS OF
THE PHASE 3 AFFIRM STUDY OF ENZALUTAMIDE (ENZA), AN ANDROGEN RECEPTOR SIGNALING INHIBITOR (ARSI).
[2012] Annals of Oncology (23) 9 : 297-297 . Impact factor : 7.384
[358]
Schlumberger, M., Jarzab, B., Cabanillas, M. E., Robinson, B., Furio, P., Ball, D. W., McCaffrey, J. C., Newbold,
K., Allison, R., Martins, R. G., Licitra, L., Shah, M. H., Bodenner, D. L., Elisei, R., Burmeister, L. A., Funahashi, Y.,
Sellecchia, R., Andresen, C., O’Brien, J. P., and Sherman, S. A PHASE II TRIAL OF THE MULTI-TARGETED KINASE
INHIBITOR LENVATINIB (E7080) IN ADVANCED MEDULLARY THYROID CANCER (MTC). [2012] Annals of Oncology
(23) 11 : 35-36. Impact factor : 7.384
[359]
Schmidinger, M., Gore, M., Porta, C., Négrier, S., and Escudier, B. MRCC management: Past, present and future.
[2012] European Journal of Cancer, Supplement (10) 2 : 1-11. Impact factor : 5.061
[360]
Schmitz, S., Kaminsky-Forrett, M. C., Henry, S., Zanetta, S., Geoffrois, L., Bompas, E., Moxhon, A., Mignion, L.,
Guigay, J., Knoops, L., Hamoir, M., and Machiels, J. P. Phase II study of figitumumab in patients with recurrent and/
or metastatic squamous cell carcinoma of the head and neck: Clinical activity and molecular response (GORTEC
2008-02). [2012] Annals of Oncology (23) 8 : 2153-2161. Impact factor : 7.384
[361]
Seitz, J., Smith, D., O’Toole, D., Lepere, C., Dromain, C., Gorana, A., Mitry, E., and Ducreux, M. P. A PHASE II TRIAL
OF BEVACIZUMAB COMBINED WITH CHEMOTHERAPY IN PATIENTS WITH METASTATIC WELL-DIFFERENTIATED
DUODENO-PANCREATIC ENDOCRINE TUMORS (BETTER STUDY). [2012] Annals of Oncology (23) 9 : 378-378.
[362]
Selle, F., Fizazi, K., Biron, P., Gravis-Mescam, G., Bui, B., Bay, J., Flechon, A., Dubot, C., Caty, A., Burcoveanu, D.,
Delva, R., De Revel, T., Miclea, J. M., Gaulet, M., Horn, E., Provent, S., Temby, I., Brindel, I., Khalil, J., GLIGOROV,
J., and Lotz, J.-P. THE TAXIF II PROTOCOL FINAL RESULTS: A PHASE II TRIAL OF HIGH-DOSE CHEMOTHERAPY
SUPPORTED BY HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH DISSEMINATED GERM-CELL
TUMORS FAILING CHEMOTHERAPY AND WITH ADVERSE PROGNOSTIC FACTORS. [2012] Annals of Oncology (23) 9 :
[363]
Serafini, M., Jakszyn, P., Lujàn-Barroso, L., Agudo, A., Bas Bueno-De-Mesquita, H., Van Duijnhoven, F. J. B.,
Jenab, M., Navarro, C., Palli, D., Boeing, H., Wallström, P., Regnér, S., Numans, M. E., Carneiro, F., BoutronRuault, M. C., Clavel-Chapelon, F., Morois, S., Grioni, S., Panico, S., Tumino, R., Sacerdote, C., Ramon Quiros,
J., Molina-Montes, E., Huerta Castano, J. M., Barricarte, A., Amiano, P., Khaw, K. T., Wareham, N., Allen, N.
E., Key, T. J., Jeurnink, S. M., Peeters, P. H. M., Bamia, C., Valanou, E., Trichopoulou, A., Kaaks, R., Lukanova,
A., Bergmann, M. M., Lindkvist, B., Stenling, R., Johansson, I., Dahm, C. C., Overvad, K., Jensen, M., Olsen, A.,
Tjonneland, A., Lund, E., Rinaldi, S., Michaud, D., Mouw, T., Riboli, E., and Gonzalez, C. A. Dietary total antioxidant
capacity and gastric cancer risk in the European prospective investigation into cancer and nutrition study. [2012]
International Journal of Cancer (131) 4 : E544-E554. Impact factor : 6.198
[364]
Shankar, A., Hall, G. W., Gorde-Grosjean, S., Hasenclever, D., Leblanc, T., Hayward, J., Lambilliotte, A., Daw,
S., Perel, Y., McCarthy, K., Lejars, O., Coulomb, A., Oberlin, W. O., Wallace, W. H., and Landman-Parker, J.
Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular
lymphocyte predominant Hodgkin’s lymphoma - An Anglo-French collaborative report. [2012] European Journal of
[365]
Sleijfer, S., Gorlia, T., Lamers, C., Burger, H., Blay, J. Y., Le Cesne, A., Scurr, M., Collin, F., Pandite, L., Marreaud,
S., and Hohenberger, P. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in
advanced soft-tissue sarcoma: An EORTC-STBSG study. [2012] British Journal of Cancer (107) 4 : 639-645. Impact
factor : 5.082
[366]
Sluijs, Ivonne, Forouhi, Nita G., Beulens, Joline W. J., van der Schouw, Yvonne T., Agnoli, Claudia, Arriola,
Larraitz, Balkau, Beverley, Barricarte, Aurelio, Boeing, Heiner, Bueno-de-Mesquita, H. Bas, Clavel-Chapelon,
Françoise, Crowe, Francesca L., Lauzon-Guillain, Blandine, Drogan, Dagmar, Franks, Paul W., Gavrila,
Diana, Gonzalez, Carlos, Halkjaer, Jytte, Kaaks, Rudolf, Moskal, Aurelie, Nilsson, Peter, Overvad, Kim, Palli,
Domenico, Panico, Salvatore, Quiros, José R., Ricceri, Fulvio, Rinaldi, Sabina, Rolandsson, Olov, Sacerdote,
Carlotta, Sanchez, Maria José, Slimani, Nadia, Spijkerman, Annemieke M. W., Teucher, Birgit, Tjonneland,
Anne, Tormo, Maria José, Tumino, Rosario, Van Der, A., Sharp, Stephen J., Langenberg, Claudia, Feskens,
Edith J. M., Riboli, Elio, and Wareham, Nicholas J. The amount and type of dairy product intake and incident type
2 diabetes: results from the EPIC-InterAct Study. [2012] American Journal of Clinical Nutrition (96) 2 : 382-390.
[367]
Solary, Eric PHAGOCYTES & GRANULOCYTES When monocyte life hangs by a thread. [2012] Blood (119) 12 : 26992700. Impact factor : 9.060
[368]
Soria, J. THE CHARACTERIZATION OF LUNG CANCER. [2012] Annals of Oncology (23) 9 : 24-24. Impact factor :
7.384
[369]
Soria, J. C., Cortes, J., Massard, C., Armand, J. P., De andreis, D., Ropert, S., Lopez, E., Catteau, A., James, J.,
Marier, J. F., Beliveau, M., Martell, R. E., and Baselga, J. Phase i safety, pharmacokinetic and pharmacodynamic
trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid
tumors. [2012] Annals of Oncology (23) 2 : 463-471. Impact factor : 7.384
[370]
Soria, J. C., Mok, T. S., Cappuzzo, F., and Jänne, P. A. EGFR-mutated oncogene-addicted non-small cell lung
cancer: Current trends and future prospects. [2012] Cancer Treatment Reviews (38) 5 : 416-430. Impact factor :
6.024
[371]
Soria, J. C., Dienstmann, R., de Braud, F., Cereda, R., Bahleda, R., Hollebecque, A., Tabernero, J., Delmonte,
A., Dromain, C., Lassau, N., Farace, F., Zucchetti, M., Marsoni, S., and Camboni, M. G. FIRST-IN-MAN STUDY OF
E-3810, A NOVEL VEGFR AND FGFR INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS. [2012] Annals of
[372]
Soucie, E., Hanssens, K., Mercher, T., Georgin-Lavialle, S., Damaj, G., Livideanu, C., Chandesris, M. O., Acin, Y.,
Létard, S., De Sepulveda, P., Hermine, O., Bernard, O. A., and Dubreuil, P. In aggressive forms of mastocytosis,
TET2 loss cooperates with c-KITD816V to transform mast cells. [2012] Blood (120) 24 : 4846-4849. Impact factor :
9.060
[373]
Spano, J. P., Lanoy, E., Mounier, N., Katlama, C., Costagliola, D., and Heard, I. Breast cancer among HIV infected
individuals from the ONCOVIH study, in France: Therapeutic implications. [2012] European Journal of Cancer (48)
18 : 3335-3341. Impact factor : 5.061
[374]
Speisky, D., Duces, A., Bièche, I., Rebours, V., Hammel, P., Sauvanet, A., Richard, S., Bedossa, P., Vidaud, M., Murat, A.,
Niccoli, P., Scoazec, J. Y., Ruszniewski, P., and Couvelard, A. Molecular profiling of pancreatic neuroendocrine tumors in
sporadic and von Hippel-Lindau patients. [2012] Clinical Cancer Research (18) 10 : 2838-2849. Impact factor : 7.837
[375]
Spielmann, M., Luporsi, E., Ray-Coquard, I., De Botton, S., Azria, D., Lasocki, S., Lafuma, A., Mahi, L., Deray,
G., and Bugat, R. Diagnosis and management of anaemia and iron deficiency in patients with haematological
malignancies or solid tumours in France in 2009-2010: The AnemOnHe study. [2012] European Journal of Cancer
(48) 1 : 101-107. Impact factor : 5.061
[376]
Spurdle, A. B., Whiley, P. J., Thompson, B., Feng, B., Healey, S., Brown, M. A., Pettigrew, C., Van Asperen,
C. J., Ausems, M. G. E. M., Kattentidt-Mouravieva, A. A., van den Ouweland, A. M. W., Lindblom, A., Pigg, M.
H., Schmutzler, R. K., Engel, C., Meindl, A., Caputo, S., Sinilnikova, O. M., Lidereau, R., Couch, F. J., Guidugli,
L., Overeem Hansen, T., Thomassen, M., Eccles, D. M., Tucker, K., Benitez, J., Domchek, S. M., Toland, A. E.,
Rensburg, Elizabeth J. V., Wappenschmidt, B., Borg, A, Vreeswijk, M. P. G., Goldgar, D. E., Hogervorst, F. B.,
Oldenburg, R. A., Wijnen, J. T., Devilee, P., van der Luijt, R. B., Gille, J. J. P., Adank, M. A., Gomez Garcia, E. B.,
Blok, M. J., Oosterwijk, J. C., van der Hout, A. H., Michils, G., Legius, E., Teugels, E., Grève, Jacques de, Arnold, N.,
Deisler, H., Gadzicki, D., Gehrig, A., Heinritz, W., Kast, K., Niederacher, D., Preisler-Adams, S., Sutter, C., VaronMateeva, R., Weber, B. H., Sévenet, N., Bonnet, F., Longy, M., Hardouin, A., Vaur, D., Krieger, S., Uhrhammer, N.,
Bignon, Y. J., Peyrat, J. P., Revillion, F., Fournier, J., Mazoyer, S., léone, M., Sobol, H., Noguchi, T., Bourdon, V.,
Remenieras, A., Rey, J. M., Bronner, M., Sokolowska-Gillois, J., Jonveaux, P., Delnatte, C., Coulet, F., Castera, L.,
Caux-Moncoutier, V., Houdayer, C., Stoppa-Lyonnet, Dominique, Delvincourt, C., Gorisse, M. C., Bièche, I., Lefol,
C., Rouleau, E., Abecassis, J., Muller, D., Toulas, C., Guillaud-Bataille, M., Bressac-de Paillerets, B., Barber, R.,
Bedenham, T., Burgess, L., Campbell, J., Cook, J., Devereau, A., Ejlertsen, B., Fields, M., Gerdes, A. M., Johnston,
E., Kruse, T. A., Luharia, A., Mckeown, C., Nathanson, K., Nielsen, F. C., Senter, L., Stayner, B., Sweet, K., Thomas,
S., Wallis, Y., and Watts, S. BRCA1 R1699Q variant displaying ambiguous Functional abrogation confers intermediate
breast And ovarian cancer risk. [2012] Journal of Medical Genetics (49) 8 : 525-532. Impact factor : 5.703
[377]
Stopeck, A. T., Richardson, G., Siena, S., Lipton, A., Brown, J., Fizazi, K., Henry, D., Saad, F., Ke, C., and Braun, A.
DENOSUMAB VERSUS ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS
WITH BONE METASTASES SECONDARY TO SOLID TUMOURS: AN INTEGRATED ANALYSIS OF THREE PHASE 3
STUDIES. [2012] European Journal of Cancer (48) 4 : S8-S8. Impact factor : 5.061
[378]
Surdez, D., Benetkiewicz, M., Perrin, V., Han, Z. Y., Pierron, G., Ballet, S., Lamoureux, F., Rëdini, F., Decouvelaere, A. V.,
Daudigeos-Dubus, E., Geoerger, B., De Pinieux, G., Delattre, O., and Tirode, F. Targeting the EWSR1-FLI1 oncogene-induced
protein kinase PKC-B abolishes ewing sarcoma growth. [2012] Cancer Research (72) 17 : 4494-4503. Impact factor : 8.650
[379]
Tailler, M., Senovilla, L., Lainey, E., Thépot, S., Métivier, D., Sébert, M., Baud, V., Billot, K., Fenaux, P., Galluzzi, L.,
Boehrer, S., Kroemer, G., and Kepp, O. Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia.
[380]
Talhaoui, Ibtissam, Couvé, Sophie, Ishchenko, Alexander A., Kunz, Christophe, Schär, Primo, and Saparbaev, Murat
7,8-dihydro-8-oxoadenine, a highly mutagenic adduct, is repaired by Escherichia coli and human mismatch-specific uracil/
thymine-DNA glycosylases. [2012] Nucleic Acids Research. Impact factor : 8.278
[381]
Tarakhovsky, A. S. and Kroemer, G. Innate immunity. [2012] Current Opinion in Immunology (24) 1 : 1-2. Impact factor : 8.771
[382]
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Coudert, J. D., Desbois, M., Ghiringhelli, F., Viaud, S., Ryffel, B.,
Yagita, H., Chen, L., Mécheri, S., Kaplanski, G., Prévost-Blondel, A., Kato, M., Schultze, J. L., Tartour, E., Kroemer, G.,
Degli-Esposti, M., Chaput, N., and Zitvogel, L. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK
cells. [2012] Cancer Research (72) 11 : 2757-2767. Impact factor : 8.650
[383]
Testori, A., Suciu, S., van Akkooi, A. C. J., Cook, M., Ghanem, G., Karra Gurunath, R., Keilholz, U., van Kempen, L.,
Leyvraz, S., Mihm, M., Newton-Bishop, J., Patel, P., Robert, C., Schadendorf, D., De Schaetzen, G., Spatz, A., De Vries,
E., and Eggermont, A. M. M. EORTC Melanoma Group achievements. [2012] European Journal of Cancer, Supplement (10)
1 : 112-119. Impact factor : 5.061
[384]
Thomas-Schoemann, A., Batteux, F., Mongaret, C., Nicco, C., Chéreau, C., Annereau, M., Dauphin, A., Goldwasser,
F., Weill, B., Lemare, F., and Alexandre, J. Arsenic trioxide exerts antitumor activity through regulatory T cell depletion
mediated by oxidative stress in a murine model of colon cancer. [2012] Journal of Immunology (189) 11 : 5171-5177.
[385]
Timofeeva, Maria N., Hung, Rayjean J., Rafnar, Thorunn, Christiani, David C., Field, John K., Bickeböller,
Heike, Risch, Angela, McKay, James D., Wang, Yufei, Dai, Juncheng, Gaborieau, Valerie, McLaughlin, John,
Brenner, Darren, Narod, Steven A., Caporaso, Neil E., Albanes, Demetrius, Thun, Michael, Eisen, Timothy,
Wichmann, H. Erich, Rosenberger, Albert, Han, Younghun, Chen, Wei, Zhu, Dakai, Spitz, Margaret, Wu,
Xifeng, Pande, Mala, Zhao, Yang, Zaridze, David, Szeszenia-Dabrowska, Neonilia, Lissowska, Jolanta, Rudnai,
Peter, Fabianova, Eleonora, Mates, Dana, Bencko, Vladimir, Foretova, Lenka, Janout, Vladimir, Krokan, Hans
E., Gabrielsen, Maiken Elvestad, Skorpen, Frank, Vatten, Lars, Njolstad, Inger, Chen, Chu, Goodman, Gary,
Lathrop, Mark, Benhamou, Simone, Vooder, T., Välk, Kristjan, Nelis, Mari, Metspalu, Andres, Raji, Olaide,
Chen, Ying, Gosney, John, Liloglou, Triantafillos, Muley, Thomas, Dienemann, Hendrik, Thorleifsson, Gudmar,
Shen, Hongbing, Stefansson, Kari, Brennan, Paul, Amos, Christopher I., Houlston, Richard, and Landi, Maria
Teresa Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485
controls. [2012] Human Molecular Genetics (21) 22 : 4980-4995. Impact factor : 7.692
[386]
Travert, M., Huang, Y., de Leval, L., Martin-Garcia, N., Delfau-Larue, M. H., Berger, F., Bosq, J., Brière, J.,
Soulier, J., Macintyre, E., Marafioti, T., De Reyniès, A., and Gaulard, P. Molecular features of hepatosplenic
T-cell lymphoma unravels potential novel therapeutic targets. [2012] Blood (119) 24 : 5795-5806. Impact
factor : 9.060
[387]
Tredan, O., You, B., Beuzeboc, P., COEFFIC, D., Lortholary, A., Fellous, M., Rouge, T. De La Motte, Andre, F.,
Arnould, L., and Ferrero, J. CHARACTERISTICS OF PATIENTS WITH HER2-POSITIVE METASTATIC (MBC) OR
LOCALLY ADVANCED BREAST CANCER (ABC), TREATED WITH TRASTUZUMAB (T) AS 1ST LINE-THERAPY AND
PROGRESSION-FREE FOR AT LEAST 3 YEARS: INTERIM ANALYSIS OF THE LORHA STUDY. [2012] Annals of
[388]
Trouilloud, I., Dupont-Gossard, A. C., Artru, P., Lecomte, T., Gauthier, M., Aparicio, T., Thirot-Bidault, A.,
Malka, D., Bonnetain, F., and Taieb, J. FIRGEM, A SEQUENTIAL FOLFIRI.3 (CPT-11 PLUS FOLINIC ACID PLUS
5-FU) FOLLOWED BY GEMCITABINE OR GEMCITABINE ALONE IN PATIENTS WITH PREVIOUSLY UNTREATED
METASTATIC PANCREATIC ADENOCARCINOMA: RESULTS OF A RANDOMIZED MULTICENTER AGEO PHASE II
TRIAL. [2012] Annals of Oncology (23) 9 : 237-237 . Impact factor : 7.384
[389]
Trouilloud, Isabelle, Dupont-Gossard, Anne Claire, Artru, Pascal, Lecomte, Thierry, Gauthier, Melanie,
Aparicio, Thomas, Thirot-Bidault, Anne, Malka, David, Lobry, Celine, Asnacios, Amani, Lacombe, Sophie,
Fein, Francine, Dubreuil, Olivier, Zaanan, Aziz, Bonnetain, Franck, Rougier, Philippe, and Taieb, Julien
FOLFIRI.3 ALTERNATING WITH GEMCITABINE IN PATIENTS WITH UNTREATED METASTATIC PANCREATIC
ADENOCARCINOMA: THE RANDOMIZED MULTICENTER AGEO PHASE II TRIAL FIRGEM. [2012] Annals of
[390]
Turato, Cristian, Buendia, Marie Annick, Fabre, Monique, Redon, Marie José, Branchereau, Sophie, Quarta,
Santina, Ruvoletto, Mariagrazia, Perilongo, Giorgio, Grotzer, Michael Andreas, Gatta, Angelo, and Pontisso,
Patrizia Over-expression of SERPINB3 in hepatoblastoma: a possible insight into the genesis of this tumour?
[391]
Turki, A., Hayot, M., Carnac, G., Pillard, F., Passerieux, E., Bommart, S., De Mauverger, E. R., Hugon, G.,
Pincemail, J., Pietri, S., Lambert, K., Belayew, A., Vassetzky, Y., Juntas Morales, R., Mercier, J., and LaoudjChenivesse, D. Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with
oxidative stress and mitochondrial dysfunction. [2012] Free Radical Biology and Medicine (53) 5 : 1068-1079.
[392]
van Akkooi, A. C. J., Cook, M. G., and Eggermont, A. M. M. Increased sampling will lead to an increase in
detection, but is it clinically relevant?: Reply letter regarding: «treatment influencing down-staging in EORTC
Melanoma Group sentinel node histological protocol compared with complete step-sectioning: A nat. [2012]
[393]
Van Der Zee, J. A., Van Eijck, C. H., Hop, W. C., Biermann, K., Dicheva, B. M., Seynhaeve, A. L., Koning, G. A.,
Eggermont, A. M., and Ten Hagen, T. L. Tumour basement membrane laminin expression predicts outcome
following curative resection of pancreatic head cancer. [2012] British Journal of Cancer (107) 7 : 1153-1158.
[394]
Van Der Zwan, J. M., Mallone, S., Van Dijk, B., Bielska-Lasota, M., Otter, R., Foschi, R., Baudin, E., and Links,
T. P. Carcinoma of endocrine organs: Results of the RARECARE project. [2012] European Journal of Cancer (48)
13 : 1923-1931. Impact factor : 5.061
[395]
Van Laethem, J. L., Verslype, C., Iovanna, J. L., Michl, P., Conroy, T., Louvet, C., Hamme, P., Mitry, E., Ducreux,
M., Maraculla, T., Uhl, W., van Tienhoven, G., Bachet, J. B., Chal, R. M., Hendlisz, A., Bali, M., Demetter, P., Ulrich,
F., Aust, D., Luttges, J., Peeters, M., Mauer, M., Roth, A., Neoptolemos, J. P., and Lutz, M. New strategies and
designs in pancreatic cancer research: Consensus guidelines report from a European expert panel. [2012] Annals of
[396]
Varraso, R., Oryszczyn, M. P., Mathieu, N., Le Moual, N., Boutron-Ruault, M. C., Clavel-Chapelon, F., Romieu, I.,
and Kauffmann, F. Farming in childhood, diet in adulthood and asthma history. [2012] EUROPEAN RESPIRATORY
JOURNAL (39) 1 : 67-75. Impact factor : 6.355
[397]
Veal, G. J., Nguyen, L., Paci, A., Riggi, M., Amiel, M., Valteau-Couanet, D., Brock, P., Ladenstein, R., and Vassal,
G. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose
myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. [2012] European
[398]
Vergnaud, A. C., Norat, T., Romaguera, D., Mouw, T., May, A. M., Romieu, I., Freisling, H., Slimani, N., BoutronRuault, M. C., Clavel-Chapelon, F., Morois, S., Kaaks, R., Teucher, B., Boeing, H., Buijsse, B., Tjonneland, A.,
Halkjaer, J., Overvad, K., Jakobsen, M. U., Rodriguez, L., Agudo, A., Sanchez, M. J., Amiano, P., Huerta, J. M.,
Gurrea, A. B., Wareham, N., Khaw, K. T., Crowe, F., Orfanos, P., Naska, A., Trichopoulou, A., Masala, G., Pala, V.,
Tumino, R., Sacerdote, C., Mattiello, A., Bueno-de-Mesquita, H. B., Van Duijnhoven, F. J. B., Drake, I., Wirfält, E.,
Johansson, I., Hallmans, G., Engeset, D., Braaten, T., Parr, C. L., Odysseos, A., Riboli, E., and Peeters, P. H. M. Fruit
and vegetable consumption and prospective weight change in participants of the European prospective investigation
into cancer and nutrition-physical activity, nutrition, alcohol, cessation of smoking, eating out of home, and obesity
study. [2012] American Journal of Clinical Nutrition (95) 1 : 184-193 . Impact factor : 6.504
[399]
Verkooijen, H. M., Hartman, M., Usel, M., Benhamou, S., Neyroud-Caspar, I., Czene, K., Vlastos, G., Chappuis, P.
O., Bouchardy, C., and Rapiti, E. Breast cancer prognosis is inherited independently of patient, tumor and treatment
characteristics. [2012] International Journal of Cancer (130) 9 : 2103-2110. Impact factor : 6.198
[400]
Vey, N., Bourhis, J. H., Boissel, N., Bordessoule, D., Prebet, T., Charbonnier, A., Etienne, A., Andre, P., Romagne,
F., Benson, D., Dombret, H., and Olive, D. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete
remission. [2012] Blood (120) 22 : 4317-4323 . Impact factor : 9.060
[401]
Vielh, P., Richon, C., Meurice, G., Job, B., Lacroix, L., Marthy, V., Motte, N., Valent, A., Caillou, B., Al Ghuzlan, A., Bidart,
J. M., El Naggar, A., Lazar, V., Dessen, P., and Schlumberger, M. Molecular Characterization of 61 Cases of Follicular
Adenomas and Carcinomas of the Thyroid. [2012] Modern Pathology (25) supplt 2 : 317A-317A. Impact factor : 5.253
[402]
Villarreal-garza, C., Cortes, J., Andre, F., and Verma, S. mTOR inhibitors in the management of hormone receptor-positive
breast cancer: The latest evidence and future directions. [2012] Annals of Oncology (23) 10 : 2526-2535. Impact factor : 7.384
[403]
Walter, T. A., Baudin, E., Kurtz, J. E., Ruszniewski, P., Bengrine-Lefevre, L., Cadiot, G., Dominguez-Tinajero,
S., Kraemer, S., Ducreux, M. P., and Mitry, E. A PHASE II TRIAL OF BEVACIZUMAB WITH CAPECITABINE IN
PROGRESSIVE, METASTATIC WELL-DIFFERENTIATED DIGESTIVE ENDOCRINE TUMORS (BETTER STUDY). [2012]
[404]
Warrick, Emilie, Garcia, Marta, Chagnoleau, Corinne, Chevallier, Odile, Bergoglio, Valerie, Sartori, Daniela, Mavilio,
Fulvio, Angulo, Jaime F., Avril, Marie Francoise, Sarasin, Alain, Larcher, Fernando, Del Rio, Marcela, Bernerd, Francoise,
and Magnaldo, Thierry Preclinical Corrective Gene Transfer in Xeroderma Pigmentosum Human Skin Stem Cells. [2012]
MOLECULAR THERAPY (20) 4 : 798-807. Impact factor : 7.041
[405]
Werutsky, G., Ducreux, M., Lutz, M., Mauer, M., Van Cutsem, E., Ruers, T., Folprecht, G., Moehler, M., Aust, D., Van
Laethem, J. L., Lordick, F., Nordlinger, B., and Roth, A. The EORTC Gastrointestinal Tract Cancer Group: 50 years
of research contributing to improved gastrointestinal cancer management. [2012] European Journal of Cancer,
Supplement (10) 1 : 51-57. Impact factor : 5.061
[406]
Weyemi, U., Lagente-Chevallier, O., Boufraqech, M., Prenois, F., Courtin, F., Caillou, B., Talbot, M., Dardalhon, M., Al Ghuzlan,
A., Bidart, J. M., Schlumberger, M., and Dupuy, C. ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic
H-Ras-induced DNA damage and subsequent senescence. [2012] Oncogene (31) 9 : 1117-1129. Impact factor : 7.357
[407]
Weyemi, U. and Dupuy, C. The emerging role of ROS-generating NADPH oxidase NOX4 in DNA-damage responses.
[2012] Mutation Research - Reviews in Mutation Research (751) 2 : 77-81. Impact factor : 6.426
[408]
Wu, X., Scelo, G., Purdue, M. P., Rothman, N., Johansson, M., Ye, Y., Wang, Z., Zelenika, D., Moore, L. E., Wood,
C. G., Prokhortchouk, E., Gaborieau, V., Jacobs, K. B., Chow, W. H., Toro, J. R., Zaridze, D., Lin, J., Lubinski, J.,
Trubicka, J., Szeszenia-Dabrowska, N., Lissowska, J., Rudnai, P., Fabianova, E., Mates, D., Jinga, V., Bencko,
V., Slamova, A., Holcatova, I., Navratilova, M., Janout, V., Boffetta, P., Colt, J. S., Davis, F. G., Schwartz,
K. L., Banks, R. E., Selby, P. J., Harnden, P., Berg, C. D., Hsing, A. W., Grubb, Robert L., Boeing, H., Vineis,
P., Clavel-Chapelon, F., Palli, D., Tumino, R., Krogh, V., Panico, S., Duell, E. J., Quiros, J. R., Sanchez, M.,
Navarro, C., Ardanaz, E., Dorronsoro, M., Khaw, K. T., Allen, N. E., Bueno-de-Mesquita, H. B., Peeters, P. H.
M., Trichopoulos, D., Linseisen, J., Ljungberg, B., Overvad, K., Tjonneland, A., Romieu, I., Riboli, E., Stevens,
V. L., Thun, M. J., Diver, W. R., Gapstur, S. M., Pharoah, P. D., Easton, D. F., Albanes, D., Virtamo, J., Vatten, L.,
Hveem, K., Fletcher, T., Koppova, K., Cussenot, O., Cancel-tassin, G., Benhamou, S., Hildebrandt, M. A., Pu,
X., Foglio, M., Lechner, D., Hutchinson, A., Yeager, M., Fraumeni, Jr, Lathrop, M., Skryabin, K. G., McKay, J. D.,
Gu, J., Brennan, P., and Chanock, S. J. A genome-wide association study identifies a novel susceptibility locus
for renal cell carcinoma on 12p11.23. [2012] Human Molecular Genetics (21) 2 : 456-462. Impact factor : 7.692
[409]
Wu, Y.-L., Mok, T., Soria, J.-C., Nakagawa, K., Zhang, X., and Miao, A. GEFITINIB/CHEMOTHERAPY VERSUS
CHEMOTHERAPY IN EGFR MUTATION-POSITIVE NSCLC AFTER PROGRESSION ON FIRST-LINE GEFITINIB:
IMPRESS STUDY DESIGN. [2012] Annals of Oncology (23) 11 : 23-23. Impact factor : 7.384
[410]
Yacoubene, K., Merad, M., Alibay, A. T., Di Palma, M., and Sami, A. FAMILY PHYSICIANS (FP) ARE RARELY
INVOLVED IN MANAGING ACUTE ONSET SYMPTOMS DURING CANCER TREATMENT. [2012] Annals of Oncology
(23) 9 : 517-517. Impact factor : 7.384
[411]
Yip, S. C., Cottere, S., and Chernoff, J. Sumoylated protein tyrosine phosphatase 1B localizes to the inner
nuclear membrane and regulates the tyrosine phosphorylation of emerin. [2012] Journal of Cell Science (125) 2
: 310-316. Impact factor : 5.877
[412]
Zhang, Y., Patel, S., Abdelouahab, H., Wittner, M., Willekens, C., Shen, S., Betems, A., Joulin, V., Opolon, P.,
Bawa, O., Pasquier, F., Ito, M., Fujii, N., Gonin, P., Solary, E., Vainchenker, W., Coppo, P., De Botton, S., and
Louache, F. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in
NOG mouse model. [2012] Cell Death and Disease (3) 10. Impact factor : 6.044
[413]
Zitvogel, L. NO CURE WITHOUT IMMUNE RESPONSES IN CANCER TREATED WITH CYTOTOXIC AGENTS. [2012]
[414]
Zitvogel, L. and Housseau, F. IKDCs or B220+ NK cells are pre-mNK cells. [2012] Blood (119) 19 : 4345-4346.
[415]
Zsiros, J., Brugières, L., Brock, P., Roebuck, D., Maibach, R., Child, M., Morland, B., Casanova, M., Pariente,
D., Paris, C., Camargo, B. D., Ronghe, M., Zimmermann, A., Plaschkes, J., Czauderna, P., and Perilongo, G.
Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma - A phase II
trial of the childhood liver tumour strategy group (SIOPEL). [2012] European Journal of Cancer (48) 18 : 34563464. Impact factor : 5.061
– Photographs: N. Guerbe, Gustave Roussy.
Gustave Roussy Communications Department – Design and production:
114, rue Édouard-Vaillant
94805 Villejuif Cedex - France
Tel.: 01 42 11 42 11
Fax: 01 42 11 53 00
www.gustaveroussy.fr
Follow us:
Page Gustave Roussy
@gustaveroussy

See the document

Transcription

Documents pareils

Consulter le programme

Gustave Caillebotte (1848-1894)

a presentation of services prepared for

Print this article - Canadian Oncology Nursing Journal

“author of new departures, poetic adventure and sensual ecstasy

GENEALOGY DATABASE ENTRY - School of Chemical Sciences

WWW .ESP ACEHIPPOMENE.CH